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ABSTRACT
The Effect of Concomitant Ecstasy-Marijuana Use on 
Auditory Verbal Learning and 
Memory Performance
by
Kimberly M. Cramer
Dr. Douglas Ferraro, Examination Committee Chair 
Professor of Psychology 
University o f Nevada, Las Vegas
Previous research indicates that ecstasy users exhibit deficits of verbal learning and
memory. This research has not considered polydrug use in ecstasy users, especially
marijuana. Marijuana is an important confound because 90 percent of ecstasy users also
use marijuana. Several studies have suggested that marijuana use alters verbal memory
functioning; consequently, it is difficult to ascertain whether the observed memory
deficits in ecstasy users are attributable to ecstasy, marijuana, or other drug use. The
present study examined the effects of marijuana and ecstasy on verbal memory function.
Marijuana use was accounted for by recruiting concurrent ecstasy-marijuana users’ and
ecstasy-naïve marijuana-only users. Furthermore, the extent of marijuana use was
controlled for in the combined ecstasy-marijuana and marijuana-only groups by assigning
marijuana users to either the marijuana light or marijuana heavy experimental groups.
Recent animal findings suggest that at low frequencies marijuana may exert
neuroprotective effects against ecstasy-induced neurotoxicity. Alternatively, other animal
iii
findings have demonstrated negative synergistic effects between ecstasy and marijuana 
and working memory performance. Polydrug use was controlled for by restricting other 
drug use to not more than 15 occasions. Based upon responses to a drug use history 
questionnaire, 109 students were retrospectively assigned to one of five groups; 
marijuana-only heavy users, marijuana-only light users, ecstasy-marijuana heavy users, 
ecstasy-marijuana light users, and non-drug using controls. Participants were matched for 
age, gender, education, and intelligence as measured by the Wechsler Adult Intelligence 
Scale, Third Edition. Verbal learning and memory performance was assessed using the 
Auditory Verbal Learning Test (AVLT) (Rey, 1964; Schmidt, 1996). The Biber Figure 
Learning Test-Extended version (BFLT-E) was administered during the 20-minute delay 
of the AVLT. AVLT performance was compared between the two marijuana-only groups 
and the controls to determine the impact of marijuana use on mnemonic function. The 
marijuana-only user groups were compared with the ecstasy-marijuana groups to evaluate 
the effects o f ecstasy on verbal memory. Overall, findings in the present study suggest 
that marijuana use more than ecstasy were associated with AVLT. Additionally, drug use 
other than ecstasy and marijuana explained some of the impairment observed on the 
AVLT and even more so for BFLT-E performance
IV
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CHAPTER 1 
INTRODUCTION
Sought after for its tempered stimulant-hallucinogenic properties and reported 
enhancement of social interaction, ecstasy’s popularity has risen to make it one of the 
four most commonly used illicit drugs in the world (Christophersen, 2000). Ethnographic 
data from the National Institute on Drug Abuse (NIDA) (2003) showed that ecstasy use is 
spreading from dance parties and raves to high schools, colleges, and other social settings 
frequented by adolescents and young adults. This is particularly alarming given that non­
human primate and other animal studies suggest that the main psychoactive ingredient of 
ecstasy, namely methylendioxymethamphetamine (MDMA), is neurotoxic upon central 
serotonergic systems (e.g., Fischer et al., 1995; Ricaurte et al., 2000).
Taking MDMA leads to an acute massive neuronal release of serotonin, followed by a 
period of depletion before levels return to normal. Serotonin is thought to play a 
prominent role in memory function and marked toxic effects of MDMA have been 
observed in the hippocampus and prefrontal cortex. These areas are crucial to memory 
and other cognitive functions (Sabol, Lew, Richards, Vosmer, & Seiden, 1996). This 
suggests that MDMA may have long-term effects on memory and cognition.
In laboratory animals, high and repeated doses of MDMA produce widespread
degeneration of serotonergic axon terminals, with a concomitant depletion of serotonin in
brain regions such as the prefrontal cortex and hippocampus (Battaglia, Sharkey, Kuhar,
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& de Souza, 1991; Ricaurte, DeLanney, Invin, & Langston, 1988; Sabol et al., 1996).
The hippocampus and the parahippocampus display relatively low rates of recovery after 
abstinence from ecstasy and abnormal patterns of reinnervation are observed in the 
hypothalamus and thalamus (Fischer et al., 1995; Hatzidimitriou et al., 1999; Ricaurte, 
Martello, Katz, & Martello, 1992).
Corresponding with the animal evidence, neuroimaging studies in human ecstasy 
users suggest MDMA use may be associated with structural alterations in serotonergic 
functioning and therefore, may be neurotoxic. Functional magnetic resonance imaging 
(fMRI), positron emission tomography (PET) and single photon emission tomography 
(SPECT) studies have yielded evidence of long-term reductions in serotonergic 
transporter densities (SERT) (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998; 
Reneman et al., 2001; Semple et al., 1999; Thomasius et al., 2003) and in cortical 5-HT2a 
serotonergic receptor densities (Reneman, Majoie, Flick, & den Heeten, 2001), 
deficiencies in cerebral metabolism (Chang et al., 1999; Chang et al., 2000; Obrocki et 
al., 1999) and reduced cerebral spinal fluid (CSF) concentrations of 5-hydroxindoleacetic 
acid (5-HIAA) (the major metabolite of serotonin; used as a marker for serotonergic 
depletion) (McCann et al., 1999) in recreational ecstasy users. These data have been 
interpreted as reflecting cumulative MDMA-induced damage to the serotonergic system, 
with recent data pointing to partial recovery after prolonged abstinence (Buchert et al., 
2003; Gouzoulis-Mayfrank et al., 2002; Reneman et al., 2001; Semple et al., 1999; 
Thomasius et al., 2003).
It remains unclear how these biological abnormalities might affect long-term 
cognitive function since neuropsychological studies of ecstasy users have yielded
inconsistent results. On the one hand, studies indicate that users of ecstasy display 
residual cognitive deficits, with a selective deficit of verbal learning and memory 
impairment being most frequently observed in ecstasy users compared to controls on a 
variety of tasks (i.e., word list learning, prose recall, associative learning) (e.g., 
Bhattachery & Powell, 2001 ; Bolla, McCann, & Ricaurte, 1998; Curran & Travill, 1997; 
Daumann et al., 2004; Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et al., 2000; 
Gouzoulis-Mayfrank et al., 2003; Krystal et al., 1992; McCann et al., 1999; McCardle et 
al., 2004; Montgomery, Fisk, & Necombe, 2005; Morgan, 1999; Parrott & Lasky, 1998; 
Quednow et al., 2006; Reneman et al., 2001; Thomasius et al., 2003; Yip & Lee, 2005). 
Delayed and inunediate measures of recall performance in particular appear to be most 
adversely affected in ecstasy users (Bhattachery & Powell, 2001; Bolla et al., 1998; 
Curran & Travill, 1997; Curran & Verheyden, 2003; Fox, Toplis et al., 2001; Gouzoulis- 
Mayfrank et al., 2000; Krystal & Price, 1992; McCardle et al., 2004; Montgomery, Fisk, 
& Necombe, 2005; Morgan, 1999; Parrott & Lasky, 1998; Quednow et al., 2006; 
Reneman et al., 2001; Rodgers, 2000, Thomasius et al., 2003; Yip & Lee, 2005).
Moreover, verbal memory performance in ecstasy users has been found to be 
negatively associated with cumulative MDMA consumption (e.g., Bhattachary & Powell, 
2001; Bolla et al., 1998; Curran & Travill, 1997; Fox, Toplis et al., 2001; Gouzoulis- 
Mayfrank et al., 2000; Krystal & Price, 1992; Quednow et al., 2006; Thomasius et al., 
2003; Yip & Lee, 2005; Zakzanis & Young, 2001), levels of 5-hydroxyindoleacetic acid 
(5-HIAA) depletion (5-HIAA is the major metabolite of serotonin) (Bolla et al., 1998; 
McCann et al., 1998) and reduced serotonergic transporter (SERT) binding and 
availability (Reneman et al., 2001; Semple et al., 1999; Thomasius et al., 2003).
On the other hand, a minority of studies have reported no differences between ecstasy 
users and controls with regard to verbal memory performance (e.g., Back-Madruga et al., 
2003; Croft et al., 2001; Dafters, Hoshi, & Talbot, 2004; Fox, Parrott, & Turner, 2001; 
Halpem et al., 2004; Lamers et al., 2006; Morgan, 1998; Parrott, 2000; Semple et al., 
1999). Some of these studies have compared combined users of ecstasy and marijuana 
with marijuana-only users and found an association between low memory performance 
and the concomitant use of marijuana rather than ecstasy (e.g., Croft et al., 2001 ; Dafters 
et al., 2004; Gouzoulis-Mayfrank et al., 2000; Lamers et al., 2006; Thomasius et al., 
2003). Other studies have failed to find significant differences in verbal memory 
performance when they compared ecstasy users with polydrug users matched for similar 
patterns of drug use (Back-Madruga et al., 2003; Fox, Parrott et al., 2001; Halpem et al., 
2004; Semple et al., 1999; Simon & Mattick, 2002)
Interpretation o f the positive findings of verbal memory deficits are questionable, 
however, because they are complicated by methodological shortcomings and potentially 
confounding variables that may have contributed to the deficits observed. First, a number 
of the earlier memory studies that demonstrate impairment did not adequately match 
samples of ecstasy users and control participants with regard to pre-morbid cognitive 
ability, education level, gender and age. More recent studies have attempted to correct for 
such differences by matching participants. With regard to pre-morbid intellectual ability, 
researchers have either matched participants or adjusted for some measure of verbal 
intelligence, since this measure is relatively immune to cortical insults.
Secondly, previous research provides little specific consideration for the concomitant 
use of other illicit drugs by ecstasy users, especially marijuana (e.g., Bolla et al., 1992;
Curran & Travill, 1997; Krystal et al., 1992; Parrott & Lasky, 1998). Marijuana use is a 
particular problem for MDMA research because it is common for ecstasy users to 
consume marijuana to enhance the MDMA-induced euphoria, as well as to mitigate the 
unpleasant come-down effects that follow when the euphoria begins to diminish (Parrott, 
2001). Subsequently, most ecstasy users have used marijuana more or less regularly 
before they started taking ecstasy and continue using marijuana parallel to their use of 
ecstasy (Gouzoulis-Mayfrank & Daumann, 2006). Strote et al. (2002) observed that 92 
percent o f college students who had taken ecstasy also used marijuana. Moreover, a 
recent survey showed that every novice ecstasy user (cumulative dose one to nine pills) 
had smoked marijuana at least once during the preceding month and 32 percent had 
smoked marijuana on five or more occasions during the preceding month. In addition, the 
more pills these novice users had taken, the more frequently they had smoked marijuana 
before (Scholey et al., 2004). Previous studies yielded similar results with rates o f 90 to 
100 percent for co-use of marijuana in ecstasy users (Rodgers, 2000; Schuster et al.,
1998; Winstock et al., 2001). Thus, a large number of ecstasy users have also used a 
substantial quantity of marijuana, making it difficult to recruit ecstasy users who have not 
also used marijuana.
In addition, a number of neuropsychological studies have reported that habitual use of 
marijuana may alter cognitive functioning, particularly verbal memory ability (e.g.. Block 
& Gonheim, 1993; Fletcher et al., 1996; Hall & Solowij, 1998; Messinis et al., 2006; 
Millsaps et al., 1994; Pope et al., 1996; Solowij et al., 2002). Furthermore, the severity of 
marijuana-induced impairment appears to depend on the duration and the frequency of 
marijuana use (e.g.. Hall & Solowij, 1998; Solowij et al., 2002). To some degree then, the
question remains as to whether cognitive deficits in ecstasy users are attributable to 
ecstasy itself or to marijuana. Because most studies addressing MDMA neurotoxicity 
have not controlled for marijuana use, more studies are needed to investigate the separate 
effects of ecstasy and marijuana on verbal learning and memory performance.
The aim of the proposed study was to assess whether ecstasy users exhibit deficits in 
explicit long-term verbal memory performance while accounting for concomitant use of 
marijuana and other illicit dmgs, as well as intelligence. To delineate the respective 
effects of marijuana and ecstasy on memory function, concomitant ecstasy-marijuana 
users were compared to ecstasy-naive marijuana-only users approximately matched for 
age, gender, level of education and intelligence. Furthermore, based on recent animal data 
illustrating interactive effects of ecstasy and marijuana, the extent o f marijuana use was 
manipulated to examine whether marijuana used in low and high recreational doses with 
ecstasy exerts additive, supra-additive and/or subtractive effects on verbal memory 
performance. Other illicit drug and alcohol use was accounted for by instituting strict 
inclusion criteria.
Explicit Long-Term Verbal Memory Studies in Ecstasy Users
Behavioral studies o f ecstasy users have been hampered by the impossibility of using 
double-blind, placebo-controlled, repeated dose regimens on ethical grounds and by 
difficulty finding suitable control populations with which to compare ecstasy users (Croft 
et al., 2001 ; Dafters et al., 2004). The fact that ecstasy users are usually polydrug users, 
particularly with a long history of marijuana use has led some researchers to abandon the 
traditional non-drug using control group, resorting instead to controlling for non-ecstasy
drug use by statistical adjustments of levels of other drug use (Curran & Verheyden,
2003; Dafters et al., 1999; Fox et al., 2001; Halpem et al., 2004; McCardle et al., 2004; 
Mongomery et al., 2005; Quednow et al., 2006; Reneman et al., 2001; Simon & Mattick, 
2002; Thomasius et al., 2003; Verkes et al., 2001). Others have attempted to compare 
ecstasy users with ecstasy -naive users with otherwise comparable drug use histories 
(e.g., Croft et al., 2001; Dafters et al., 2004; Gouzoulis-Mayfrank et al., 2000; Lamers et 
al., 2006; McCann et al., 1999; Morgan, 1998, 1999; Morgan et al., 2002; Quednow et 
al., 2006; Rogers, 2000; Thomasius et al., 2003).
Tables 1 and 2 (see Appendix I) summarize previous findings regarding ecstasy- 
related performance on explicit long-term verbal memory tests. The studies are split into 
two tables because they vary in the degree of specificity with which any cohort 
differences can be attributed to ecstasy. With the exception of the ecstasy users recruited 
by Yip and Lee (2005), Gouzoulis-Mayfrank et al. (2000) and Halpem et al. (2004), the 
majority of ecstasy users in studies also used a variety of other drugs and alcohol. This is 
tolerated in this field of research because it is generally considered impractical to obtain 
samples that do not use alcohol and other drugs. Consequently, evidence with the greatest 
degree of specificity to ecstasy comes from studies that statistically control for the use of 
other drugs and/or compare ecstasy users to a control group of individuals who have 
similar drug use patterns, but have never used ecstasy.
Additionally, studies with a high degree of specificity to the long-term effects of 
ecstasy control for other potential covariates by excluding individuals with a history of 
relevant psychiatric conditions and by statistical controlling for and/or matching cohorts 
on gender, age, estimated pre-morbid intelligence and level of education.
The studies in Table 1 exercised a relatively higher degree of control over possible 
confounding variables compared to those in Table 2, namely other illicit drug use and 
pre-morbid IQ. Thus, the degree of assurance with which one can derive conclusions 
from these data is greater for the studies reported in Table 1 than in Table 2. Hence, the 
verbal memory findings reported in Table 2 must be interpreted with caution.
Both tables report the findings of immediate and delayed recall performance and in 
some cases other measures of memory performance (e.g., recognition). Delayed recall 
performance is the measure that is most specific to explicit verbal memory and is 
typically assessed after a 20- or 30-minute delay. Presumably, delayed recall performance 
represents one’s ability to encode, store and retrieve incoming information. A number of 
studies have examined the impact of recreational ecstasy use on delayed recall 
performance in ecstasy users. While significant deficits in ecstasy users have been 
observed using a variety o f tests, the results are far from consistent across studies.
Of the studies in Table 1 that assessed delayed memory performance, seven reported 
a significant deficit in ecstasy users compared to other dmg users (except when noted). 
Despite being statistically significant, the size of the deficit detected in ecstasy users 
compared to controls was quite small, typically seven percent to 28 percent, such that 
ecstasy users only recall one or two words less than controls on a list of 15 words (e.g., 
Curran & Verheyden, 2003; Fox, Toplis et al., 2001; McCardle et al., 2004). Larger 
deficits in ecstasy users were found by Reneman et al. (2001,22 percent, ecstasy users = 
10.1 words versus polydrug users = 13.1 words on the AVLT), as well as Yip and Lee 
(2005,61 percent, ecstasy users = 5.28 words versus non-drug users = 13.52 words on the 
AVLT).
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Yip and Lee’s (2005) study deserves particular consideration, not just because large 
deficits in both immediate and delayed recall performance were observed in ecstasy 
users, but because a large sample of ecstasy users was tested (N = 100). Moreover, the 
ecstasy users recruited were unusual in that they were relatively “pure” ecstasy users. 
They were “pure” in the sense that they did not report any history of substance abuse 
other than ecstasy use. The authors attributed recruitment of such subjects to the fact that 
the use of ecstasy had only recently become a popular trend in Hong Kong.
What’s more interesting is that Yip and Lee (2005) observed deficits in ecstasy users 
with relatively low lifetime ecstasy consumption. Ecstasy users had on average consumed 
35.8 tablets (range 16 to 60 tablets). The only other study to report significant deficits in 
ecstasy users with such a low average use of ecstasy was McCardle et al. (2004), but the 
deficit detected was only seven percent (ecstasy users =11.18 words versus polydrug 
users =12.13 words on the AVLT). In comparison, deficits of 28 percent were obtained 
by Curran and Verheyden (2003) in users with an average lifetime dose of 707 tablets 
(ecstasy users = 5.81 words versus polydrug users = 8.06 words on the RBMT-Prose 
Recall) and Fox, Toplis et al. (2001) in users with an average lifetime dose of 811.5 
tablets (ecstasy users = 10.6 words versus polydrug users = 12.7 words on the AVLT).
Others have not found a statistically significant deficit in users who have also used 
several hundred ecstasy tablets in their lifetime (e.g., Semple et al., 1999; Simon & 
Mattick, 2002). For example, ecstasy users in Simon and Mattick’s (2002) study had 
consumed a mean lifetime 258 tablets, whereas in Semple et al., (1999) the mean lifetime 
consumption of ecstasy users was 672 tablets. Although Semple and colleagues (1999) 
did not find significant differences in delayed recall, they did obtain an association
between lifetime numbers of ecstasy tablets and verbal memory performance. Larger 
lifetime doses of ecstasy were associated with reduced verbal memory performance in the 
CVLT.
Other evidence for ecstasy-related verbal memory impairment has been provided by 
four studies (e.g., Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et al., 2000; Quednow et 
al., 2006; Thomasius et al., 2003) that too, observed dose-related impairment between 
some measure of ecstasy use and the delayed recall performance. For example, 
Gouzoulis-Mayfrank et al. (2000), Quednow et al. (2006) and Thomasius et al. (2003) 
observed a negative association between cumulative lifetime consumption and delayed 
recall scores as measured by the Auditory Verbal Learning Test (AVLT). That is, heavier 
ecstasy use was associated with lower delayed recall scores. With the exception of 
Gouzoulis-Mayfrank et al. (2000) (M = 93 tablets), cumulative lifetime consumption of 
ecstasy was high (e.g.. Fox et al., M = 811 tablets; Quednow et al., M = 457 tablets; 
Thomasius et al., M = 1,033 tablets). Fox and colleagues (2001) also found that delayed 
recall scores were negatively associated with both the usual and largest number of ecstasy 
tablets consumed on any one occasion.
Lifetime consumption of marijuana has also been observed to be associated with 
AVLT immediate memory performance (Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et 
al., 2000; Morgan, 1999; Quednow et al., 2006; Thomasius et al., 2003). For example, the 
extent of marijuana use was associated with performance on AVLT-Trial two in the Fox, 
Toplis et al. (2001) study, whereas in Gouzoulis-Mayfrank et al. (2000) younger age of 
onset of marijuana use and higher frequency of use were associated with learning 
performance or sum of AVLT Trials one through five. Thomasius and colleagues (2003)
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found the amount of marijuana smoked in the year prior to testing best predicted AVLT- 
Trial six performance (immediate recall of interference list B) (R  ̂= 0.05, p = 0.023).
In addition to cumulative lifetime consumption, an association between duration of 
abstinence from MDMA and delayed recall scores has been observed (Bhattachary & 
Powell, 2001). This is suggestive of some degree of recovery of function with cessation 
of ecstasy use. However, studies of ecstasy users who have been abstinent for at least one 
year have demonstrated persistent mnemonic deficits (Curran & Verheyden, 2003; 
Reneman et al., 2001). These findings suggest that the after effects of ecstasy use may be 
long lasting or permanent. A single, small scale longitudinal study of ecstasy users (N = 
15) found that continued use of ecstasy over a one-year follow up period was associated 
with progression of deficits in both immediate and delayed verbal memory (Zakzanis & 
Young, 2001).
The reported frequency of ecstasy use at baseline ranged from one to 55 tablets (mean 
= 19 tablets) (Zakzanis & Young, 2001). At the one-year follow-up, this increased from a 
minimum of three tablets to reportedly as many as 225 tablets (mean = 55 tablets). 
Average use in the ecstasy users had gone up by an average of 4 tablets per month, but 
the use of various other illicit drugs also increased over the same period complicating the 
conclusions about ecstasy’s long-term effects on memory. While this study is far from a 
final say on the matter, its longitudinal design is more convincing than simple 
comparison group testing.
Like Zakzanis and Young (2001), findings of significant verbal memory deficits in 
ecstasy users in six other studies in Table 2 are complicated by the absence of statistical 
evaluation of the potential influence of other drugs (Bhattachery & Powell, 2001 ; Bolla et
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al., 1998; Krystal et al., 1992; Morgan, 1999; Parrott & Lasky, 1998; Reneman, Majoie et 
al., 2001). This makes it difficult to identify the relative contribution of these substances 
to verbal long-term impairment. Consequently, these findings must be treated with more 
caution because drug use other than ecstasy may have contributed to the observed 
deficits.
In contrast to the number o f significant findings for delayed recall, five of the 
relatively well controlled studies in Table 1 failed to detect a difference between ecstasy 
users and controls on delayed verbal memory or detected a difference that failed to 
remain significant after controlling for other drug use and/or other covariates (Croft et al., 
2001; Dafters et al., 2004; Halpem et al., 2004; Lamers et al., 2006; Semple et al., 1999; 
Simon & Mattick, 2002). For example, Dafters and colleagues (2004) compared the 
verbal memory performance of subjects who used both ecstasy and marijuana, marijuana- 
only, and neither drug, on the Rivermead Behavioral Memory Test (RBMT), which 
involved the recall of an audio taped story after a 30-minute delay. In addition, free recall 
performance of 30 words (i.e., subjects listen to 30 words and are instructed to recall as 
many as they can remember) was tested. All the drug user groups displayed significantly 
impaired memory fimction compared to the non-drug users. However, there were no 
significant differences between subjects who used ecstasy-marijuana and those who used 
only marijuana.
Likewise, Lamers et al. (2006) and Croft et al. (2001) found that combined ecstasy- 
marijuana users and marijuana-only users did not differ from each other in their delayed 
recall performance. A variety of tests were used to assess delayed recall performance, 
including the AVLT (Lamers et al., 2006), Coughlan List Test (Croft et al., 2001) and the
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Weschler Memory Scale III test (WMS-III) (Simon & Mattick, 2002). In addition, the 
sample sizes of the Lamers et al. (2006) and Croft et al. (2001) studies were relatively 
small (Lamers et al., 2006, ecstasy-marijuana users N = 11, marijuana-only users N = 15, 
non-drug users N = 15). The sample size in the Simon and Mattick (2002) study was 
larger (ecstasy users N = 40, marijuana-only users N = 37). Taken together, these results 
provide very little support for an effect of ecstasy use on delayed verbal memory 
performance. These studies suggest that marijuana use, rather than MDMA use, may 
better account for many of the verbal memory deficits among ecstasy users reported 
elsewhere in the literature.
The majority of studies in Tables 1 and 2 also assessed immediate recall. Immediate 
recall performance presumably reflects some combination of long-term memory and 
working memory performance because there is no inhibition of the use o f working 
memory to retain items between study and test (Fox, Toplis et al., 2001). In the AVLT, 
for example, the number of words recalled on trial six (the trial immediately following 
recall of words from interference list B) is typically used to represent participants 
immediate recall score. However, trials one through five have also been interpreted to 
reflect immediate recall performance.
Like the delayed recall memory results, there has been a mix of significant and non­
significant results across studies with regard to immediate recall performance (e.g., 13 
studies have found deficits, whereas 13 studies have not). Yip and Lee (2005) have 
observed the most profound deficit in ecstasy users immediate recall performance (51 
percent). On average, the ecstasy user group recalled 5.20 words whereas the non-users 
recalled an average of 10.51 words. Mean recognition performance in the ecstasy users
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was also significantly impaired relative to non-users (ecstasy users M = 5.64 v. non-users 
M = 12.80 words) (Yip & Lee, 2005).
Negative correlations between inunediate recall scores and patterns o f ecstasy use 
have also been observed. For example, Reneman Lavalaye et al. (2001) found that 
immediate recall scores on the AVLT were lower in ecstasy users who had reported 
greater lifetime consumption and/or used higher lifetime doses of ecstasy. Furthermore, 
Thomasius et al. (2003) showed that immediate recall on the first trial was best predicted 
by the average number of exposures to ecstasy.
Immediate recall deficits have often been observed in relatively heavy ecstasy users. 
For example, Quednow and colleagues (2006) demonstrated immediate memory deficits 
in ecstasy users with more than 450 tablets per lifetime. Studies showing no or only weak 
impairment in immediate recall (e.g., Back-Madruga et al., 2003; Croft et al., 2001; 
Gouzoulis-Mayfrank et al., 2000; McCardle et al., 2004; Simon & Mattick, 2002) in 
ecstasy users examined mostly users with a lifetime dose lower than 100 tablets. 
However, ecstasy users in the Simon and Mattick (2002) study had consumed a 
somewhat higher dose of 258 tablets.
Explanations for the Diversity o f  Findings
Several factors may contribute to the diversity of findings. y\mong them are failure to 
comprehensively to assess intelligence and control for IQ differences between groups, 
lack of a normal control group in some studies, age and/or educational differences 
between subjects and controls and relatively small sample sizes. One of the most crucial 
influencing factors to the diversity of finding is the relative use of marijuana and ecstasy.
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Table 3 (see Appendix I) summarizes the mean lifetime consumption of ecstasy users in 
the verbal memory studies reviewed in Tables 1 and 2. As Table 3 depicts, there is a great 
deal of variability across studies with regard to cumulative MDMA exposure. Moreover, 
verbal memory deficits have been detected in ecstasy users who have used a small 
number of tablets (mean = 20 tablets, Rodgers, 2000), whereas others have failed to find 
deficits in ecstasy users who have consumed a substantial number of tablets (mean = 672 
tablets, Semple et al., 1999). In addition, in some studies the extent of use of marijuana 
was significantly greater than ecstasy use. For example, in Croft et al. (2001a), the mean 
lifetime use of marijuana was 10,964 occasions, whereas the use of ecstasy was 41 
occasions. Similarly, participants in Simon and Mattick’s (2002) study (ecstasy users and 
marijuana-only users) were also heavy marijuana users, with a mean 67.9 joints smoked 
per month in the ecstasy user group and a mean 62.6 joints smoked per month in the 
marijuana-only group, but generally lighter ecstasy users (mean lifetime exposure 258 
tablets). It could be posited that the higher use of marijuana may have contributed to 
these researchers finding that the verbal memory deficits were related to marijuana, rather 
than ecstasy.
The Marijuana Confound
Marijuana may confound MDMA studies in two ways. First, the main psychoactive 
constituent of marijuana, delta-9- tetrahydrocannabinol (THC), has been shown to 
interact with the dopamine system (Tanda et al., 2000) and dopamine has been shown 
largely to determine MDMA-related serotonin impairment in rats (Aguirre et al., 1998; 
Sprague et al., 1998; Stone et al., 1989). Thus, marijuana may interact with MDMA in
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determining serotonin deficit in recreational users. Second, rat hippocampus is impaired 
following chronic marijuana administration (Ameri et al., 1999; Scallet, 1991) and as the 
hippocampus plays a significant role in memory (Sun et al., 1999), marijuana may also 
impair neurocognitive function.
Brain imaging studies of marijuana users have demonstrated altered function, blood 
flow, and metabolism in prefrontal and cerebellar regions (Block et al., 1999; Loeber & 
Yurgelun-Todd, 1999; Lundqvist, 2005). Thus, marijuana produces various metabolic 
changes in the brain. Long-term marijuana users appear to have lower resting levels of 
regional cerebral blood flow (rCBF) compared with non-smokers. Marijuana increases 
rCBF and brain metabolism in experienced users, while it decreases rCBF in non-users. 
These effects have been particularly apparent in frontal cortical areas. Decreases in rCBF 
were localized to brain regions that mediate sensory processing and attention.
Studies using a challenge paradigm indicate that even after an extended washout 
period, specific differential patterns o f cortical activation exist in subjects with a history 
of heavy marijuana use. During a challenge paradigm, smokers who completed a 24-hour 
washout showed diminished activation in the dorsolateral prefrontal cortex (DLPFC).
The effect remained diminished after 28 days of washout, although some increase in the 
DLPFC activation was noted, relative to the 24-hour time point (Yurgelun-Todd et al., 
1999). Memory-related blood flow in frequent marijuana users showed decreases relative 
to controls in the prefrontal cortex, increases in memory-relevant regions of the 
cerebellum, and altered lateralization in the hippocampus (Block et al., 2002). The 
greatest differences between users and controls occurred in brain activity related to 
episodic memory encoding.
16
Behavioral studies corroborate the brain imaging data and provide good consensus 
that heavy marijuana use produces residual deficits on measures such as memory of word 
lists (Fletcher et al., 1996; Pope & Yurgelun-Todd, 1996; Pope et al., 1995, 2001 ;
Solowij et al., 2002) and complex attention tasks (Fletcher et al., 1996; Pope et al., 2001) 
that may last for many days after cessation. For example. Pope and colleagues (2001) 
found persistent deficits among users who conunenced marijuana use prior to the age of 
17. Bolla et al. (2002) found dose-related decrements in neuropsychological performance 
after 28 days of abstinence using a very similar neuropsychological test battery. Solowij 
and colleagues (1995) have observed partial recovery, but with persistence of some 
selective attention deficits after a mean, abstinence of two years, however, at present, 
consensus is still lacking on the question of whether increasing duration of marijuana 
exposure causes increasing cognitive deficits. To date, the results of different studies 
indicate that marijuana-associated cognitive deficits may be reversible and related to 
recent marijuana exposure (Pope et al., 2002).
In summary, both neuropsychological assessment studies and studies based on brain 
imaging techniques indicate that heavy chronic marijuana use may be associated with 
dysfunction on tests of verbal memory that were found previously to differentiate ecstasy 
users from controls (e.g.. Block & Gonheim, 1993; Bolla et al., 2002; Fletcher et al., 
1996; Fried, Watkinson, James, & Gray, 2002; Hall & Solowij, 1998; Messinis et al., 
2006; Pope et al., 2001; Solowij et al., 2002). This raises the question of whether the 
adverse cognitive profiles of ecstasy users who also concomitantly use marijuana, are 
more closely associated with the extent of marijuana use rather than ecstasy use. To date.
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investigations regarding the contribution of marijuana to the long-term memory effects of 
MDMA have yielded inconsistent findings.
Evidence Demonstrating Interactive Effects o f MDMA and Marijuana
The potential mechanism(s) by which MDMA and marijuana interact is not well 
known. Parrott and colleagues (2004) have suggested that the effects of marijuana and 
MDMA may interact when taken together. This notion has been partially based on the 
acute profiles of MDMA and marijuana, which are opposite in certain crucial aspects. For 
example, MDMA is a powerful central nervous system (CNS) stimulant whereas 
marijuana has sedative and relaxant properties. MDMA is hyperthermic, whereas 
marijuana is hypothermic, MDMA increases oxidative stress while cannabinoids are 
powerful antioxidants (Croxford, 2003). This led Parrott et al. (2004) to generate the 
tentative hypothesis that when taken together marijuana may act to ameliorate the 
stimulatory effects of ecstasy. Furthermore, they suggested that if  marijuana does reduce 
the acute neuronal over-stimulation induced by ecstasy, it may then also attenuate 
MDMA-induced neurotoxicity (Parrott et al., 2004). There is animal evidence which 
lends support to the notion that marijuana may interact with MDMA to mitigate MDMA- 
induced neurotoxicity.
Morley and colleagues (2004) found that administration of the main psychoactive 
constituent o f marijuana, delta 9 tetrahydrocannabinol (THC), or the synthetic 
cannabinoid CP 55940, in male wistar rats attenuated the hyperthermic and serotonin 
depleting effects of MDMA, which previously have been found to cause neurotoxicity. 
MDMA alone, THC alone, a combination of MDMA-THC, a synthetic cannabinoid
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agonist CP 55940 and a cannabinoid antagonist SR 141716 were administered in repeated 
injections every four hours for two days. Body temperature, locomotor activity, 
emergence (a measure of anxiety), social interaction, and neurochemical analyses in the 
hippocampus, amygdala, and prefrontal cortex (known to be depleted of serotonin when 
MDMA is taken) were assessed.
With regard to body temperature, MDMA alone caused hyperthermia whereas THC 
caused modest hypothermia. Interestingly, the co-administration of MDMA-THC 
induced greater hypothermia than THC given alone, particularly within the first two 
hours of testing. A similar robust hypothermia was also evident when the effect of 
synthetic cannabinoid CP 55940 was combined with MDMA. Co-administration of the 
CBi antagonist SR 141716 prevented this hypothermia suggesting the involvement of 
CBi receptors in the effect.
In addition, in the MDMA-THC group, THC at a high dose (2.5 mg/kg every four 
hours for two days) partially prevented the depletion of serotonin and 5-HIAA in each of 
the prefrontal cortex, amygdala and hippocampus compared to when MDMA was given 
alone. Subsequently, the combination of MDMA-THC tended to decrease MDMA- 
induced hyperactivity and increases in anxiety seen in the emergence test. These findings 
were taken as evidence that THC when combined with MDMA provided some degree of 
neuroprotection against MDMA-related neurotoxicity.
Morley and colleagues (2004) have suggested that the mechanism of neuroprotection 
may be due to THC’s antioxidant properties, possibly by counteracting MDMA-induced 
oxidative stress (Morley et al., 2004). There is evidence which suggests that THC has a 
structural resemblance to the powerful antioxidant vitamin E (Chen & Buck, 2000).
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Furthermore, cannabinoids have been found to exert antioxidant effects in vitro and are 
neuroprotective in animal models of stroke (Leker et al., 1999; Mishima et al., 2005).
However, Morley and colleagues (2004) caution that their findings do not suggest 
that human MDMA users should resort to consuming THC to minimize harm. Firstly, the 
protective doses of THC used in their study were high and these effects are unlikely to be 
obtained with the relatively small amounts of THC typically consumed during 
recreational marijuana use. Secondly, the effect of cannabinoids on MDMA-induced 
neurotoxicity in cannabinoid tolerant animals is not known. Thus, protection from the 
neurotoxic effects of MDMA may not necessarily be obtained in frequent marijuana 
users. Finally, the neuroprotective effects of THC were by no means complete and were 
in fact only partial in all brain regions examined.
Croft et al. (2001) has also suggested that marijuana may exert neuroprotective 
effects against MDMA-induced neurotoxicity by inducing dopamine down regulation. 
Marijuana indirectly augments levels of dopamine in the mesocortical pathway (Diana, 
Melis, & Gessa, 1998). A possible mechanism explaining this increase in dopamine 
levels is through an indirect excitatory action of marijuana on the ventral tegmental area 
(VTA) dopaminergic neurons, the main ascending dopaminergic projection to the nucleus 
accumbens (Cheer et al., 2004). Cannabinoid receptor (CBi) agonists have been found to 
enhance the firing rate of dopaminergic neurons (Cheer et al., 2003) via a reduction of 
afferent GABAergic transmission (Szabo et al., 2002). Marijuana binds to CB, receptors 
located on pre-synaptic glutamatergic neurons that project to the nucleus accumbens, 
effectively controlling the firing of the nucleus accumbens GABAergic neurons, which in 
turn inhibit the dopaminergic neurons of the VTA. Via the reduction of excitatory
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transmission in the nucleus accumbens, marijuana could disinhibit dopamine cells of the 
VTA, increase their firing rate, and trigger the release of dopamine in the nucleus 
accumbens (Robbe et al., 2001).
Long-term over stimulation of dopamine decreases the number of receptors (down 
regulation) and the remaining receptors become desensitized. Down regulation is thought 
to be an underlying mechanism for psychodynamic tolerance, where exposure to a drug 
causes less response than previously obtained.
In contrast to the hypothesis that marijuana attenuates MDMA-induced neurotoxicity, 
there are other animal data which suggest that ecstasy and marijuana may interact to 
produce greater impairment than that which is observed when either drug is used alone. 
Young, McGregor, and Mallet (2005) tested working memory using a double-Y maze 
task in male wistar rats. The double-Y maze task involved the presentation of two 
consecutive tasks on each trial: a spatial discrimination task in the first “Y”, followed by 
a delayed alternation task in the second “Y”. The spatial discrimination component of the 
double-Y maze requires the use of reference memory only, whereas the delayed 
alternation component also requires the use of working memory (Mallet & Beninger, 
1993).
Low (THC 0.25 mg/kg and MDMA 1.25 mg/kg), medium (THC 0.5 mg/kg and 
MDMA 2.5 mg/kg), and high (THC 1.0 mg/kg and MDMA 5.0 mg/kg) drug doses were 
administered alone and together. At low doses, THC and MDMA alone did not impair 
memory. Combined however THC and MDMA significantly impaired working memory, 
which was evidenced by impaired choice accuracy in the delayed alternation component, 
but no effect in the spatial discrimination component of the maze task. At medium doses,
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the administration of THC or MDMA alone or in combination had no significant effect in 
the spatial discrimination task of the double-Y maze. THC, but not MDMA significantly 
impaired choice accuracy in the delayed alternation component. The combined drug 
treatment led to a further impairment of choice accuracy in the delayed alternation. At 
high doses, THC and MDMA treatments alone both caused increased errors in the 
delayed alternation component, with THC causing greater impairment than MDMA. Co­
administration of THC and MDMA rendered the rats incapable of completing either maze 
task. These findings provide strong evidence of a synergistic interaction of THC and 
MDMA on memory fimction.
To summarize. Young and colleagues findings revealed that MDMA alone did not 
significantly affect memory at the low or medium doses tested (which are within a dose 
range relevant to human consumption), but MDMA at these doses interacted with THC to 
produce an impairment of memory that was greater than that observed with THC alone. 
MDMA and THC acted synergistically to impair memory.
Young and colleagues (2005) posited that the neurochemical basis for the observed 
synergistic effects of THC and MDMA may involve dopamine. THC primarily exerts its 
effects via activation of cannabinoid CBi receptors, which are predominately located on 
pre-synaptic hippocampal neurons (Tsou et al., 1998). THC is known to increase 
dopamine production in several areas including prefrontal mesocortical areas, strongly 
connected with working memory function (Bergson et al., 2003). MDMA has direct 
action on the serotonin, dopamine, and norepinephrine neurotransmitter systems (Climko 
et al., 1986), suggesting that an interaction of the two drugs may occur within the 
dopamine system.
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The Proposed Investigation
Most investigations examining explicit long-term verbal memory function in 
recreational ecstasy users have not controlled for other illicit drug use. Marijuana use is a 
particular problem for MDMA research because it is common for ecstasy users to 
consume marijuana to alleviate the residual negative effects that result from taking 
ecstasy. Thus, a large number of ecstasy users have also used a substantial quantity of 
marijuana. This is problematic because marijuana use by itself has been associated with 
deficits on tests of verbal learning and memory previously found to differentiate ecstasy 
users from controls (e.g., Bolla et al., 2002; Hall & Solowij, 1998; Pope et al., 1996; 
Solowij et al., 2002). These findings suggest that at least some of the widely reported 
deficits in memory performance in ecstasy users might be attributable to marijuana rather 
than ecstasy.
The primary aim of the proposed study was to delineate the respective effects of 
marijuana and ecstasy on verbal learning and memory performance. The Auditory Verbal 
Learning Test (AVLT) (Rey, 1964; Schmidt, 1996) was used to assess verbal memory 
performance. Participants completed a drug use history questionnaire, which explored 
participants’ prior illicit drug use and demographic information.
Illicit drug use beyond ecstasy and marijuana was controlled for by setting strict 
criteria that limited other drug use to 15 or fewer occasions in a lifetime. Additionally, to 
control for individual differences participants were matched for age, gender, and level of 
education. Participants also were matched on intelligence, which was assessed using the 
vocabulary subtest of the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III) 
(Wechsler, 1997).
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Concurrent ecstasy-marijuana users, ecstasy-naïve marijuana-only users and non-drug 
users were recruited for participation. The extent of marijuana use was controlled for in 
the drug user groups by classifying marijuana use as either light or heavy. Categorization 
of marijuana use as light or heavy was based on retrospective examination of participants 
self-report data collected from the drug use history questionnaire. The marijuana use 
criterion resembled that used by Fried, Watkinson, James, and Gray (2002). Heavy 
marijuana use was defined as using marijuana five or more times per week and light 
marijuana use was defined as using marijuana fewer than five times a week.
Moreover, the comparison of heavy and light marijuana users in the concurrent 
ecstasy-marijuana and marijuana-only users enabled the assessment o f potential 
interactive effects of combined marijuana and ecstasy use. The rationale for examining 
the interactive effects o f these two drugs is found in recent animal findings. One set of 
findings has suggested that marijuana at high doses may exert positive neuroprotective 
effects against MDMA-induced neurotoxicity (Morley et al., 2004). In contrast, another 
set of animal findings has demonstrated a negative synergistic disruption in working 
memory performance by co-administration of THC and MDMA (Young et al., 2005).
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CHAPTER 2 
REVIEW OF RELATED LITERATURE
History o f MDMA
The German pharmaceutical company Merck first synthesized MDMA in 1912. 
MDMA was incidentally created as a by-product while trying to synthesize a different 
drug. For reasons that have been lost over time, Merck did little to explore its properties 
as a drug. In fact, there was little interest in MDMA until the 1950s when the U.S. Army 
studied it as a potential chemical warfare agent that would temporarily disable enemy 
troops. In the 1970s, despite a lack of any meaningful controlled clinical trials, many 
psychotherapists used it as a therapeutic agent. The use of MDMA as an adjunct to 
therapy was based on the notion that MDMA lowers defensiveness and heightens the 
effects of physical contact, which purportedly allows users to achieve important healing 
insights about their problems (Rochester & Kirchner, 1999).
In the 1980s, MDMA earned a new nickname, ecstasy (also XTC or E), given to it by 
the newest group to experiment with it, our nation’s youth. At about the same time that 
MDMA first appeared as a so called “party” or “club” drug at raves or all-night dance 
parties, evidence was emerging that this compound was not benign, and could cause 
damaging effects on serotonergic neurons.
In 1985, MDMA was found to have toxic effects on brain serotonin neurons in 
rodents (Ricaurte et al., 1985). Subsequently, the U.S. Drug Enforcement Agency (DEA)
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added MDMA to the Schedule I list of drugs having high abuse potential with no 
accepted medical use. Despite MDMA’s classification as a Schedule I drug, it continues 
to be used illegally.
Neuropharmacology o f MDMA
MDMA is a derivative of methamphetamine (known by such street names as “speed,” 
“crystal,” and “meth”) and its parent compound amphetamine. Ecstasy differs from 
amphetamine and methamphetamine in that it has a methylenedioxy (-0-CH2-0-) group 
attached to positions three and four of the aromatic ring of the amphetamine molecule 
(i.e., it is ring substituted). In this respect, it resembles the structure of the hallucinogenic 
material mescaline (Nichols, 1986; Shulgin, 1986). As a result, the pharmacological 
effects of MDMA are a blend of those of the amphetamines and hallucinogenic 
mescaline. 3,4-methylenedioxyamphetamine (MDA) and methylenedioxiethyl- 
amphetamine (MDEA) are also amphetamine-mescaline derivatives (i.e., they are similar 
in chemical structure to MDMA) and therefore, produce pharmacological effects similar 
to MDMA. This group of substances is frequently referred to as “designer drugs” because 
when illicit laboratories began to produce them for non-medical use, the blend of 
amphetamine-like and mescaline-like effects was intentionally sought and could be 
achieved reliably by the appropriate design of the drug molecule (Kalant, 2001).
MDMA blocks the reuptake of serotonin by binding with a high affinity to the 
serotonergic transporters (SERTS). This action is similar to serotonin specific reuptake 
inhibitors (SSRIs), such as anti-depressants like fluoxetine (Prozac), sertraline (Zoloft), 
and paroxetine (Paxil). Unlike SSRIs, but similar to the action of the amphetamines,
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MDMA appears to enter the nerve terminal itself, either through passive diffusion or 
directly through the SERT, by exchange diffusion (a concentration gradient that involves 
the reversal o f the normal inward bound direction of serotonin with MDMA) and causes 
the release of serotonin. This release is calcium-independent (i.e., independent of the 
firing of the serotonin neuron) and appears to come from cytoplasmic stores rather than 
from synaptic vesicles. The released serotonin then enters the synaptic cleft through the 
serotonin transporter, by exchange diffusion with MDMA. MDMA acts on serotonin 
release in much the same way as amphetamines act on dopamine release.
It is thought that the movement of serotonin into the synaptic cleft, and the 
subsequent action of serotonin on pre- and post-synaptic binding sites is central to 
MDMA's neuropharmacology. MDMA has potency for the serotonin 5-HT2a, muscarinic 
Ml, adrenergic alpha (a-2) and histamine Hi receptors (Nichols et al., 1982; Berger et al., 
1992b). Animal studies indicate that 5 -HT2 receptors might be involved in MDMA’s 
effects because 5-HT2 antagonists reduced several effects of MDMA, such as MDMA- 
induced serotonergic neurotoxicity, acute hyperthermia and disruption of sensorimotor 
gating (Schmidt et al. 1990). 5-HT2a receptors have been implicated in the hallucinogenic 
effects of classic psychedelic drugs such as LSD (Vollenweider et al. 1998). It is possible 
that some of MDMA's psychedelic effects occur because of interactions with this 
receptor. The a -2 adrenergic receptor also may be associated with some of the 
cardiovascular effects of MDMA (Berger et al., 1992).
MDMA also triggers the releases of dopamine, which may be central to both its 
psychological action and to its neurotoxicity in animal studies (Johnson et al., 1991). In 
mice, MDMA produces a selective long-term loss of dopamine nerve endings (Miller &
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0 ’Callaghan, 1994). Pre-treatment of an animal with a drug that blocks dopamine 
release, appears to block MDMA neurotoxicity (Colado, 0 ’ Shea, & Green, 2004). Also, 
serotonin specific releasing agents, which are non-dopaminergic have been synthesized 
and been found to be devoid of MDMA's neurotoxicity and psychological effects in 
animals. MDMA tends to indirectly inhibit the firing and release of dopamine in 
nigrostriatal dopamine neurons (i.e., neurons projecting from the substantia nigra to the 
striatum) due to local serotonin release (Colado, O’ Shea, & Green, 2004).
In summary, MDMA affects serotonin similarly to the way that amphetamines affect 
dopamine, by inhibiting the reuptake and causing the release of serotonin. This effect is 
somewhat similar to the effect that SSRI antidepressant drugs have. Subsequently, 
MDMA influences the 5-HT2a (psychedelic) and a -2 adrenergic (cardiovascular) receptor 
sites. MDMA’s effects on dopamine appear, at this point, to be involved both with its 
neurotoxicity and psychological effects.
The Serotonin System
Serotonin, also called 5-hydroxytryptamine or 5-HT is found in mast cells, blood 
platelets, intestinal tissue, and especially in the brain. In the brain, serotonin acts as a 
primary neurotransmitter. It is synthesized from tryptophan through the intermediate 5- 
hydroxytryptophan in the axon terminals of serotonin neurons. After serotonin is 
manufactured, it is stored in sacks called synaptic vesicles located in the 5-HT axon 
terminals. These vesicles release their serotonin into the synaptic cleft via exocytosis (the 
excretion of neurotransmitter through the membrane of a pre-synaptic terminal and into 
the synaptic cleft), in response to the firing of the serotonin neurons.
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In the synaptic cleft, the serotonin neurotransmitter exerts its action on both pre- 
synaptic and post-synaptic receptor sites (sites on the serotonin neuron itself and on the 
neuron with which it is communicating). Serotonin is then taken back into the pre- 
synaptic serotonin neuron (from the synaptic cleft) via a reuptake pump referred to as the 
synaptic membrane serotonin transporter (SERT). Thus, the concentration of serotonin in 
the synaptic cleft is controlled directly by its reuptake into the pre-synaptic terminal. 
Serotonin that is reclaimed is again stored in the vesicles or metabolized by monoamine 
oxidase (MAO-A) into 5-hydroxyindileacetic acid (5-HIAA).
Serotonergic Neuron Distribution and Pathways
Serotonergic neurons are widely distributed in pathways throughout the CNS. As 
Figure 1 depicts, the largest group of serotonergic neurons is B7, which is continuous 
with a smaller group of serotonergic cells, B6. Groups B6 and B7 often are considered 
together as the dorsal raphe nucleus, with B6 being its caudal (tail or hind end) extension. 
Another prominent serotonergic cell body group is B8, which corresponds to the median 
raphe nucleus. Group B9, part of the ventrolateral tegmentum of the pons and midbrain, 
forms a lateral extension of the median raphe and therefore is not considered one of the 
midline raphe nuclei. Ascending serotonergic projections innervating the cerebral cortex 
and other regions of the forebrain arise primarily from the dorsal raphe, median raphe and 
B9 cell group.
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Figure 1. Schematic drawing depicting the location of the serotonergic cell body 
groups in a sagittal section of the rat central nervous system and their major projections. 
Serotonergic cell bodies are located within the B cell groups of Dahlstrom and Fuxe 
(1964), from which they project caudally to the spinal cord and rostrally to many 
forebrain structures. OT, olfactory tuberculum; Sept, septum; C. Put, nucleus caudate- 
putamen; G. Pal, globus pallidus; T, thalamus; H, habenula; S. Nigra, substantia nigra. 
(Modified from Consolazione & Cuello, 1982).
Two distinct ascending projections arise from the rostral (head or front end) 
serotonergic system. The two main ascending serotonergic pathways emerging from the 
midbrain raphe nuclei to the forebrain are the dorsal periventricular path and the ventral 
tegmental radiations. Both pathways converge in the caudal hypothalamus, where they 
join the medial forebrain bundle. Axons of both dopaminergic and noradrenergic neurons 
run through the medial forebrain bundle as well.
Ascending projections from the raphe nuclei to forebrain structures are organized in a 
topographical manner. The dorsal and median raphe nuclei give rise to distinct 
projections to forebrain regions. The median raphe projects heavily to the hippocampus.
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septum and hypothalamus, whereas the striatum is innervated predominantly by the 
dorsal raphe nuclei. The dorsal and median raphe nuclei send overlapping neuronal 
projections to the neocortex.
Within the dorsal and median raphe, cells are organized in particular zones or groups 
that send axons to specific areas of the brain. For example, the frontal cortex receives 
heavy innervation from the rostral and lateral sub-regions of the dorsal raphe nucleus. 
Raphe neurons send collateral axons to areas of the brain that are related in function, such 
as the amygdala and hippocampus or the substantia nigra and caudate putamen. The 
specific and highly organized innervation o f forebrain structures by raphe neurons 
implies independent functions of sets of serotonergic neurons dependent on their origin 
and terminal projections, as opposed to a nonselective or general role for serotonin in the 
CNS.
The existence of specific pathways projecting from the raphe nuclei to the forebrain 
and the density of serotonin receptors in these and other areas, such as the hippocampus, 
amygdala and cortex, supports the growing body of evidence implicating serotonin in the 
processes of learning and memory (Buhot, 1997; Buhot, Martin, & Segu, 2000). Spoont 
(1992) has proposed that serotonin may play a role in cognition and that extreme 
deviations of serotonin activity can result in biases in cognitive processing. There is also 
evidence that suggests that serotonin is particularly likely to be involved in learning (e.g.. 
Hunter, 1988), visuospatial memory (Wenk, 1997), visual discrimination, associative 
functions and aspects of planning (Park et al., 1994), and general memory consolidation 
and retrieval (Meneses & Hong, 1994).
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Serotonin has been also implicated in the regulation of mood, anxiety, aggression, 
impulsiveness, sexual activity, appetite, sleep, pain, circadian and seasonal rhythms, 
motor activity, and body temperature (Morgan, 2000). Transient reductions in serotonin 
activity, induced by tryptophan depletion have been reported to produce a rapid lowering 
o f mood in normal males (Young et al., 1985) and relapse in recently remitted depressed 
patients (Delgado et al., 1990). Furthermore, there is evidence that disorders o f central 
serotonergic neurotransmission, as reflected by low levels 5-HIAA (the major metabolite 
o f serotonin) are associated with anxiety disorders (e.g., Garvey et al., 1995) and 
impulsive and aggressive personality traits (e.g., Linnoila et al., 1993).
Serotonergic Receptors
Over the past decade, more than 14 different serotonin receptors have been located in 
the central and peripheral nervous system (CNS/PNS) (see Table 4). Researchers have 
also cloned serotonin receptors through molecular biological techniques, which has 
facilitated the identification of new therapeutic targets and aided an understanding of the 
multiple roles played by 5-HT in the brain.
Table 4 Different serotonin (5-HT) receptor subtypes
5-HT, 5-HT2 5-HT3 5-HT4 5-HT; 5-HT6
5-HTy  ̂
5-HT,b 
5-HT,d 
5-HT,e 
5-HT,F
5-HT2A
5-HT2B
5-HT2C
5-HT3A
5-HT3B
5-HT5A
5-HT5B
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Serotonergic receptors are divided into seven distinct classes based on their structural 
and operational characteristics. With the exception of the 5-HT3 receptor, a ligand gated 
ion channel, all other 5-HT receptors are G-protein coupled seven transmembrane (or 
heptahelical) receptors that activate an intracellular second messenger cascade. Binding 
of serotonin to the receptor causes a conformational change in the intracellular domain of 
the receptor, which then affects its interaction with the GTP-binding G-protein on the 
cytosolic side of the plasma membrane. The occupied receptor causes replacement of the 
GDP bound to the alpha subunit of the G-protein by GTP, activating the G-protein. This 
activated G- protein regulates an enzyme which generates an intracellular second 
messenger. If the G- protein is a stimulatory G-protein, it acts on the membrane bound 
enzyme to increase the concentration of the intracellular second messenger, while an 
inhibitory G-protein acts to decrease the second messenger concentration (e.g., Linnoila 
et al., 1993).
At least five receptor subtypes have been classified within the family o f 5-HTi 
receptors (5-HTia, 5-HTib, 5-HTid, 5-HTie, 5-HTif). They exhibit high affinity for 
serotonin and cause the cell membrane to hyperpolarize, which keeps the neuron from 
firing (Bames & Sharp, 1999). Selective agonist (a drug that binds to a receptor of a cell 
and triggers a response by the cell) for 5-HT, receptors include 8-hydroxy-2-di-n- 
propylamino-tetralin (8-OH-DPAT), which modulate adenylyl cyclase activity in the 
hippocampus. 5-HT,A receptors are found in the hippocampus, cerebral cortex, raphe 
nuclei, thalamus and amygdala.
The cell body of 5-HT,a receptor functions as an autoreceptor sensing the 
extracellular serotonin concentration and modulating the firing rate o f the neurons of the
33
raphe nuclei (Hamon et al, 1999). When activated, 5-HTja autoreceptors inhibit firing 
and consequently inhibit subsequent release o f serotonin from distal axon terminals.
5-HTia ligands with agonist activity seem to possess anti-anxiety, anti-depressant, 
anti-aggressive, as well as anti-craving, anti-cataleptic, anti-emetic and neuroprotective 
properties. For example, Buspirone is a 5-HTia agonist that is useful in the management 
of anxiety. The main therapeutic potential of 5-HTia receptors has been in the treatment 
of anxiety and depression. Work with 5-HTia (partial) agonists indicates that the anti­
anxiety actions of 5-HTia may involve primarily pre-synaptic somatodendritic 5-HTia 
receptors (leading to reduced release of 5-HT in terminal areas), whereas the anti­
depressant action of 5-HT, A agents may primarily involve post-synaptic 5-HTia 
receptors. 5-HTia receptors also may be involved in obsessive-compulsive disorders, 
impulsivity, sexual behavior, appetite control, thermoregulation, and cardiovascular 
function.
5-HTib receptors were one of the first 5-HTi-like receptors to be described. It was 
later shown that the distribution and second messenger coupling of 5-HT,B receptors in 
rodent brain was similar to that of 5-HTm receptors in mammalian brain, leading to 
speculation that 5-HTib and 5-HTid receptors might constitute species variants of the 
same receptor. 5-HTib receptors are located pre-synaptically where they control the 
release of 5-HT and post-synaptically where the highest density o f 5-HTib receptors in 
rat and mouse brain is found in the substantia nigra, globus pallidus, and dorsal 
subiculum. 5-HTib receptors are negatively coupled to adenylate cyclase.
Rodent 5-HTib receptors play a role in thermoregulation, respiration, appetite control, 
sexual behavior, aggression, and anxiety (Liechti et al., 2000). Past studies, however,
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utilized agents that are now recognized as lacking selectivity for 5-HTib receptors. In 
addition, the possible existence of multiple populations of 5-HTib receptors and the 
relationship between 5-HTib and 5-HTid receptors has raised new questions.
Nonetheless, recent studies support a role for 5-HTib receptors in the regulation of sleep, 
sensorimotor inhibition, and to some extent, locomotor activity (Vollenweider et al., 
1998).
Another method for obtaining information about 5-HTib receptors is by use of 5- 
HTib receptor knock-out mice (Schmidt et al., 1990). Such mutant mice failed to display 
any obvious developmental or behavioral deficit but supported earlier suggestions that 5- 
HTIB receptors might be involved in locomotor activity and aggressive behavior.
5-HTid receptors are widely distributed throughout the CNS (Liechti et al., 2000) and 
are negatively coupled to inhibit adenylate cyclase activity. The clinical significance o f 5- 
HTid receptors remains largely unknown. There has been speculation that these receptors 
might be involved in anxiety, depression, and other neuropsychiatrie disorders, but this 
remains for the most part to be substantiated. With the availability o f the 5-HT id 
antagonists, it has been shown for example that GR127935 blocks the effect o f anti­
depressants in the mouse tail suspension test. Further, the localization o f 5-HTid 
receptors in human brain is thought to be consistent with potential involvement in 
Huntington's disease (Slassi et al., 2004). The causes of migraine headaches are 
unknown, but appear to include dilation of the cerebral blood vessels. Both 5-HT,g and 5- 
HTid receptors mediate vasoconstriction, and 5-HTid agonists (e.g., sumatriptan) are 
useful in the treatment of migraine headaches (Whale et al., 2000). Sumatriptan also
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called Imitrix is effective after the onset o f migraine headaches, yet is not as effective in 
preventing migraines.
The 5 -HT2 receptor family consists of three specific receptor subtypes (5-HT2a, 5- 
HT2B, and 5-HT2c). 5-HT2a receptors (originally referred to as 5-HT2 receptors) were 
among the first 5-HT receptors to be identified. The 5-HT2 receptor family stimulates 
phosphoinositide-specific phospholipase C. 5-HT2A receptors are widely distributed at 
varying densities throughout the brain, with the highest density is in the neocortex. 
Relative to 5-HT] receptors, 5-HT2 receptors exhibit slightly lower affinity for serotonin. 
In the CNS, the 5-HT2a receptors function to suppress cell firing, as well as inhibit 
neurotransmitter release (e.g., dopamine, acetylcholine, noradrenaline).
5 -HT2A receptors display a high homology with 5-HT2C receptors. Moreover, recent 
evidence suggests some of the roles attributed to the 5-HT2a receptors may in fact be 
mediated by 5-HT2c receptors. This suggestion was partly based on the finding that 5- 
HT2A ligands bind nearly equally well at both types of receptors. Nevertheless, 5-HT2A 
receptors are believed to play a role in appetite control, thermoregulation, and sleep. They 
are also involved, along with various other 5-HT receptor populations, in cardiovascular 
function and muscle contraction.
In addition, 5-HT2A receptors have also received considerable attention from a 
neuropsychiatrie standpoint. Various anti-psychotic agents and anti-depressants bind with 
relatively high affinity at 5 -HT2A receptors (Vollenweider et al., 1998). Although there is 
no direct correlation between their receptor affinities and clinically effective doses, 
evidence is strong that these disorders involve, at least to some extent, 5-HT2a (or 
perhaps 5-HT2c) receptors (Liechti et al., 2000). For example, chronic administration of
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5-HT2A antagonists results in a paradoxical down-regulation of 5-HT2a receptors, such a 
down-regulation would be of benefit in the treatment of depression. There also are 
indications that 5-HT2a antagonists (a drug that blocks an action) possess anxiolytic 
properties. For example, ritanserin produced anti-anxiety effect in humans. 5-HT2a 
receptors are also involved in the actions of the classical hallucinogens (e.g., LSD, 
mescaline, MDMA) (Sanders-Bush, Burries, & Knoth, 1988).
5-HT2C receptors (once referred to as 5-HT2a) have been found in low densities in 
various brain regions of different animal species. 5-HT2c receptors may play a greater 
role than 5-HT2a receptors in migraine (Liechti et al., 2000). On the basis o f a significant 
correlation between migraine prophylactic activity and binding affinity, 5-HT2c receptors 
may be involved in the initiation of migraine attacks (Whale et al., 2001). For the most 
part, the specific role of 5-HT2b receptors is unknown.
The 5 -HT3 receptors are different fi’om the other serotonin receptors in that they are 
non-selective sodium-potassium ion channel receptors, which allow them to alter fast 
synaptic transmission. They are found in both the PNS and CNS. In the CNS, 5-HT3 
receptors are localized in the entorhinal cortex, fi’ontal cortex, and hippocampus.
5 -HT3 antagonists (e.g., ondansetron, granisetron, tropisetron) have proven clinically 
effective for the treatment of chemotherapy-induced or radiation-induced nausea and 
vomiting. Preclinical studies suggest that 5 -HT3 antagonists may enhance memory and be 
of benefit in the treatment of anxiety, depression, pain, and dementia. In addition, 5-HT3 
receptors can control dopamine release and may also be involved in acetylcholine release 
and control of the GABAergic system. Dopamine itself acts as a 5 -HT3 partial agonist.
37
5-HT4 receptors are localized on neurons and may mediate slow excitatory responses 
to serotonin. It has been suggested that 5-HT4 agonists may restore deficits in cognitive 
function and may be useful as anxiolytics or in the treatment of dopamine-related 
disorders. The marked decrease in 5 -HT4 receptors in patients with Alzheimer's disease 
suggests the 5-HT4 receptors may be involved in memory and learning (Peroutka, 
Newman, & Harris, 1988). A high density of 5-HT4 receptors in the nucleus accumbens 
has led some researchers to speculate that these receptors may be involved in the reward 
system and may influence self-administration behavior (e.g., Geyer, 1994).
The 5-HT5 class of serotonin receptors has been found to not have a high efficiency 
of coupling to G-proteins. This suggests these may in fact be coupled to ion channels. 
The pharmacological function of 5-HTs receptors is currently unknown. It has been 
speculated that on the basis of their localization they may be involved in motor control, 
feeding, anxiety, depression, learning, memory consolidation, adaptive behavior, and 
brain development (Liechti & Vollenweider, 2000). 5-HTsa receptors may also be 
involved in a neuronally-driven mechanism for regulating astrocyte physiology, with 
relevance to gliosis (Liechti et al., 2000). Disruption of 5-HT neuron-glial interactions 
(i.e., gliosis) may be involved in the development of certain CNS pathologies, including 
Alzheimer's disease, Down's syndrome, and some drug-induced developmental deficits 
(Liechti et al., 2000).
5-HTô receptors are found primarily in the CNS and recent evidence suggests that 
these play a role in many neuropsychiatrie disorders (Vollenweider et al., 1999). This is 
because numerous anti-depressants (clomipramine, amitriptylamine) and antipsychotic
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agents (rilapine, clozapine, olanzapine) bind with a high affinity for these type of 
receptors acting as antagonists (Glennon, Dukat, & Westkaemper, 1999).
The newest classes of 5-HT receptors (5-HT?A and 5-HT?B) are thought to be 
involved in both mood and learning, as well as in neuroendocrine and vegetative 
behaviors. It has recently been found that these two receptors also have a high affinity for 
many anti-depressants and anti-psychotic agents (Naughton, Mulrooney, & Leonard, 
2000).
MDMA and Serotonin Receptors
MDMA causes a profound release of serotonin by binding with high affinity to the 
serotonin transporter (SERT). The binding of MDMA to the SERT inhibits the reuptake 
of serotonin into the serotonin neurons, consequently flooding the brain with serotonin. 
Recent studies suggest that the body responds to these extraordinarily high levels of 
serotonin by decreasing the amount o f serotonin receptors in the brain. When serotonin 
levels return to normal, but there are less 5-HT receptors in the brain this may lead to 
changes in behavior (Rutty & Milroy, 1998).
Indeed, the major effect associated with the long-term abuse of the drug ecstasy has 
been the development of clinical depression in frequent users (e.g. Parrott, 2004; 
Thomasius et al., 2003). As MDMA affects serotonin release, and since serotonin has 
long been known to be linked to depression, it was assumed that MDMA eventually 
caused a lower production in the amount o f serotonin released. If this were true, then 
treatment with anti-depressants should have fixed the problem.
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Most anti-depressants are known as SSRI's, or selective serotonin reuptake inhibitors. 
This class of drugs works in that they inhibit the reuptake of serotonin back into the nerve 
terminal, therefore increasing the amount of available synaptic 5-HT, and thus, reversing 
depression (Connor et al, 2001). However, in ecstasy users, the administration of SSRI's 
had no effect, suggesting that the problem was not in the serotonin levels after all, as the 
increased serotonin levels did not provide the expected results.
After studies found that even high levels of SSRI administration didn't work to 
decrease depression, it was then postulated that the problem wasn't in the levels of 
serotonin, but in the 5-HT receptors. Autopsy observations on humans who have died 
from complications of ecstasy use (heart failure, heat stroke, seizures) found that their 
serotonin levels were normal (as measured by high performance liquid chromatography 
or HPLC), further suggesting that the problem was in the serotonin receptors. However, it 
still wasn't known if the 5-HT receptors were merely dysfunctional or if  they had actually 
been completely depleted. However, evidence now exists that it is actually in the number 
of receptors, as studies in rodents have found a reduction in post-synaptic 5-HT receptors 
following MDMA dosage (e.g., Battaglia et al., 1991).
The depletion of serotonin receptors is much like Type II Diabetes Mellitus, in that 
the ligand is present in normal amounts, but the low concentration of receptors is what 
causes the problems. Therefore, anti-depressants show no effect, as the increased levels 
of serotonin aren't any help because the receptors aren't present to take up the ligand 
(Colado et al., 2004).
The mild hallucinogen-like perceptual effects of MDMA appear to be due to 
serotonergic 5-HT%A receptor stimulation whereas MDMA-induced hyperactivity is
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mediated in part by 5-HT]g and 5-HTzA receptors. In contrast, the stimulation of 5-HT2c 
receptors results in inhibition of the expression of MDMA-stimulated hyperactivity 
(Liechti & Vollenweider, 2000).
The positive mood effects of MDMA may be related in part to dopaminergic D; 
receptor stimulation. Serotonin neurons innervate dopamine nigrostriatal and 
mesocorticolimbic circuits, including the projection from dopamine cell bodies in the 
substantia nigra (SN) and ventral tegmental area (VTA) to the dorsal striatum and nucleus 
accumbens. These pathways are known to be critical in mediating the behavioral effects 
of psychostimulants.
The 5-HTib, 5-HT2a, and 5-HT2c are among the 5-HT receptors that have been 
suggested to control brain dopamine function and also play a role in the behavioral effects 
of MDMA. The 5-HT] g and its homolog, 5-HT]d function pre-synaptically as an 
inhibitory autoreceptor (a receptor located on pre-synaptic nerve cell terminals and serves 
as a part of a feedback loop in signal transduction; it is sensitive only to those 
neurotransmitters or hormones that are released by the neuron in whose membrane the 
autoreceptor sits) and post-synaptically as an inhibitory heteroreceptor (a receptor 
regulating the synthesis and/or the release o f neurotransmitter(s) other than its own 
ligand) to control release of neurotransmitters (Barnes & Sharp, 1999). Localization and 
lesion studies support the hypothesis that 5-HT]g are localized on the axon terminals of Y- 
aminobutyric acid (GABA) efferents projecting from the striatum and nucleus 
accumbens. 5-HTig receptors provide inhibitory feedback to the origins o f nigrostriatal 
and mesoaccumbens dopamine pathways (e.g., Brocke et al., 2000).
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Stimulation of 5-HTig by direct (5-HT) or indirect agonists (e.g., cocaine) has been 
shown to inhibit GAB A release from terminals that innervate dopamine neurons in the 
substantia nigra (Johnson etal., 1998) and VTA suggesting an important role for the 5- 
HTig in the control of dopamine function. In support of this hypothesis, microdialysis 
studies have shown that 5-HTig agonists facilitate release of dopamine in the nucleus 
accumbens (Parsons et al., 1999) and striatum (Ng et al., 1993).
Neuropsychopharmacological Effects o f  MDMA in Experimental Animals
The effect of MDMA on brain concentrations of serotonin is biphasic in the rodent 
brain, and can be divided into acute and long-lasting phases. An acute, reversible phase 
of serotonin depletion occurs within three to six hours after drug administration, after 
which serotonin concentrations return to normal values (Schmidt, 1987). A long-lasting 
depletion of serotonin occurs two to three days after drug treatment, and this depletion of 
serotonin is evident in most brain regions containing serotonin terminals (Sabol et al., 
1996). There is only a partial recovery to control concentrations of serotonin after 
depletion produced by MDMA. Serotonin concentrations remain depleted in most brain 
regions up to one year following MDMA administration (Lew et al., 1996; Sabol et al., 
1996).
MDMA administration in rats also results in hyperthermia or an increase in core body 
temperature (Colado et al., 1993; Dafters, 1994; Gordon, Wilkinson, O'Callaghan, & 
Miller, 1991). Hyperthermia is related to the ambient temperature. Both Gordon et al. 
(1991) and Dafters (1994) showed that at normal (24“C) and high (30“C) ambient 
temperatures, MDMA administration resulted in an increase in temperature of
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approximately 2.0°C, whereas administering the drug to animals that had been kept at 
low ambient temperature (11 ®C) for 24-hours before injection resulted in a fall in 
temperature. Transferring the rats to a low temperature room 30-minutes after drug 
administration attenuated the temperature rise (Dafters, 1994).
Hyperthermia that follows MDMA administration was once thought to be serotonin 
receptor-mediated, however, more recent data suggests that it is a consequence of 
dopamine release (Meehan et al., 2002a; Sugimoto et al., 2001). Support for this proposal 
comes from findings that show that selective serotonin receptor antagonists do not block 
MDMA-induced hyperthermia (Meehan et al., 2002a). In addition, it has been shown that 
the administration of Prozac almost totally inhibited the increase in extracellular 
serotonin levels, but had no effect on the hyperthermic response in the same animals 
(Berger et al., 1992; Malberg et al., 1996; Schmidt et al., 1990). What is more, Meehan 
and colleagues (2002a) observed that a dopamine D| receptor antagonist (SCH 23390), 
dose-dependently inhibited MDMA-induced hyperthermia. These researchers postulated 
that MDMA might be producing hyperthermia, by enhancing the release o f dopamine, 
which then acts on dopamine Di receptors.
Another major consequence of MDMA administration in rats is the appearance of 
hyperactivity and the “serotonin behavioral syndrome” (Grahame-Smith, 1971a; Colado 
et al., 1993; Slikker et al., 1989). The syndrome consists of hyperactivity accompanied 
by, head-weaving, piloerection, fore-paw treading, penile erection, ejaculation, and 
salivation (Green et al., 2003). Callaway et al. (1990) reported that MDMA produced a 
dose-related increase in locomotor activity that was prevented by pretreatment with 
Prozac. This finding shows that serotonin release plays a key role in the behavioral
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effects o f MDMA. In addition, Kehne et ai. (1996a) demonstrated a reduction o f the 
MDMA-induced locomotor response following pretreatment with a serotonin 5-HT2a 
receptor antagonist, indicating the importance of 5-HT2a receptors in the expression of 
MDMA-induced locomotor responses.
Acute Subjective Effects o f MDMA in Humans
Commonly consumed in oral tablet form, the average recreational dose of ecstasy is 
between one and two tablets, each containing approximately 60-120 milligrams (mg) of 
MDMA (Morgan, 2000). Most individuals use the drtig on weekends, once a week or less 
because tolerance to its positive effects develops rapidly (Peroutka, Newman, & Harris, 
1988; Solowij, Hall, & Lee, 1992).
Recreational users typically describe a range of positive moods while on MDMA, 
including euphoria, feelings of intimacy and closeness to others, heightened arousal, self- 
confidence, increased sensory sensitivity, increased depth of emotion, and decreased 
appetite (Curran & Travill, 1997; Davison & Parrott, 1997; Parrott, 1997; Peroutka et al., 
1988). The commonly reported acute adverse physiological side effects include increased 
heart rate, jaw clenching, bruxism (tooth grinding), pupil dilation, gait instability, and 
nausea (Davison & Parrott, 1997; Petroutka et al., 1988).
Long-Lasting Subjective Effects o f  Ecstasy in Humans
Following the acute subjective effects, ecstasy users generally report a 24- to 48-hour 
period characterized by the persistence of an array of negative moods, such as feelings of 
lethargy, irritability, aggression, and depression. The negative moods presumably
44
develop as a consequence of central serotonergic depletion. This cycle of positive moods 
while on the drug and negative moods afterward was confirmed in a prospective study by 
Curran and Travill (1997). Twelve recreational MDMA users were compared with 12 
alcohol users (controls), at a Saturday night dance club, over a period of four days 
following consumption. MDMA users reported comparatively better moods on the 
Saturday night (i.e., day one), and worse moods in the days afterwards, at which point 
some participants scored within the range of clinical depression. In contrast, alcohol users 
showed less pronounced changes, which followed a U-shaped curve, with the lowest 
point being day two.
Mechanisms o f MDMA-Induced Neurotoxicity
MDMA predominately causes serotonin to be released from its storage sites in 
neurons, thereby, dramatically increasing brain activity. An acute dose of MDMA can 
release around 80 percent of central serotonin stores within four hours of administration 
(Green, Cross, & Goodwin, 1995). Through the release of large amounts of serotonin, 
MDMA causes a significant depletion of central serotonin stores, which can take two 
weeks or longer to replenish (Green et al., 2003).
Neurotoxicity appears to develop because MDMA interferes with the synthesis of 
serotonin neurons. That is, MDMA triggers both oxidative and metabolic stress in 
serotonergic neurons, which adversely affects the ability of these neurons to produce 
serotonin. For example. Stone, Johnson, Hanson, and Gibb (1989) found that MDMA- 
induced oxidation rapidly destroyed tryptophan hydroxylase (an enzyme essential for the 
synthesis of serotonin), which causes a long-term depletion of serotonin in affected
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neurons, and eventual cell death, particularly in the striatum and the cortex (Ricaurte et 
al., 1985).
It appears that oxidation is triggered by MDMA binding to the serotonin transporter 
and by MDMA-induced release of dopamine. Researchers have discovered that blocking 
either dopamine release or MDMA binding to the serotonin transporter blocks the 
production of free radicals (a usually short-lived, highly reactive molecular fragment that 
contained one or more impaired electrons) and the destruction of tryptophan hydroxylase. 
In addition, investigators have shown that the formation of reactive oxygen triggered by 
MDMA and other amphetamine derivatives increases with body temperature, which 
explains observations that hyperthermia increases MDMA-induced toxicity.
Other evidence that MDMA induces oxidative stress comes from studies that have 
measured the levels of the major metabolite of serotonin, 5-HIAA, and the serotonin 
transporter. These studies have observed that 5-HIAA and the serotonin transporter levels 
decrease markedly after MDMA administration and appear to remain low for months 
after exposure. For example, in a study of rhesus monkeys, Taffe and colleagues (2001) 
found that a four-day course of twice daily injections of a moderate dose of MDMA 
produced four-to-five fold reductions in cortical serotonin levels 17 months after 
exposure.
MDMA may also produce neurotoxicity by triggering the production of hydroxl 
radicals, which cause an acute depletion of brain serotonin. Shankaran, Yamamoto, and 
Gudelsky (1999) measured the production of hydroxl radicals within the brains of rats 
given MDMA. These investigators found that following MDMA injection, there was an 
immediate rise in hydroxl radicals, in serotonergic neurons in the striatum.
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What is more, MDMA leads to a reduction in antioxidant (enzymes that prevent the 
formation o f hydroxl radicals) levels. For example, experimenters found decreased levels 
of the antioxidants ascorbic acid (vitamin C) and vitamin E in the striatum of rat brains 
following MDMA administration. Subsequent studies, however, have found that 
artificially boosting the levels of antioxidant enzymes may reduce MDMA’s damaging 
effects on serotonergic and also dopaminergic neurons (e.g.. Cadet & Thiriet, 2001). It 
also appears that drugs, such as Prozac, which inhibits the serotonin transporter 
specifically, may decrease the number of free radicals produced by MDMA use. For 
example, in the Shankaran et al. (1999) study mentioned above, researchers administered 
Prozac an hour prior to MDMA injection and observed a dramatic reduction in hydroxl 
radical formation and in the amount of serotonin released in the striatum. MDMA- 
induced dopamine release in the striatum was also suppressed. The same effect was seen 
even when Prozac was administered four hours after MDMA. This finding suggests that 
these neurotoxic effects involve MDMA’s actions at the serotonin transporter.
Histological studies have provided more dramatic evidence for the serotonin 
neurotoxicity produced by MDMA. Two weeks after receiving 20 mg/km of MDMA, 
twice daily for four days, tissue taken from rat brains showed a substantial decrease in 
neurons containing serotonin. Furthermore, the axons of these neurons appeared to be 
missing. More recently, investigators observed similar findings in squirrel monkeys 
showing that the loss of serotonin axons from four-day exposure to MDMA was severe 
18 months after exposure and persisted seven years later (Hatzidimitriou, McCann, & 
Ricaurte, 1999).
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Further examination of this structural damage suggests that MDMA “prunes” or 
reduces in number serotonin axons and axon terminals in some brain regions, like the 
striatum, while sparing others, such as the amygdala (Ricaurte, 2001). This pattern is a 
hallmark of axon pruning, since neurons will often grow replacement axon terminals 
upstream of the damaged terminals. Taken together, these results provide evidence not 
only of MDMA’s neurotoxicity but of the brain attempting to rewire the serotonin system 
after damage.
Finally, the regulation of serotonin receptors may also be involved in the mechanism 
of neurotoxicity. During the acute action of MDMA, there is an adaptive down regulation 
of serotonin receptors in the cerebral cortex (Sprague, Everman, & Nichols, 1998). This 
may lead to many of the conditions associated with low serotonin levels, primarily 
depression, even after brain serotonin levels have been restored, due to the inability of 
serotonin to bind to its down regulated receptors (Morgan, 2000). In contrast, in long­
term users, in the drug-free state, there is upregulation of receptors (an adaptive response 
to the decrease in serotonin release) (Reneman et al., 2000).
Although it was initially thought that the development of toxicity required multiple 
exposures to relatively high doses o f MDMA, studies in rats (Cami et al., 2000) have 
shown that even a single exposure can produce some neuronal damage. Neurotoxic 
effects found in non-human primates are long lasting and possibly permanent. Monkeys, 
for example, have shown decrements in serotonin levels for as long as 18 months after 
MDMA intake (Ricaurte et al., 1992). Repeated exposures to MDMA increase the 
behavioral and biochemical responses o f the animals to the drug and sensitization seems 
to occur after repeated exposure to low doses (Rodgers, 2000).
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Evidence o f the Neurotoxic Effects o f MDMA in Animals
In animals, there is extensive evidence that MDMA causes dose-related reductions of 
brain serotonin and 5-HIAA concentrations, the density of serotonin uptake sites, and the 
activity o f tryptophan hydroxylase. These neurochemical deficits, which last well beyond 
the period of drug administration, have been correlated with the disappearance of 
serotonin axons, suggesting that they are related to axonal damage. Moreover, it appears 
that MDMA damages only those serotonergic axons in the cortical region of the brain, in 
particular, those that arise from the dorsal raphe nucleus (Green et al., 2003).
The profile of neurodegenerative changes produced by MDMA is remarkably 
consistent across a variety of species, including rats, mice, guinea pigs, and non-human 
primates. Mice appear to be less sensitive to MDMA neurotoxicity, whereas non-human 
primates show more MDMA-induced serotonergic damage.
The magnitude ^ d  duration of MDMA’s effects are dependent on the dose and the 
number of injections given. Single doses (20 mg/kg or more) or several more moderate 
doses, typically 5 mg/kg twice daily for four consecutive days (Battaglia et al., 1988; 
Colado et al., 1993; O’Shea et al., 1998; Ricaurte et al., 1992) produce marked depletion 
of serotonin and 5-HIAA. The neurotoxic effects are evident for up to one year after drug 
administration in rats (Battaglia et al., 1987), and have been observed up to seven years 
after drug administration in non-human primates (Hatzidimitriou et al., 1999). The lowest 
MDMA dose that elicited long-term structural damage in non-human primates was 
5mg/kg twice daily, for four consecutive days (Ricaurte et al., 1992). This is higher and 
more frequent dosing than is typical in human recreational users. However, principles of 
interspecies scaling suggest that a dose of 5 mg/kg of MDMA, in a squirrel monkey, is
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equivalent to 1.4 mg/kg in humans (Ricaurte et al., 2000). Furthermore, it has been 
reported that up to one third of recreational users “binge” by taking several tablets at once 
or over a period of hours to days (Topp et al., 1999).
With regard to regional brain sensitivity to the neurotoxic effects of MDMA, areas 
rich in serotonin terminals, such as the cerebral cortex, show more severe deficits than 
brain regions containing fibers of passage (e.g., hypothalamus) or cell bodies (brain stem) 
(Commins et al., 1987; Steele et al., 1994). In particular, repeated administration of 
MDMA has been found to produce especially long-lasting degeneration of serotonin 
axons and decreases in brain serotonin and 5-HIAA concentrations in many regions of 
the forebrain. These include the neocortex (prefrontal cortex), hippocampus, caudate 
nucleus, putamen, and many thalamic nuclei (Hatzidimitriou et al., 1999; Ricaurte et al., 
1992).
Following MDMA injury, there is evidence of a lasting reorganization of ascending 
serotonin axon projections. Projections to distant forebrain sites like the dorsal prefrontal 
cortex, exhibit little or no evidence o f recovery, while projections to more proximal 
targets, such as the hypothalamus, recover fully, and in excess (Fischer et al., 1995). 
Moreover, Fischer and colleagues (1995) reported that altered reinnervation patterns 
develop much more frequently in MDMA-treated primates than in MDMA-treated 
rodents.
Similar evidence has also been obtained using positron emission tomography (PET). 
Scheffel and colleagues (1998) utilized a radioligand (a radio active chemical marker 
which binds to certain cells and is used to allow areas inside the brain to be mapped or 
measured) that selectively labels the serotonin transporter to investigate the long-term
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neurotoxic effects in a baboon that had been administered 5 mg/kg MDMA, twice daily 
for four consecutive days. In agreement with the results of Fischer et al. (1995), PET 
scans nine and thirteen months post-MDMA showed regional differences in the recovery 
of serotonin transporters. For example, an increase in transporters was observed in the 
hypothalamus whereas a persistent decrease in transporters occurred in the prefrontal 
cortex.
Taken together, the available animal evidence, which focus on the neurotoxic effects 
of MDMA, suggests that repeated administration of high oral doses of MDMA may 
produce long-term reductions in serotonin activity and degeneration of serotonin axons.
In particular, non-human primates show increased sensitivity to such effects, with a lesser 
tendency for reinnervation to occur in cortical serotonin systems.
Evidence o f Neurotoxic Effects o f MDMA in Humans
The neurotoxic dose of MDMA in non-human primates approaches the dose of 
MDMA typically taken by recreational users (Ricaurte & McCann, 1992). This raises the 
concern that human MDMA users might also incur MDMA-induced serotonin damage. 
Since there are no currently available methods for directly evaluating the status of 
serotonin neurons in living humans, studies of MDMA’s neurotoxic potential in humans 
rely on indirect methods. These methods include measurements o f the concentration of 5- 
HIAA in cerebral spinal fluid (CSF) (levels of serotonin metabolites in the CSF reflect 
the amount of release during neuronal activity in the brain), quantification of serotonin 
transporter density, neuroendocrine challenge (the administration of drugs that stimulate 
serotonergic pathways, and a variety of neuroimaging techniques.
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The earliest study to measure 5-HIAA concentrations in CSF failed to find evidence 
of reduced levels of 5-HIAA in recreational users (Peroutka et al., 1987). More recent 
data, however, has reported significantly lower levels of CSF 5-HIAA in recreational 
ecstasy users compared to polydrug users who had never used ecstasy (e.g., Bolla et al., 
1998; McCann et al., 1994; 1999; Ricaurte et al., 1990).
In addition to a marked reduction in 5-HIAA levels, investigators have consistently 
observed decreases in the number of serotonin transporters in MDMA users. Serotonin 
transporters are sites on the pre-synaptic axons and axon terminals of serotonin neurons 
that reabsorb serotonin from the synapse. They are considered to be a reliable marker of 
serotonin neurotoxic changes (Renenman et al., 2001). Thomasius and colleagues (2003) 
utilized single photon emission computed tomography (SPECT) to measure serotonin 
transporter densities in 30 current and 31 ex-MDMA users (with MDMA abstinence of at 
least five months), and 29 polydrug and 30 drug naïve controls. Current ecstasy users 
showed significantly reduced distribution volume ratios of serotonin transporter 
availability in the mesencephalon and caudate nucleus. Furthermore, regression analyses 
indicated that the number of ecstasy tablets taken, best-predicted serotonergic alterations.
Similarly, Reneman et al. (2001) compared serotonin transporter densities in 22 
recent MDMA users, 16 ex-MDMA users (individuals who had stopped using MDMA 
for more than one year), and 13 drug naive controls. These investigators found that recent 
MDMA users showed global decreases in cortical serotonin transporter densities (nine 
percent reduction), whereas ex-MDMA users densities did not differ from those of 
controls. Semple, Ebmeier, Glabus, O’Carroll, and Johnstone (1999) also reported a ten 
percent reduction in serotonin transporter densities in the occipital cortex of recent
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MDMA users. In addition, recent MDMA users showed a widespread reduction of 
cortical serotonin transporter binding. What is more, decrease correlated with the extent 
of previous use. Semple and colleagues (1999) observation of reduced transporter binding 
corroborate earlier PET findings (McCann et al., 1998).
There is also evidence that brain atrophy might occur in association with chronic 
ecstasy use. Magnetic resonance spectroscopy (MRS) has been used to investigate myo­
inositol concentrations, a specific marker of glial cell density and neuronal damage. 
Increases in the number o f glial cells are indicative of brain injury (Kalant, 2001). Chang 
et al. (2001) reported that myo-inositol concentrations were elevated in the parietal white 
matter o f heavy ecstasy users compared to that of drug naïve subjects. A significant effect 
of the cumulative lifetime ecstasy dose on the parietal white matter and in the occipital 
cortex was also observed. Similarly, the duration of MDMA use was related to myo­
inositol in the parietal white matter, as well as in the frontal cortex.
There is also neuroimaging evidence that the hippocampus, amygdala, and frontal 
region o f the cortex may be particularly affected by extensive exposure to ecstasy. 
Obrocki et al. (1999) employed positron emission tomography (PET) to investigate 
regional brain glucose metabolism in seven heavy ecstasy users, who had used between 
12 and 840 single doses and had remained drug free for 2 -  16 months. The ecstasy users 
exhibited bilaterally reduced glucose metabolic uptake in the hippocampus, amygdala, 
and cingulate cortex. Moreover, glucose metabolism was significantly more affected in 
MDMA users who began taking the drug before age 18.
Other evidence of potential MDMA-induced brain alterations is provided by 
functional magnetic resonance imaging (fMRI) and evoked potential studies. For
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example, Cowan and colleagues (2001) found that MDMA users showed less brain 
activity in the visual cortex following a light flash than did drug-naive control subjects. 
Subsequently, a comparison of the auditory evoked potentials of heavy ecstasy users with 
those o f two matched control groups, a non-user and a marijuana-user group found that 
ecstasy users demonstrated altered patterns of cortical brain activation relative to both 
control groups (Tuchtenhagen et al., 2000). Specifically, ecstasy users (who had been 
dmg free for seven days to a year) exhibited an increase in the amplitude o f the tangential 
N1/P2 source activity, with higher stimulus intensities. High intensity dependence of the 
tangential N1/P2 source activity has been associated with low levels of serotonergic 
neurotransmission in humans (Hergerl & Juckel, 1993).
A major limitation of these studies is that, even if they demonstrate decreased 
numbers of serotonin cells and reduced serotonin system function in the brains of 
MDMA users, they cannot prove that the MDMA use necessarily caused the changes.
The alterations in serotonin function may have been present before the drug use began or, 
alternatively, they may have contributed to the initiation of drug use (Kalant, 2001). 
However, several studies have shown that the degree of change in serotonin function is 
proportional to the duration and intensity of the preceding use of MDMA. This finding is 
more compatible with the MDMA use being the cause rather than the consequence of 
impaired serotonin function.
Although none of the studies whether animal or human have proven without a doubt 
that MDMA is exerting long-term or permanent neurotoxic effects on serotonergic 
neurons, all of the experimental results presented above appear to converge on that 
notion. Evidence from both animal and human studies strongly suggest that MDMA
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produces a lasting decrease in serotonergic activity by permanently disrupting its neuron 
terminals. The animal and human MDMA studies carried out thus far have made a great 
deal of progress toward clarifying MDMA’s neurotoxic effects. However, much more 
still needs to be done in order to elucidate the whole MDMA picture, including its exact 
neurotoxic effects and the dosages, which bring about those effects. Nevertheless, the 
fuzzy MDMA picture painted so far is enough to raise real concerns over the escalating 
MDMA usage seen in the 1990’s and 2000’s. In conclusion, individuals who use MDMA 
as a recreational drug may be putting themselves at risk of developing permanent brain 
serotonergic system injuries.
Evidence that MDMA Induces Residual Effects on Cognition
If MDMA induces neurotoxic effects in serotonergic neurons, functional changes can 
be expected in psychological functions that are related to serotonergic processes. 
Learning and memory are two such processes. There is some evidence that repeated 
treatment of rats with high doses of MDMA produces persistent impairments in learning 
and memory. For instance, MDMA-induced 73 percent depletion of neocortical 
serotonin, which resulted in a mild impairment of the ability to develop an efficient 
search strategy in a place-havigation task (Robinson et al., 1993). Furthermore, a 
selective, delay-dependent deficit in delayed non-match to place performance developed 
12 days after rats were exposed to high doses of MDMA for three days (Marston et al.,
1999).
There is evidence that suggests human recreational MDMA users may display 
residual cognitive dysfunction. Some studies have observed that recreational ecstasy
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users perform more poorly than other drug users and non-drug users on tests of visual- 
spatial and verbal working memory, as well as executive function (e.g.. Fox et al., 2002; 
Gouzoulis-Mayffank et al., 2000; Montgomery et al., 2005; Morgan, 2002; von Gesuau et 
al., 2004; Wareing et al., 2004; Wareing et al., 2000; Zakzanis & Yoimg, 2001).
However, the most robust finding in the MDMA literature is that recreational ecstasy 
users exhibit a selective deficit in verbal learning and memory performance (e.g., 
Bhattachery & Powell, 2001; Bolla et al., 1998; Curran & Verheyden, 2003; Fox et al., 
2001; Gouzoulis-Mayfrank et al., 2000; Krystal et al., 1992; McCann et al., 2001; 
McCardle et al., 2004; Morgan, 1999; Parrott & Lasky, 1998; Parrott et al., 1998; 
Quednow et al., 2006; Reneman et al., 2001 ; Rodgers, 2000; Verkes et al., 2001 ; Yip & 
Lee, 2005; Zakzanis & Yoimg, 2001). Moreover, there appears to be a dose-dependent 
relationship between memory problems and extent of ecstasy use, such that higher 
cumulative lifetime dose of ecstasy is associated with lower memory scores.
Bolla et al. (1998) compared 24 abstinent MDMA users who had used MDMA on at 
least 25 occasions (and had abstained from use for >2 weeks) and 24 control subjects 
matched for age, gender, level of education, vocabulary score, and prior drug use (had no 
self-reported prior use of MDMA, but other drugs were used). Subjects were assessed on 
the Rey-Auditory Verbal Learning Test (AVLT), the Wechsler Memory Scale-Revised 
(WMS-R) and the Rey-Osterrieth Complex Figure (RCF) tasks. Bolla and colleagues 
(1998) found that greater use of MDMA (in terms of total mg/per month) was associated 
with greater impairments in immediate verbal memory and delayed visual memory. The 
relation among CSF 5-HIAA, average total MDMA per dose per month, and memory 
function were also analyzed. The mean concentration of 5-HIAA in the CSF was lower in
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the MDMA users compared to control subjects and CSF 5-HIAA levels decreased with 
increasing MDMA dose. Furthermore, the lower CSF 5-HIAA concentrations resulted in 
worse memory performance. These data suggest that MDMA-induced brain serotonin 
neurotoxicity might account for the observed memory deficits.
Morgan (1999) utilized subtests of the Rivermead Behavioral Memory Test (RBMT), 
to investigate immediate and delayed recall. He asked MDMA users and controls to listen 
to a brief, audio-taped news story o f five sentences and 65 words and then write down as 
much o f what they had heard as possible, immediately after the story and again 40 
minutes later. Members o f the MDMA group, all o f whom had taken the drug on at least 
20 occasions, but were abstinent from all psychoactive drugs on the day of the study, 
scored substantially lower than either the polydrug group or non-drug group on both 
immediate and delayed recall. Though the analysis found that there was no correlation 
between the amount of MDMA taken over an individual’s lifetime and memory 
performance, there was a trend suggesting that the immediate recall abilities might be 
related to the average dose taken per occasion.
Other neuropsychological test batteries yield similar findings with regard to cognitive 
fimction. For example, McCann et al. (1999) assessed cognitive performance in 22 
MDMA users (who had used MDMA on at least 25 separate occasions) and 23 control 
subjects (who had never used MDMA) using a computerized version o f the Walter Reed 
Army Institute of Research Performance Assessment Battery (WRAIR PAB).
The test battery consisted of seven tests designed to assess a variety o f psychomotor 
and cognitive fimctions, including the Time Wall task, the Serial Add and Subtract test, 
the Logical Reasoning Task, the Manikin task. Code Substitution, the Matching to
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Sample task, and the Delayed Recall test. CSF 5-HIAA measures were also obtained. 
Compared to control subjects, MDMA users who had abstained from drug use for at least 
three weeks had impaired performance deficits on four of seven cognitive tests in the 
WRAIR PAB. Specifically, performance deficits were found on a sustained attention task 
requiring arithmetic calculations, a task requiring visual discrimination and working 
memory, a short-term memory task, and a task of semantic recognition and verbal 
reasoning. Performance deficits on the working memory task were directly associated 
with the extent of prior MDMA use. Significant reductions in CSF 5-HIAA (the major 
metabolite o f 5-HT) concentrations were also observed in ecstasy users relative to 
controls. McCann et al.’s (1999) findings extend those from previous investigations 
demonstrating deficits in verbal and visual memory in MDMA users to include a variety 
of different psychomotor, perceptive and cognitive tasks (e.g., Curran & Travill, 1997; 
Parrott et al., 1998).
The evidence that impaired serotonergic function may be associated with memory 
deficits in recreational ecstasy users is further extended by correlations between 
alterations in cortical serotonin 5-HT2a receptor binding (Reneman et al., 2000), altered 
D-fenfluramine-induced cortisol responses (Verkes et al., 2001), altered tryptophan 
metabolism (Curran & Verheyden, 2003), and memory deficits. For example, Reneman 
et al. (2000) demonstrated higher overall serotonin 5-HT2a receptor binding ratios in the 
brains of an ecstasy user group compared to control subjects. These differences reached 
statistical significance in the occipital cortex, and the authors suggested that the increased 
binding was due to MDMA-induced serotonin depletion resulting in an upregulation of 
serotonin 5-HT2a receptors. The ecstasy users also demonstrated a significant impairment
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in delayed recall as measured by the AVLT, which directly correlated with the increase in 
serotonin 5-HT2a receptor binding ratios (Reneman et al., 2000). Verkes et al. (2001) 
demonstrated a significantly reduced cortisol response to D-fenfluramine in ecstasy users 
compared to control subjects. In addition, ecstasy users also had significantly longer 
reaction times to visual and auditory stimuli, lower visual recall, and lower working 
memory scores. The reduced cortisol response was demonstrated to correlate 
significantly with visual recall scores, indicating a significant association between 
chronic ecstasy use, diminished memory performance, and serotonergic neuroendocrine 
functional deficits (Verkes et al., 2001).
Furthermore, Curran and Verheyden (2003) observed increased plasma tryptophan 
levels following a tryptophan challenge (an indirect method of assessing the integrity of 
serotonin function) in ex-ecstasy users (ex-users had stopped using ecstasy for at least a 
year and on average, 2.4 years), which correlated very highly with ex-users poorer 
immediate and delayed prose recall. Elevated plasma levels of tryptophan may imply 
there is a disruption in tryptophan metabolism in ex-ecstasy users. If tryptophan is not 
metabolized into serotonin, then the concentration of tryptophan in the brain will 
increase, thereby reducing the transport gradient between the brain and plasma resulting 
in elevated levels of plasma tryptophan (Curran & Verheyden, 2003). This decreased 
metabolism may, therefore, reflect alterations in serotonin function in ex-users. In 
conjunction with findings from non-human primates (Hatzidimitriou et al., 1999), it is 
possible that this relates to degeneration o f serotonin axonal terminals.
Other memory investigations have attempted to assess whether long-term ecstasy use 
or long-term marijuana use is responsible for the memory impairment often observed in
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recreational ecstasy users (e.g., Croft et al., 2001; Dafters et al., 2004; Gouzoulis- 
Mayffank et al., 2000; Halpem et al., 2004; Lamers et al., 2006; Quednow et al., 2006; 
Rodgers, 2000; Simon & Mattick, 2002). For example, in a well-controlled study, 
Gouzoulis-Mayffank et al. (2000) compared three groups of 28 subjects; ecstasy users 
(average lifetime dose of 93 tablets), marijuana users, and non-drug users. The marijuana 
group had the same exposure to marijuana as the ecstasy group, but no other regular drug 
use. The groups were well-matched for age, sex and education (with slightly lower 
education in ecstasy users).
A cognitive test battery was administered. Memory was assessed using a German 
version of the AVLT (delayed recall was not assessed), the digit span forward/backward 
task to tap working memory and a visual memory task. Test scores in all three groups 
were within the normal range. Ecstasy users scored significantly lower than non-drug 
controls in immediate verbal and visual recall and in working memory (digit span 
backward), and required more repetitions to learn the AVLT word list. Subsequently, the 
ecstasy group also performed worse than the marijuana users in immediate visual recall 
and required more repetitions to learn the word list. Ecstasy users further showed poorer 
performance than the other two groups in tests of selective attention, logical thinking, 
problem solving and general knowledge. Decreasing immediate verbal recall and 
working memory performance correlated with increasing lifetime doses of ecstasy. An 
increasing ffequency of marijuana use correlated with an increasing number of repetitions 
required to learn the word list. Taken together, theses findings indicate that poorer 
memory performance in ecstasy users may not be solely accounted for by concomitant 
marijuana use.
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Like Gouzoulis-Mayfrank et al. (2001), findings from Rodgers (2000) study suggest 
that marijuana use may be responsible for some proportion of the impairment seen in 
ecstasy users verbal memory performance. Three groups of 15 subjects were recruited: 
ecstasy users (mean ecstasy use o f 20 tablets), exclusive marijuana users, and non-drug 
users. All groups were matched for age, sex and education. Marijuana and ecstasy users 
were matched for their marijuana use. The marijuana users had consumed marijuana four 
days a week for about 11 years and the ecstasy users had consumed marijuana for about 
ten years. With regard to drugs other than ecstasy and marijuana, the ecstasy group was 
not matched to the other groups.
Memory was assessed with the Wechsler Memory Scale (WMS), which includes 
measures for verbal and visual memory (both immediate and delayed). A further series of 
tasks assessed basic and complex reaction time. Ecstasy users scored lower than controls 
in one test of immediate verbal recall, which required them to retell brief stories from 
memory, but not in another one that required memorizing associated word pairs. 
Marijuana users showed the same pattern of significantly lower scores in the former, but 
not the latter test for immediate verbal recall. Ecstasy users were also substantially worse 
than controls and marijuana users in tests of verbal and visual delayed recall. In the 
delayed story recall condition, both ecstasy and marijuana users scored significantly 
worse than controls. No group differences were found in tests of immediate visual 
memory, attention, and basic and complex reaction time.
One major concern with this study is in the extent of use of marijuana and ecstasy in 
the ecstasy users. The ecstasy users were very light users of ecstasy (mean = 20 tablets), 
but very heavy users of marijuana. It seems more appropriate to say that this study tested
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regular marijuana users with an occasional use of ecstasy, then to speak o f ecstasy users 
with concomitant marijuana use. From this perspective, the fact that the additional light 
ecstasy use in one of the marijuana groups was associated with lower scores in delayed 
memory performance above those seen in exclusive marijuana users seems remarkable. 
The main suggestion offered by this work is that marijuana use could be responsible for 
some proportion of the lowered memory scores (particularly in immediate verbal recall), 
but that additional, even moderate ecstasy use, can extend the impact on memory to 
include delayed memory performance.
This view is in partial agreement with Gouzoulis-Mayfrank et al. (2000) who reported 
that marijuana use is likely to have affected cognition and to have contributed to some 
extent to the poorer performance o f ecstasy users. However, in the Gouzoulis-Mayfrank 
et al. study, marijuana users did not perform significantly worse than non-drug controls. 
The reason for this may be that their use o f marijuana, although comparable in frequency 
to the marijuana users in Rodgers’ (2000) study had spanned only three years compared 
to 11 years.
Croft et al. (2001) compared the cognitive performance of 11 ecstasy users with 
concomitant marijuana use with 18 ecstasy-naive marijuana users and 31 non-drug user 
controls. Ecstasy and marijuana users had both used a substantial amount o f marijuana 
(10,965 V. 7,762 lifetime joints). Long-term memory performance was assessed using the 
Coughlin List and Design Learning Test and a facial recognition test. Other cognitive 
tests were included in the test battery (forward/backward digit span, verbal fluency, 
spatial associative learning, the Stroop test, a pegboard test). The only difference between 
ecstasy users and marijuana users were higher scores in design learning and the pegboard
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test in the ecstasy group. The pooled ecstasy and marijuana groups performed worse than 
the non-drug controls in tests for auditory verbal learning, immediate and delayed recall, 
forward and backward digit span, face recognition, as well as in non-memory tests 
including spatial associative learning, verbal fluency, and the Stroop test for speed of 
processing.
Most interestingly, when statistically removing the effect of marijuana use none of 
the significant differences remained except for in the Stroop test for speed o f processing. 
This means all but one difference in cognitive test performance between the drug using 
subjects and the controls could be statistically accounted for by marijuana use, while 
ecstasy use only accounted for the difference in the Stroop test. This finding suggests that 
concomitant marijuana use may be responsible for much, if not all of the cognitive 
differences between ecstasy users and control subjects that have been reported thus far. 
However, an alternative explanation for this result is that MDMA did cause cognitive 
impairment, but the lack of difference between the MDMA-marijuana and marijuana- 
only group was due to some interaction between the drugs. Croft et al. (2001) have 
suggested that marijuana might attenuate the effects of ecstasy through marijuana-related 
dopamine down regulation thereby exerting neuroprotection against MDMA-induced 
serotonergic deficits.
Nevertheless, the Croft et al. (2001) study clearly shows the need to adequately 
control for marijuana use in fiiture studies. In that respect it adds to the studies of 
Rodgers (2000) and Gouzoulis-Mayfrank et al. (2000) that already demonstrated an 
involvement o f marijuana in verbal memory deficits found in ecstasy users. However, an 
important difference with the latter studies is that Croft et al. (2001) found no relative
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impairment o f the ecstasy users compared to the marijuana users, while Gouzoulis- 
Mayfrank et al. (2000) and Rodgers (2000) found poorer verbal learning and recall, as 
well as visual recall in ecstasy plus marijuana users compared to marijuana but not 
ecstasy users. Thus, although the jury is still out on this, it seems that the putative effects 
of ecstasy use on cognitive performance can extend beyond those of marijuana use (given 
the particularly careful methodology of the Gouzoulis-Mayfrank et al. (2000) study). 
However, this does not preclude the possibility that a substantial part of the observed 
cognitive differences may be the consequence of regular marijuana use.
Other, more recent investigations corroborate Croft et al.’s (2001) finding of no 
significant differences between ecstasy and marijuana users verbal memory performance, 
after controlling for marijuana use (e.g., Dafters et al., 2004; Halpem et al., 2004; Lamers 
et al., 2006; Simon & Mattick, 2002). These investigations have found that marijuana 
users, whether or not they also used ecstasy, exhibit significant impairment in memory 
fimction when compared to the non-drug user controls. However, there is no significant 
difference between the ecstasy and marijuana users.
There are, o f course well-designed investigations that have controlled for marijuana 
use and demonstrated verbal memory deficits are more closely associated with ecstasy 
use, rather than marijuana. For example. Yip and Lee (2005) observed large deficits in 
both immediate and delayed recall performance on a Chinese version of the AVLT, in a 
large sample of ecstasy users (N = 100). Moreover, these researchers were able to recruit 
exclusive ecstasy users (no other illicit drug use) because ecstasy use had only recently 
become a popular trend in Hong Kong.
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What’s more interesting is that Yip and Lee (2005) observed deficits in ecstasy users 
with relatively low lifetime ecstasy consumption. Ecstasy users had on average consumed 
35.8 tablets (range 16 to 60 tablets). The only other study to report significant deficits in 
ecstasy users with such a low average use of ecstasy was McCardle et al. (2004), but the 
deficit detected was only 7 percent (ecstasy users = 11.18 words versus polydrug users = 
12.13 words on the AVLT).
Like Yip and Lee (2005), Quednow et al. (2006) conducted a well-designed study 
that supports the claim that deficits in delayed recall performance in recreational ecstasy 
users are attributable to ecstasy use instead of marijuana. Quednow and colleagues (2006) 
examined AVLT performance in three groups of 19 male participants: abstinent ecstasy 
users, abstinent marijuana users and non-drug users. The comparison with a control group 
of marijuana users allowed these researchers to estimate the influence of concomitant 
marijuana use in ecstasy users.
Ecstasy users showed widespread marked verbal deficits compared to non-drug user 
controls, as well as compared to marijuana users, whereas marijuana users’ memory 
performance did not differ from controls subjects. Ecstasy users revealed impairments in 
learning, consolidation, recall and recognition. In addition to that, they have also 
displayed a worse organization of memory information which is reflected in a high 
inconsistency of recall and a diminished retroactive interference, which is expressed by a 
high loss after interference. The ecstasy users also did show slightly worse performance 
in the supraspan (AVLT-trial 1), which may indicate a moderate deficit in working 
memory. These results remained significant after statistically covarying for marijuana use 
and verbal IQ.
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Taken together, the findings are mixed with regard to whether long-term ecstasy use 
or long-term marijuana use is responsible for the changes sometimes observed in ecstasy 
users. Interpretation of the positive findings of verbal memory deficits are questionable, 
however, because they are complicated by methodological shortcomings and potentially 
confounding variables that may have contributed to the deficits observed. For instance, a 
number of the earlier memory studies that demonstrated impairment did not adequately 
match samples of ecstasy users and control participants with regard to pre-morbid 
intellectual function, education level, gender and age. More recent studies have attempted 
to correct for such differences by matching participants.
In addition, much of the earlier research provides little specific consideration for the 
concomitant use of other illicit drugs by ecstasy users, especially marijuana. A large 
number of ecstasy users have also used a substantial quantity of marijuana. 
Neuropsychological studies have reported that the heavy chronic use of marijuana may 
produce subtle deficits in attention and verbal learning and memory (e.g.. Block & 
Gonheim, 1993; Fletcher et al., 1996; Hall & Solowij, 1998; Messinis et al., 2005; 
Millsaps et al., 1994; Pope et al., 1996; Solowij et al., 2002). The severity o f marijuana- 
induced impairment appears to depend on the duration and the frequency of marijuana 
use (e.g.. Holla et al., 1998; Hall & Solowij, 1998; Solowij et al., 2002). To some degree 
then, the question remains as to whether cognitive deficits in ecstasy users are attributable 
to ecstasy itself or to marijuana.
Alternatively, recent work with male wistar rats suggests that MDMA and THC (the 
main psychoactive component in marijuana) may interact synergistically, such that the 
combined effect of MDMA and THC is greater than the sum of their individual effects
66
(Morley et al., 2004; Young et al., 2005). For instance. Young and colleagues (2005) 
observed a greater acute impairment in working memory performance in rats that were 
co-administered both MDMA and THC relative to rats that received either drug alone.
In contrast, Morley et al.’s (2004) findings revealed positive synergistic effects of 
MDMA and THC. When THC was administered with MDMA, THC at high doses 
attenuated the typical negative effects associated with MDMA up to six weeks following 
drug administration. For example, Morley et al. (2004) found that THC reduced body 
temperature, serotonin depletion in the hippocampus, amygdala and prefi^ontal cortex, as 
well as reduced anxiety.
Executive Function
Executive functions are general-purpose control mechanisms that modulate the 
operation of various cognitive subprocesses and thereby regulate the dynamics of human 
cognition (Miyake, Friedman, Emerson, Witzki, & Howerter, 2000). It is proposed that 
these functions make possible the anticipation of and establishment of goals, the 
designing of plans, the self-regulation and monitoring of tasks, the appropriate selection 
of, organization and sequencing of behaviors in space and time, the monitoring of 
behavior with regard to affective and motivational states, adaptive decision-making, and 
effective execution and feedback (Damasio, 1994).
Executive functions have been neuroanatomically associated with different neural 
interaction pathways involving the prefrontal cortex (Roberts, Robbins, & Weiskrantz, 
1998). In particular, the dorsolateral portion of the prefrontal cortex (DLPFC) is the area 
that seems to be involved in executive function. Moreover, the psychopharmacological
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literature suggests that DLPFC function is underpinned by dopaminergic systems, which 
are in turn modulated by serotonin activity. Given that MDMA affects serotonin activity, 
this raises the possibility that MDMA disrupts the modulating role of serotonin in the 
DLPFC.
Indeed, there is evidence, which suggests that MDMA use may be associated with 
selective impairments in executive function, and like the findings on memory 
performance, it appears that increases in MDMA consumption might relate to more 
pronounced impairment in executive function. For example, in their assessment of 26 
MDMA users (a minimum consumption of 10 ecstasy tablets was required with at least 
one occasion in the most recent year) and 33 non-users, von Geusau et al. (2004) found 
that MDMA users performed significantly worse on tasks that tapped cognitive flexibility 
(i.e., Dots-Triangles test and Local-Global test). Moreover, male MDMA users 
performed poorly on the cognitive flexibility task and made more perseverative errors 
whereas no significant difference were found in female MDMA users relative to control 
subjects. Significant differences between male MDMA users and controls were also 
found on the complex executive function tasks (i.e., WCST and Tower of London 
(TOL)). In the WCST, users performed worse on virtually all the dependent measures 
(e.g., total number of correct responses, number of perseverative errors). This finding is 
consistent with those reported by Fox et al. (2001), who also observed more errors of 
perseveration in MDMA users on the TOL task.
Verdejo-Garcia et al. (2005) analyzed the relationship between severity of 
consumption of different drugs and performance on tasks sensitive to impairment in the 
executive subprocesses of working memory, response inhibition, cognitive flexibility,
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and abstract reasoning in a sample of 38 detoxified polydrug abusers. A significant effect 
of MDMA was found on the working memory and analogical reasoning components of 
executive function.
In another study, Zdczanis and Young (2002) observed that MDMA users scored 
appreciably lower on the Behavioral Assessment of Dysexecutive Syndrome, a test 
designed to measure mental organization, planning strategies, thinking ahead, mental rule 
formation, and the estimation of temporal activities. In addition, several significant 
product moment correlations were found suggesting that increases in MDMA 
consumption may relate to more pronounced impairment in executive function. Similarly, 
Semple et al. (1999), using the Spatial Working Memory subtest of the Cambridge 
Neuropsychological Test Automated Battery (CANTAB), Trail Making Test (Part B), 
phonemic word fluency, and the Stroop task to examine executive function in abstinent 
ecstasy users found that larger lifetime doses of MDMA were associated with more errors 
on the Spatial Working Memory test.
Wareing and colleagues (2000; 2004), utilizing a random letter-generating task 
sensitive to the central executive of working memory, also showed that recreational users 
of MDMA generated fewer letters and exhibited a greater degree of redundancy and a 
greater number of intrusions. Subsequently, Gouzoulis-Mayfrank et al. (2000), 
employing a digit span backward task demonstrated impairments that persisted for at 
least six months after abstinence in ecstasy users.
In contrast to the above-mentioned findings, other researchers have failed to observe 
impairments in executive function in MDMA users. For instance. Fox et al. (2002) 
examined the neuropsychological performance of 20 MDMA polydrug abusers and 20
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non-MDMA polydrug abusers who had never taken ecstasy, on a computer-assisted 
neuropsychological battery designed to assess memory and executive functioning. Both 
groups had remained abstinent for a minimum period of two weeks. Their results showed 
significant differences in performance of the polydrug ecstasy abusers on tasks of visual 
short-term memory, working memory, and verbal fluency. Although working memory 
and fluency processes have been associated with prefrontal executive deficits, the 
polydrug ecstasy group did not show significant impairments on other tasks designed to 
evaluate planning, impulse control, or decision-making abilities. The authors interpreted 
their results in terms of a selective profile of temporal dysfunction.
Subsequently, Gouzoulis-Mayfrank et al. (2003) compared the performance of 60 
abstinent MDMA users (30 heavy users and 30 moderate users) and 30 non-user controls 
on tests aimed to judge general intelligence, memory, working memory, and executive 
control processes. They reported that heavy ecstasy users were significantly impaired 
compared to moderate users and healthy controls, in the general intelligence and memory 
domains whereas these users did not show significant impairments on tests of planning, 
impulse control, and working memory. However, memory deficits were still significant 
when general intelligence was included as a covariate and they were significantly related 
to a measure o f frequency of MDMA use.
Likewise, Thomasius et al. (2003) compared a group of 31 former ecstasy users who 
quit using ecstasy at least 20 weeks before the study, a group of 29 polydrug users who 
had never taken ecstasy and were asked to abstain from consumption for at least six days 
and a group of 30 healthy controls on neuropsychological tests of intelligence, learning, 
and memory, divided attention, impulse control, and mental flexibility. Results showed
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that former ecstasy abusers were significantly more impaired in memory functions and 
that polydrug, non-MDMA users made significantly more preservative errors on the 
WCST. Finally, no significant group differences were detected on premorbid intelligence 
and complex attention. Finally, Simon and Mattick (2002) did not detect significant 
differences between 40 ecstasy users asked to abstain for a minimum of 24-hours and a 
group o f 37 controls and novice ecstasy users on the Wechsler Memory Scale-Ill (WSM- 
III).
Taken together, the available evidence seems to suggest that sustained MDMA 
consumption incurs a selective impairment on the cognitive flexibility component of 
executive function (as shown by performance on switch tasks and the WCST). Moreover, 
heavy ecstasy users appear to exhibit greater impairment, relative to moderate users and 
drug naive controls. Thus, the recreational use o f ecstasy may result in deficiencies in the 
adaptive ability to adjust behavior in response to changing environmental demands.
Methodological Challenges
While the neuropsychological data strongly suggests that MDMA damages the central 
serotonergic system and produces long-lasting behavioral deficits, there are a number of 
methodological challenges. These challenges are not unique to MDMA investigations but 
are common problems in all drug research involving human subjects. Nevertheless, this 
makes it difficult to unequivocally prove a cause and effect relationship between MDMA 
use and specific psychological damage in humans.
A fundamental difficulty in such research is knowing how to interpret the causality of 
associations between outcome measures and recreational use of MDMA. Any differences
71
between MDMA users and nonusers could indicate either a persistent effect of exposure 
to the drug or pre-existing differences between the two groups. It is possible that there is 
a biologically vulnerable set of individuals whose use of MDMA and other psychoactive 
substances reflects preexisting predispositions to such use. High levels of impulsivity and 
other related personality traits could be a predisposing factor. Individuals with low 
serotonergic function may be more impulsive and thus more predisposed to using 
MDMA and other drugs (Ricaurte et al., 2000). In fact, they may be equally depressed 
and predisposed to using drugs (Reneman et al., 2000). Furthermore, differences in 
memory function and indirect measures of serotonin activity (e.g., 5-HI A A levels in CSF 
and serotonin transporter density) between MDMA users and non-users may also have 
existed before the onset o f substance use. For example, individuals with low 5-HIAA 
levels may both have memory problems and be predisposed to MDMA use (McGuie, 
Cope, & Fahy, 1994).
Another major concern is that few clinically based controlled prospective studies 
have been performed. Most of the controlled studies have been conducted, 
retrospectively, on small numbers of subjects, who have consumed widely varying 
amounts of MDMA tablets. Given that there is little quality control of street drugs, most 
investigations provide only an estimate at best when calculating each subjects MDMA 
intake. Thus, there has been no control over MDMA administration nor has there been 
confirmation of the dose or purity of MDMA consumed. Published reports (e.g., Schifano 
et al., 1998; Wolff, Hay, Sherlock, & Conner, 1995), however do suggest that the 
majority of tablets sold as “ecstasy” in fact contain MDMA.
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The method of self-report, which relies on the drug user’s recollection of prior drug 
experience, is also an issue. Self-report of drug taking behavior in drug users is 
notoriously unreliable (Parrott, 2000). Memory for how much and how often MDMA is 
actually consumed over many years is likely to be undependable.
Most ecstasy users are polydrug users, which raises the possibility that one or several 
o f these other drugs are responsible for decrements in performance. MDMA users have a 
tendency to use a variety of illicit substances, including amphetamine, cocaine, ketamine, 
LSD, sedatives (e.g., opiates), and especially, marijuana (Fox et al., 2001; Milani et al., 
2000). Preliminary investigations of recreational MDMA users did not collect data on 
other illicit substances (e.g., Curran & Travill, 1997; Parrott, 1997). Researchers have 
since refined their methodology to control for the problem of polydrug use by using a 
control group comprising individuals who have never used MDMA, but who otherwise 
have closely matched histories of using other drugs of abuse.
The recruitment of subjects is another methodological concern. MDMA users tend to 
be exclusively recruited through targeted sampling techniques, by advertising for 
volunteers or through word of mouth. This is problematic because it introduces an 
unknown bias into each study, since it is possible that these self-referred individuals are 
not representative of MDMA users as a whole. Ideally, researchers would like to be able 
to study MDMA’s effects in drug naïve individuals, but, given the ethical issues involved 
in conducting such studies, there is little likelihood of studying MDMA’s effects on 
substantial numbers of volunteers.
Finally, the applicability of the animal neurotoxicity evidence to human subjects has 
been contested, largely because the dosage used in animal experiments is perceived to be
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much higher than that taken by humans (Ricaurte et al., 2000). The lowest MDMA dose 
reported to elicit long-term structural damage in serotonergic neurons of non-human 
primates is 10 mg/kg subcutaneously daily for four days (Gouzoulis-Mayfrank et al.,
2000). According to principles o f interspecies scaling, this is equivalent to 1.4 mg/kg in 
humans (Ricaurte et al., 2000), an amount similar to that used for recreational purposes 
(Burgess, O’Donohue, & Gill, 2000).
Despite the many methodological concerns, the pattern of cognitive dysfunction seen 
in the frontal cortex (i.e., impulsivity and impaired higher executive processing) and the 
hippocampus (i.e., memory deficits) in human MDMA users is consistent with damage 
that has been found in animals exposed to MDMA (Volkow et al., 2001).
Directions for Future Research
All of the methodological shortcomings with the previous research, outlined earlier, 
should be addressed in future studies. It might be possible, in the future, to randomly 
select a large sample of individuals with different patterns of drug use and then 
investigate the persistent psychological consequences of a variety of different illicit drugs 
simultaneously. Researchers should also attempt to corroborate self-reported current drug 
use and prior drug use with urine and hair analysis. If it is not possible to recruit 
exclusive ecstasy users, investigators should consider employing a design that facilitates 
the statistical control of previous use of other illicit drugs (e.g., Morgan, 1999).
A prospective, randomized study of the chronic effects of pharmaceutical MDMA 
would be necessary to definitively determine its persistent effects on human behavior, but 
ethical and legal constraints prevent such a study, at least in the United States. It may be
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possible in the future, however, to conduct a prospective study on the long-term 
psychological consequences of recreational MDMA use. For example, it might be 
possible to assess a large sample of adolescents before they have taken ecstasy and then 
again at subsequent time points, on the assumption that some proportion will go on to 
experiment with the drug. However, this type of study is not without ethical issues.
Future research should also explicitly investigate which aspect o f recreational ecstasy 
use plays the most significant role in determining subsequent persistent psychological 
problems. The results of some of the studies reviewed earlier suggest that a gross 
estimate of lifelong exposure to ecstasy can predict the risk of future persistent 
psychological problems. But it is likely that the pattern of use also plays a significant 
role. For example, Topp et al. (1999) have reported that young, female polydrug users, 
and those who have binged on ecstasy for 48 hours or more, appeared most at risk for 
experiencing harm that they attributed to their ecstasy use. Thus, it was useful to further 
investigate the relationship between ecstasy exposure variables, (for example, total past 
ecstasy dose, average monthly dose, frequency of use, and bingeing) and cognitive 
dysfunction and determine if risk factors for the development of ecstasy-related cognitive 
deficits can be identified (for example, gender, IQ, and psychiatric history).
There is also a pressing need for more information concerning the longevity of the 
psychological impairments exhibited by heavy ecstasy users. Clearly, longitudinal studies 
designed to follow ecstasy users, both as they continue to use the drug and after they have 
stopped using it are needed. Such studies would give important insight into how age and 
length of use affect ecstasy’s acute and long-term neurochemical toxicity. In addition, 
such studies would allow researchers to determine if deficits appear later in life, long
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after use stops, or if adverse effects diminish over time. Such studies, if  designed with 
regular assessment intervals, might also allow researchers to develop better measures of 
MDMA toxicity, and to more accurately determine how much drug is used and in what 
circumstances.
In addition, little is presently known about the decline of serotonergic function in 
humans over the life span. One possible direction for future research would be to 
compare markers of serotonin transporter binding in healthy young individuals with those 
of healthy older individuals with SPECT or PET. Finally, other neuroimaging techniques, 
such as fMRI and EEG are required to investigate the effects of experimentally 
manipulated serotonin neurotransmission on brain activity and cognitive function in 
ecstasy users.
Summary and Conclusions
Since the late 1980s recreational use of ecstasy has become increasingly popular. We 
now know much about the pharmacology of this drug in experimental animals, both in 
terms of its acute actions and its longer-term neurotoxic effects. In general, MDMA’s 
effects are consistent across species, with the exception of the mouse. Importantly, its 
acute effects in humans are also very similar to those seen in experimental animals. What 
is uncertain is whether the clear and consistent long-term neurotoxic effects seen in 
animals can and do occur in humans. There are data suggesting that damage may occur in 
the human brain and this should be cause for concern. It appears that adverse effects 
(both acute and long-term) are related to both dose and frequency of administration.
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The major problems in investigating the effects of MDMA are the facts that 
prospective studies are generally unethical, so retrospective studies must be performed, 
the purity of the ingested drug, the doses taken, and frequency of administration are 
unknown, and many of the subjects are polydrug users either by choice or unknowingly 
because of the impure nature of the tablets ingested.
Marijuana
Marijuana or marijuana has been used for centuries, for its medicinal and euphoric 
properties, and its fibers, to make hemp cloth and paper. Medicinally, between 1850 and 
1942, it was prescribed in the United States Pharmacopeia as a remedy for a variety of 
ailments including gout, tetanus, depression, and cramps (Farthing, 1992). Today, it is 
used for reducing intraocular pressure due to glaucoma, as an anti-emetic to relieve 
nausea associated with chemotherapy and as an appetite stimulant for AIDS patients. 
Recreationally, marijuana is the most widely used illicit drug, especially among young 
adults (Chan, Hinds, Impey, & Storm, 1998). According to the 2003 National Survey on 
Drug Use and Health (NSDUH), more than 94 million Americans (40 percent) age 12 
and older have tried marijuana at least once.
Marijuana contains chemicals called cannabinoids, including cannabinol, cannabidiol, 
cannabinolidic acids, caimabigerol, cannabichromene, and several isomers of delta 9 
tetrahydrocannabinol (THC). One of these isomers, delta 9-THC is believed to be 
responsible for most of the characteristic psychoactive effects of marijuana.
Marijuana refers to the leaves and flowering tops of the marijuana plant. The buds of 
the marijuana plant are often preferred because of their higher THC content. Hashish
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consists of the THC-rich resinous secretions o f the plant, which are collected, dried, 
compressed and smoked. Hashish oil is produced by extracting the cannabinoids from 
plant material with a solvent. In the U.S., marijuana, hashish and hashish oil are Schedule 
I controlled substances.
Smoking remains the most efficient means of delivering THC and experienced users 
can titrate the dose by adjusting the frequency and depth of inhalation. A typical joint 
contains between 0.5 grams and one gram of marijuana. As little as two to three 
milligrams of available THC will produce a “high” in occasional users, but regular users 
may smoke five or more joints a day (Iversen, 2003). THC or marijuana extracts may 
also be taken orally in fat-containing foods (e.g., brownies), but marijuana is mostly 
smoked because this is the easiest way to achieve the desired psychoactive effects.
Metabolism o f Cannabinoids
Different methods of using marijuana lead to differing absorption, metabolism and 
excretion of THC. When smoked, THC is absorbed from the lungs into the bloodstream 
within minutes. It is first metabolized in the lungs, and then in the liver where it is 
transformed into a number of metabolites. THC rapidly disappears from the blood plasma 
and is taken up in fat where it remains with a half life decay rate of five to seven days. 
This means that after a single dose of THC, less than one percent of the primary active 
ingredient remains in fatty tissue after approximately 35 to 50 days (Nahas, 1984). When 
swallowed, THC takes one to three hours to enter the bloodstream delaying the onset of 
psychoactive effects (Tart, 1970).
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THC and its metabolites account for most of the psychological effects of marijuana. 
Peak blood levels of THC are usually reached within ten minutes of smoking and decline 
to about five to ten percent of their initial level within an hour. This rate o f decline 
reflects the rapid conversion of THC to its metabolites and the distribution of THC to 
fatty tissues including the brain. THC and its metabolites are lipophilic or highly fat 
soluble and readily cross the blood-brain barrier. They may remain in the fatty tissues of 
the body for long periods of time. THC and its metabolites accumulate in the body 
because of their slow rate of clearance. Thus, they may be detected in the blood for 
several days and traces may persist for several weeks.
The acute toxicity of cannabinoids is very low. There are no confirmed published 
cases worldwide of human deaths from marijuana poisoning, and the dose of THC 
required to produce 50 percent mortality in rodents is extremely high compared with 
other commonly used drugs (Degenhardt, Hall, & Lynskey, 2003).
Cannabinoid Receptors
Two types of G-protein-linked cannabinoid receptors (CBi and CB2) have been 
identified. CBi receptors are expressed predominantly in neurons of the CNS, while CB2 
peripheral cannabinoid receptors appear to play an important immunomodulatory role the 
PNS.
Cannabinoid receptor activation is linked to inhibition of adenylate cyclase activity 
(Hewlett et al., 1991). Advances in cannabinoid pharmacology have generated a number 
of selective agonists and antagonists for these receptor subtypes (Pertwee, 1997). One of 
these compounds rimonabant (SR141716A), which acts selectively to block CBi
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receptors has been widely used in studies of the actions of cannabinoids in the CNS 
(Rinaldi-Carmona et al., 1998).
The distribution of cannabinoid receptors was first mapped in the rat brain by 
Herkenham et al. (1991). The mapping studies in the rat brain showed that CBi receptors 
are mainly localized to axons and nerve terminals in the CNS and are largely absent from 
the neuronal soma and dendrites. Consequently, cannabinoid receptors are predominantly 
pre-synaptic rather than post-synaptic.
In both animals and humans, there are high densities of CB| receptors in the fi'ontal 
regions of the cerebral cortex, the basal ganglia and in the cerebellum. A high density of 
cannabinoid receptors in the caudate nucleus and the cerebellum are consistent with the 
marked effects of cannabinoids on motor behavior. In addition, CBi receptors are found 
in particularly high densities in the limbic forebrain, including in the hypothalamus, the 
anterior cingulate cortex and the hippocampus (Herkenham et al., 1991). CBi receptor 
density is highest in the hippocampus, the brain structure known to be involved in human 
memory processes (Pertwee, 1999).
Within the hippocampus, CBi receptors are expressed at especially high densities in 
the dentate gyrus, CAl, and CA3 regions (Herkenham et al., 1991; Matsuda et al., 1990; 
Tsou et al., 1998). Furthermore, immunohistological staining has demonstrated that CB, 
receptors are found primarily on hippocampal GABAergic intemeurons (Katona et al., 
1999; Marciano & Lutz, 1999; Tsou et al., 1999). High densities of CB| receptors in 
limbic brain regions correlate with cannabinoids effects on perception, cognition, 
memory, learning, endocrine function, food intake, and regulation of body temperature
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(Hall & Pacula, 2003). CB2 receptors have been localized in the spleen, thymus and 
tonsils and on mast cells and plasmocytes (Matsuda et al., 1990).
In addition to cannabinoid receptors, the brain produces its own cannabinoid 
substances called endocannabinoids. Endocannabinoids are neurotransmitters that bind to 
the same receptors as marijuana, however, these compounds act with much shorter 
duration compared to marijuana because they are rapidly degraded by specific enzymes 
in the brain cells. Two endocannabinoid ligands, anandamide and 2-arachidonylglycerol 
(2-AG) have been identified suggesting the existence of a cannabinoid neuromodulatory 
system. Together with the cannabinoid receptors, this carmabimimetic system is thought 
to have a widespread role in fine-tuning a variety of brain fimctions, including 
nociception, control of movement, memory and neuroendocrine regulation (Iversen, 
2003).
It is noteworthy that the highest levels of anandamide are expressed in the 
hippocampus (Felder et al., 1996). Interestingly, Tomaso and colleagues (1996) have 
speculated that part of the pleasure of chocolate comes from anandamide. These 
researchers discovered three compounds in dark chocolate strongly resemble 
anandamide.
Mechanisms o f Action
Marijuana exerts its effects in the CNS by binding to the CBi receptor. The CBi 
receptor modifies the activity of several intracellular enzymes, particularly cyclic AMP 
(cAMP) whose activity is reduced. Less cAMP means less protein kinase A and the 
reduced activity of this enzyme affects the potassium and calcium channels, so as to
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reduce the amount of neurotransmitters released. Consequently, the general excitability of 
the brain’s neural networks is reduced.
However, in the reward circuit just as in the case of other drugs more dopamine is 
released. The reward circuit includes the ventral tegmental area (VTA), which is 
connected to the nucleus accumbens and the prefrontal cortex in the pathway where they 
communicate through neurons. The paradoxical increase in dopamine is explained by the 
fact that the dopaminergic neurons in this circuit do not have CBi receptors, but are 
normally inhibited by G ABA neurons that do have them. Marijuana removes this 
inhibition by the GABAergic neurons and thereby activates the dopamine neurons.
Does Marijuana Produce Dependence, Tolerance and Withdrawal?
Animals develop tolerance to the effects of repeated doses of THC (Compton et al., 
1991) and studies suggest that cannabinoids may affect the same reward system as 
alcohol, cocaine and opioids (Wickelgreen, 1998). Heavy smokers of marijuana also 
develop tolerance to its subjective and cardiovascular effects (Compton et al., 1991) and 
some report withdrawal symptoms on the abrupt cessation of marijuana use (Compton et 
al., 1991 ; Weisbeck et al., 1996). Studies in clinical and non-clinical samples of long­
term marijuana users have reported withdrawal symptoms, such as anxiety, insomnia, 
appetite disturbance and depression (e.g., Copeland, Swift, & Rees, 2001; Stephens, 
Roffman, & Simpson, 1994).
Also, there is evidence that a marijuana dependence syndrome occurs with heavy 
chronic use in individuals who report problems in controlling their use and who continue 
to use the drug despite experiencing adverse personal consequences (Hall, Solowij, &
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Lemon, 1994). Marijuana dependence is the most common form of drug dependence after 
alcohol and tobacco in the U.S (NIDA, 2006). About one in ten of those who ever use 
marijuana become dependent on it at some time during their four or five years of heaviest 
use (Anthony, Warner, & Kessler, 1994). This risk is more like the equivalent risk for 
alcohol (15 percent) than for nicotine (32 percent) or opioids (23 percent).
Acute Physiological Effects o f  Marijuana
The most immediate physiological effect of smoking marijuana is an increase in heart 
rate by 20 to 50 percent within a few minutes to a quarter of an hour of smoking (Chesher 
& Hall, 1999). Changes in blood pressure also occur. These depend upon posture, that is, 
blood pressure is increased while the person is sitting and decreases while they are 
standing. A sudden change from lying down to standing up may produce postural 
hypotension and a feeling of lightheadedness and faintness that is often the earliest 
indication o f intoxication in naïve users (Maykut, 1984).
Marijuana reliably induces a swelling of the minor conjunctival blood vessels in the 
membranes around the eye, producing a slight “blood-shot” appearance, termed 
conjunctival congestion. This is similar to that seen with alcohol. A reduction in 
intraocular (within the eye) fluid pressure has also been reported with marijuana and may 
have therapeutic significance (Adler & Geller, 1986).
Acute Psychological Effects o f  Marijuana
A variety of psychological effects are produced by marijuana. At low doses, 
marijuana typically induces euphoria and relaxation, perceptual alterations, time
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distortion, and the intensification o f ordinary experiences, such as eating, watching films, 
and listening to music (Jaffe, 1985). However, at high doses marijuana use often results 
in confusion, amnesia, delusions, hallucinations, anxiety and agitation, especially by 
users who are unfamiliar with the effects of marijuana (Jaffe, 1985; Hall & Solowij,
1998).
Psychotic symptoms, such as delusions and hallucinations, are very rare experiences 
that may occur at very high doses o f THC and in susceptible individuals at lower doses 
(Thomas, 1993). More experienced users may report these effects after swallowing 
marijuana because its effects may be more pronounced and of longer duration than they 
usually experience after smoking (Hall & Pacula, 2003).
Appetite, Noiception and Anti-Emetic Acute Effects o f  Marijuana
Marijuana intoxication produces an increase in appetite that results in increased food 
intake, with a preference for sweet foods, even in subjects who were previously satiated 
(Hubbard, Franco, & Onaivi, 1999). This effect has been confirmed under labortatory 
conditions (e.g., Hollister & Gillespie, 1970; Mattes et al., 1994). For example, controlled 
clinical trials in patients suffering from AIDS-related wasting syndrome showed that 
THC (dronabinol) had significant beneficial effects on counteracting appetite loss and 
reductions in body weight in (Beal et al., 1995).
Anti-nausea and anti-emetic effects of THC and other cannabinoids also have been 
well demonstrated (e.g., Zimmerman, 1998). Studies in experimental animals have 
confirmed that the anti-emetic effects of cannabinoids are mediated through CB, 
receptors (Darmani, 2002).
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In addition to its effects on appetite, marijuana intoxication diminishes pain 
perception and increases pain tolerance. These analgesic effects involve actions at a 
number of different levels, including peripheral sensory neurons (Lynch & Taylor, 2005), 
spinal cord (Neeleman, 2000) and central pathways (Cichewicz, Martin, Smith, & Welch,
1999). In the brain and spinal cord, a cannabinoid interaction with the opioidergic system 
may act to modulate the perception of painful stimuli (Pertwee, 2001). Cannabinoids 
ameliorate pain by modulating rostral ventromedial medulla (RVM) neuron activity in 
the brainstem in a manner similar to morphine (Meng et al., 1998). Cannabinoids also 
inhibit synaptic transmission in the midbrain. This area forms part of a descending 
antinociceptive pathway that via the RVM modulates nociceptive transmission at the 
level of the spinal cord (Fields, Heinricher, & Mason, 1991).
Acute Cognitive Effects o f  Marijuana
Attention and Perception
Marijuana intoxication produces minor distortions in sensory awareness, including 
some reports of heightened sensory perception (Hollister, 1986). In monkeys, acute 
marijuana exposure had no serious deleterious effects on simple visual discrimination 
tasks (Schwartz et al., 1989). However, there are reports of significant effects of 
cannabinoids on attention processes in both humans and animals.
THC produced dose-dependent effects on both the accuracy and latency of responses 
to differential tone discrimination (e.g., Campbell et al., 1986) and on signal detection 
performance in rats (e.g., Heyser, Hampson, & Deadwyler, 1993). The performance of 
monkeys trained to respond in a choice reaction time task was significantly disrupted by
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acute exposure to marijuana smoke (Paule et ai., 1992). In humans, marijuana 
intoxication produced detrimental effects on both attention span and divided attention 
tasks (e.g., Chait & Pierre, 1992; Hall & Solowij, 1998; Solowij et al., 2002).
These data suggest that cannabinoid receptor activation does not appear to affect the 
performance of tasks that do not require focused attention or persistent detailed 
perception. On the other hand, discriminatory processes may become susceptible to the 
influence of cannabinoid agonists when more sustained or divided attention is necessary. 
In general, in animal models the outcome of cannabinoid receptor activation on attention 
or perception tasks is thought to resemble that of hippocampal lesions (Irving et al.,
2000).
Learning and Memory
The main acute effects of cannabinoids on cognition in humans relate to the 
disruption of short-term memory (Chait & Pierri, 1992; Miller & Branconnier, 1983). 
Marijuana produces dose-related memory impairment in the ability to freely recall words 
from a list. Free recall is impaired both immediately after list presentation (immediate 
recall) and 20 or 30 minutes following list presentation (delayed recall). In the case of 
immediate free recall, words presented at the end of a list are more likely to be recalled 
than those presented earlier in the list, suggesting that some aspect of memory storage has 
been disrupted (Chait & Pierre, 1992). This pattern of memory deficits seen following 
marijuana intoxication is similar to that seen in patients with hippocampal dysfunction 
induced by encephalitis, Korsakoff’s syndrome, or Alzheimer’s disease (Miller & 
Branconnier, 1983).
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Experiments in animals also demonstrate cannabinoid-mediated memory deficits and 
these are related to impairment of the function of the hippocampus, a structure that is 
intimately involved in the processes that underlie learning and memory (Sullivan, 2000). 
Studies have shown that activation of cannabinoid receptors produces memory deficits 
similar to those produced by neurochemical lesions of the hippocampus (Hampson & 
Deadwyler, 1999). Such lesions impair performance in short-term spatial memory tasks 
learned prior to the lesion.
In rats, THC reduced exploratory parameters and motor activity and caused more 
errors in maze tests and problems with information retention (Sullivan, 2000). In 
monkeys, the administration of THC prior to testing impairs performance on delayed 
non-match-to-sample memory task, in which the animal must identify which of a 
presented pair of objects was displayed 15-minutes earlier (Aigner, 1988). In contrast, 
cannabinoids have no effect on concurrent discrimination learning, during which the 
drugged animal must learn over several sessions separated by 24-hours, to identify which 
of two objects is always paired with food. This differential effect of THC on delayed non- 
match-to-sample performance and concurrent discrimination learning is similar to the 
pattern of deficits seen after amygdalo-hippocampal lesions in monkeys (Aigner, 1988).
Most behavioral and physiological effects of THC return to baseline levels within 
three to six hours after exposure (Chait & Pierri, 1992; Hollister, 1986), although, some 
investigators have demonstrated residual effects in specific behaviors up to 24-hoursafter 
drug (Leirer, Yesavage, & Morrow, 1991). More research is needed to define the onset, 
magnitude, and duration of marijuana’s behavioral effects, especially following long­
term, frequent use of the drug.
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Long-term Residual Effects o f  Marijuana Use on Neuropsychological Functioning
Findings in Brain Imaging Studies
Neuroimaging studies illustrate that differential patterns o f cortical activation exist in 
chronic marijuana users. Two types of paradigms have been employed in the 
neuroimaging studies. These include the resting paradigm and the cognitive challenge 
paradigm. In the resting condition, the subject is instmcted to lie down, relax and not to 
think whereas, in the challenge condition, the subject is engaged with a task.
Resting paradigm studies employing different techniques (e.g., regional cerebral 
blood flow (rCBF), positron emission tomography (PET), single photon emission 
computed tomography (SPECT), functional magnetic resonance imaging (fMRI)), have 
shown subnormal cerebral blood flow (Mathew et al., 1998; Tunving et al., 1986) or 
lower cerebellar metabolism (Amen & Waugh, 1998; Volkow et al., 1996) in long-term 
marijuana users who were assessed within one week of cessation o f use. For example, 
Lundqvist et al. (2001) measured brain blood flow levels after cessation o f marijuana use 
(mean 1.6 days). The findings showed significantly lower mean hemispheric blood flow 
values and significantly lower frontal values in the marijuana subjects compared to 
normal controls. Block et al. (2000) found that after 26 hours of controlled abstinence, 
young frequent marijuana users showed hypoactivity relative to controls in a large region 
of the bilateral posterior cerebellar hemispheres, vermis and in the left and right ventral 
prefrontal cortex (Brodmann’s area 11). Compared with average whole brain activity in 
controls, marijuana users showed nine percent lower values. Block et al. (2000) also used 
magnetic resonance imaging (MRI) to investigate brain structures in young currently
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frequent marijuana users. The users showed no evidence of cerebral atrophy or global or 
regional changes in tissue volumes compared to controls.
Cognition in an everyday situation demands cognitive effort. It is therefore necessary 
to involve studies, which have a challenge within their paradigm. Yurgelun-Todd et al. 
(1999) assessed chronic marijuana smokers twice with fMRI after 24-hours and 28 days 
of abstinence, on a visual working memory task. The control subjects produced 
significant activation in the dorsolateral prefrontal cortex (DLPFC) during the task. 
Marijuana smokers who completed 24-hours o f washout showed diminished activation in 
this region. The effect remained diminished after 28 days of washout, although some 
increase in the DLPFC activation was noted relative to the 24-hour time point. In 
contrast, smokers produced increased activation in the cingulate during both washout 
conditions, whereas controls did not. These results indicate that even after an extended 
washout period, specific differential patterns o f cortical activation exist in subjects with a 
history of heavy marijuana use.
Block et al. (2002) measured cerebral blood flow during the performance of verbal 
memory recall tasks and during a selective attention task. Memory-related blood flow in 
frequent marijuana users showed decreases relative to controls in prefrontal cortex, 
increases in memory-relevant regions of the cerebellum, and altered lateralization in the 
hippocampus. The greatest differences between users and controls occurred in brain 
activity related to episodic memory encoding.
Eldreth and colleagues (2004) used PET imaging and a modified version of the 
Stroop task to determine if 25 day abstinent heavy marijuana users have persistent 
deficits in executive function and brain activity. The 25 day abstinent marijuana users
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showed no deficits in performance on the modified version of the Stroop task when 
compared to the comparison group. Despite the lack of performance differences, the 
marijuana users showed hypoactivity in the left anterior cingulate cortex and the left 
lateral prefrontal cortex and hyperactivity in the hippocampus bilaterally, when compared 
to the comparison group. Eldreth and colleagues (2004) results suggest that marijuana 
users display persistent metabolic alterations in brain regions responsible for executive 
fimction. They have suggested that it may be that marijuana users recruit an alternative 
neural network as a compensatory mechanism during performance on a modified version 
of the Stroop task.
Kanayama et al. (2004) found in an fMRI study that heavy long-term marijuana 
abusers displayed greater and more widespread brain activation than normal subjects 
attempting to perform a spatial working memory task. This observation suggests that 
heavy long-term marijuana abusers may experience subtle neurophysiological deficits 
and that they compensate for these deficits by “ working harder,”  that is, calling upon 
additional brain regions to meet the demands of the task.
Behavioral Findings Related to the Residual Effects o f  Marijuana
Research into the neuropsychological impairments associated with the use of 
marijuana developed a growing literature during the 1960s and 1970s, although these first 
studies produced contradictory results. From the 1980s onwards, the increase in 
methodological control and the progressive refinement of the experimental designs 
provided a much more exact delimitation of the possible neuropsychological deficits that 
may result from the use of marijuana (Pope et al., 1995).
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O f the studies conducted in the 1970s and at the beginning of the 1980s, none of 
those that used controlled doses managed to detect significant differences between users 
and non-users of marijuana (e.g., Barrat et al., 1972; Cohen et al., 1976; Dombush et al., 
1972; Frank et al., 1976; Jones & Benowitz, 1976), whereas the assessment studies of 
recreational users have yielded about the same number of positive results (e.g., 
Mendihiratta et al., 1978, Souief, 1976; Wig & Varma, 1977) as negative ones (e.g.. 
Culver & King, 1974; Grant et al., 1976; Mendelson et al., 1976). Carlin and Trupin 
(1977) and Schaefer et al. (1981) even documented superior neuropsychological 
performance among marijuana users.
During the 1980s, probably because o f the progressive increase in methodological 
control, including supervised abstinence periods and matched control groups, several 
studies began to detect neuropsychological deficits associated with the effects of 
marijuana. Varma et al. (1988) conducted a study that supervised a 12-hour controlled 
abstinence period prior to the neuropsychological evaluation. They detected deficits on 
two of the tests used (Pencil Tapping, estimation of size and time). Page et al. (1988) 
carried out a study in Costa Rica with subjects who had consumed marijuana for more 
than 25 years and with a non-supervised abstinence interval o f between 12- and 24-hours. 
They observed significantly impaired performance in the marijuana users on information 
processing, attention and memory compared to a control group.
This same sample of Costa Rican marijuana users was the object of a large 
prospective study, which included different groups of young and adult users (Fletcher et 
al., 1996). Fletcher and colleagues (1996) detected memory deficits on free recall tasks 
and on learning lists of words, as well as on selective and divided attention tasks. Their
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results suggested deterioration in functions like attention or memory could be more 
lasting over time than those in more basic functions.
Solowij and colleagues (1993; 1992) assessed the relationships between degree of 
impairment and the frequency and duration of marijuana use. Thirty-two marijuana users 
were divided into four groups of equal size (N -  8) defined by frequency (light: two or 
fewer times per week versus heavy: more than three times per week) and duration (short: 
four or fewer years of use versus long: five or more years of marijuana use). Subjects 
were matched to a group of nonuser controls (N = 16). The marijuana users performed 
worse than the controls and the greatest impairment was in the heavy user group. The 
long duration user group found it harder to ignore irrelevant stimuli than the short 
duration users and controls that did not differ. This impairment increased with the 
number of years of use but it was not related to frequency of use. There were no 
differences between groups defined on frequency of use on this measure. Speed of 
information processing was related to frequency of marijuana use but not to duration of 
use.
Solowij et al. (2002) conducted a multi-site cross sectional study in the U.S. between 
1997 and 2000 among 102 near daily marijuana users, 51 long-term users (mean - 2 3 . 9  
years of use), 51 shorter-term users (mean = 10.2 years) and 33 non-users. They assessed 
attention, memory, and executive function from nine standard neuropsychological tests 
prior to users’ entry into a treatment program and following a median 17 hour abstinence 
period. Solowij and colleagues (2002) found that long-term marijuana users displayed 
memory impairment, as measured by performance on the AVLT. Specifically, they 
recalled fewer words and showed impaired learning, retention, and retrieval compared
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with controls and shorter-term users. Moreover, performance measures correlated 
significantly with the duration o f marijuana use being worse with increasing years of 
regular marijuana use.
Similarly, Bolla and colleagues (2002) found as joints smoked per week increased, 
performance decreased on tests measuring memory (AVLT) and executive function 
(Wisconsin Card Sorting Test (WCST)) in 28 day abstinent heavy marijuana users. There 
is also event related potential (ERP) data that shows that the degree of impairment 
increases with the length of marijuana use. For instance, Solovrij (1995) assessed whether 
these ERP changes in long-term marijuana users persisted after extended abstinence fi’om 
marijuana. She studied 32 former users who had used marijuana for a mean of nine years 
and who had been abstinent for a mean of two years. Some partial recovery of 
fimctioning was found, that is, the speed of information processing was not reduced in the 
ex-users but their ability to ignore irrelevant stimuli remained impaired. These findings 
corroborate earlier evidence provided by a NIDA-funded study by Struve et al. (1993). 
These researchers observed larger changes in electroencephalogram (EEG) frequency, 
primarily in the frontal-central cortex, in daily marijuana users of up to 30 years duration 
compared to shorter-term users and nonusers.
Similarly, Pope and Yurgelun-Todd (1996) compared heavy marijuana users (N = 65) 
cognitive functioning to that of a comparison group of light users (N = 64). Subjects in 
both groups had smoked marijuana for at least two years and none had smoked regularly 
for more than a decade. To ensure that the subjects did not smoke marijuana or use other 
illicit drugs or alcohol during the study, researchers monitored them for 19- to 24-hours. 
Then the subjects performed a battery of standard tests designed to assess their ability to
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pay attention, leam, and recall new information. The tests indicated that heavy marijuana 
users had more difficulty than light users in sustaining and shifting attention and hence in 
registering, organizing, and using information. Heavy users exhibited these cognitive 
deficits by being less able than light users to leam word lists, by making a greater number 
of errors in sorting cards by different characteristics, such as by color or shape, and by 
making more errors when the rules for sorting the cards were changed without warning. 
Men in the heavy users group showed somewhat greater impairment than women in the 
same group.
More recently, Ehrenreich and co-workers (1999) administered a computer-assisted 
battery for the assessment of a wide spectrum of attentional functions to a sample o f 99 
pure marijuana users and 49 healthy controls. They reported on the relationship between 
impairments in visual-attentional processing and the early use of marijuana (before 16 
years o f age). Divided attention was also impaired in marijuana users, but not related to 
earlier onset of abuse, whereas flexibility and working memory functions were not 
impaired in these users.
Croft et al. (2001) compared the performance of 18 pure marijuana users, 11 MDMA- 
marijuana users and 31 normal controls on neuropsychological tests of memory, 
attention, and executive and motor functions. They showed that impairments in memory 
and verbal fluency were more related to marijuana consumption in concurrent ecstasy 
users. Tapert et al. (2002), in a follow-up study that administered an extensive 
neuropsychological battery to a sample of 65 adolescent abusers and 40 community youth 
controls showed cumulative marijuana use was related to attentional functioning 
impairments.
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Nevertheless, recent studies have suggested that the marijuana-related 
neuropsychological impairments may be largely due to the residual effects of the 
substance, rather than to long-term effects. In this sense. Pope et al. (2001) compared the 
neuropsychological performance of a group o f 45 former heavy users and a group of 63 
current users who were asked to abstain over a period of 28 days, with 72 normal controls 
on a neuropsychological battery designed to assess general intelligence, memory, 
attention and executive function. Results showed subtle impairments in several cognitive 
domains of the current marijuana user group during the first week of abstinence, which 
were related to the urinary concentrations of the THC metabolite. However, at the end of 
the 28-day abstinence period, neuropsychological performance o f current users was 
indistinguishable from former long-term users or normal controls.
A recent meta-analytic study (Grant et al., 2003), which included most of the studies 
mentioned above has also failed to find a significant detrimental effect o f marijuana use 
on several neuropsychological functions. These researchers calculated effect sizes for 
each neuropsychological test administered within the 11 studies that were analyzed. Then 
within each of the studies, the individual effect sizes were linearly combined by subsets 
into one of eight neurocognitive ability domains. These domains were simple reaction 
time, attention (e.g., WAIS-R Digit Span, Digit Vigilance), verbal/language (e.g., WAIS- 
R Vocabulary, Verbal Fluency), abstraction/executive function (e.g., WCST, Raven’s 
Progressive Matrices), perceptual motor (e.g., WAIS-R Block Design, WAIS-R Object 
Assembly), simple motor (e.g.. Grooved Pegboard, Finger Tapping), learning (CVLT- 
Leaming Trials, AVLT-Leaming Trials), and forgetting/retrieval (e.g., CVLT-Recall,
95
AVLT-Delayed Recall). The only significant effect of long-term heavy marijuana use 
was subtle selective memory impairment for learning and forgetting.
In summary, it appears that the long-term heavy use of marijuana does not produce 
severe, grossly debilitating impairment in cognitive function that is found for example 
with chronic, heavy alcohol use. Electrophysiological and neuropsychological studies 
show that marijuana produces subtle impairments in attention, executive function, and 
memory performance.
The longer marijuana has been used, the more pronounced the cognitive impairment. 
The impairments are subtle, so it remains unclear how important they are for everyday 
functioning and whether they are reversed after an extended period of abstinence. Early 
studies that suggested gross structural brain damage with heavy use have not been 
supported by better controlled studies with better methods.
Is Marijuana Neurotoxic?
Although there have been claims that chronic marijuana use may permanently 
damage the brain, there is little scientific evidence to support these claims (e.g., Hollister, 
1998; Zimmer & Morgan, 1997). As mentioned earlier, some studies have revealed a 
modestly impaired ability to focus attention and filter out irrelevant information, as well 
as an impairment in learning and remembering in ex-marijuana users (e.g., Bolla et al., 
2002; Solowij et al., 2002; Solowij et al., 1998), while others have failed to find 
impairments in cognitive function (e.g.. Pope et al., 2001).
Animal studies have yielded conflicting results. Treatment of rats with high doses of 
THC given orally for three months (Scallet et al., 1991) or subcutaneously for eight
96
months (Landfield et al., 1988) were reported to lead to neural damage in the 
hippocampal CA3 zone, with shrunken neurons, reduced synaptic density and loss of 
cells. However, in another study the potent synthetic cannabinoid WIN 552122 was 
administered twice daily (2 mg/kg) to rats and led to an apparent increase in hippocampal 
granule cell density and increased dendritic length in the CA3 zone. In perhaps, the most 
severe test of all, rats and mice were treated with THC five days each week for two years 
and no histopathological changes were observed in brain tissue, even after administration 
of large doses THC (50 mg/kg/day in rats and 250 mg/kg/day in mice) (Chan et al.,
1996). Although claims were made that exposure of marijuana smoke in a small number 
of rhesus monkeys led to structural changes in the septum and the hippocampus (Heath et 
al., 1980), subsequent larger scale studies failed to show any marijuana-induced 
histopathology in the monkey brain (Scallet et al., 1991).
Studies of the effects of cannabinoids on neurons in vitro have also yielded 
inconsistent results as well. Exposure of rat cortical neurons to THC was reported to 
decrease their survival, with twice as many cells dead after two hours of exposure to 5 
pM THC than in control cultures (Downer et al., 2001). Significant effects were also 
demonstrated with low concentrations of THC (O.I pM). The effects of THC were 
accompanied by release of cytochrome C, activation of caspase-3 and DNA 
fragmentation, suggesting an apoptotic mechanism. All of the effects of THC could be 
blocked by the synthetic cannabinoid antagonist AM-251 or by pertussis toxin, 
suggesting that they were mediated through CBi receptors.
Toxic effects of THC have also been reported on hippocampal neurons in culture, 
with 50 percent of cell death after two hours of exposure to 10 pM THC or after five days
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exposure to 1 pM THC drug (Chan et al., 1998). THC caused the shrinkage of cell bodies 
and nuclei of neurons and also caused genomic DNA strands to break. The synthetic 
cannabinoid antagonist rimonabant blocked these effects, but not pertussis toxin. Chan et 
al. (1998) proposed a toxic mechanism involving arachidonic acid release and formation 
of free radicals. However, other authors failed to observe any damage in rat cortical 
neurons exposed for up to 15 days to 1 pM THC (e.g., Sanchez et al., 1998).
In a remarkable study, injections of THC into solid tumors of C6 glioma in rodent 
brain led to increased survival times and a complete eradication of the tumors was 
evident in 20 to 35 percent of the treated animals (Galve-Roperh et al., 2000). The anti­
proliferative effects of cannabinoids suggest a potential utility for use in cancer treatment 
(Guzman et al., 2001).
Other studies have reported neuroprotective actions of cannabinoids. For example, 
administration of WIN 552122 was found in vivo to reduce neuronal damage in the rat 
hippocampus and cerebral cortex following global ischemia or focal ischemia (Nagayama 
et al., 1999). Subsequently, Panikashvili and colleagues (2001) found the 
endocannabinoid 2-AG protected against damage elicited by closed head injury in the 
mouse brain. Van der Stelt et al. (2001) observed THC had a similar effect in vivo in 
protecting against damage elicited by ouabain (ouabain is a poisonous cardiac molecule 
that is used by researchers for in vitro studies to block the sodium-potassium pump). 
Furthermore, rat hippocampal neurons in tissue culture were protected against glutamate- 
mediated damage by low concentrations of WIN 552122 or CP 55940 and these effects 
were mediated through CB, receptors (Shen & Thayer, 1998).
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Not all of the neuroprotective effects seem to require mediation via cannabinoid 
receptors. For example, Zhuang and colleagues (2005) findings suggest that cannabinoids 
prevent cell death by initiating a time and dose dependent inhibition of adenylyl cyclase, 
which outlasts direct action at the CBi receptor. Also, Nagayama et al. (1999) reported 
protective effects of WIN 552122 that did not require either cannabinoid receptor in 
cortical neurons exposed to hypoxia. Similar findings were reported for the protective 
actions of anandamide and 2-AG in cortical neuron cultures (Sinor et al., 2000). 
Subsequently, both THC and cannabidiol, which is not active on cannabinoid receptors 
protected rat cortical neurons against glutamate toxicity (Hampson et al., 1998). The 
authors suggested that the protective effects of THC in their studies might be due to the 
antioxidant properties of these polyphenolic molecules, which have redox potentials 
higher than those of known antioxidants (e.g., vitamins C and E).
Further support for the antioxidant properties of cannabinoids is provided in a recent 
study by Morley et al. (2004). These researchers investigated whether co-administered 
cannabinoids and MDMA affected the long-term neurotoxic properties o f MDMA in rats. 
They found that co-administration of THC or CP 55940 (synthetic cannabinoid) 
prevented hyperthermia. Hyperthermia has been found to induce oxidative stress which 
results in excessive free radical formation and abnormal free radical reactions (Green et 
al., 2003).
In addition to reversing hyperthermia, Morley et al. (2004) found that THC partially 
attenuated the long-term serotonin depletion produced by MDMA. Rats given either THC 
or the higher dose of CP 55940 in conjunction with MDMA displayed serotonin and 5- 
HIAA levels in the hippocampus, prefrontal cortex and amygdala that were intermediate
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between MDMA treated rats. The lower co-administered dose of THC and CP 55940 (0.1 
mg/kg) was largely ineffective in preventing MDMA-induced serotonin depletion, 
suggesting that the protective effect o f cannabinoids requires relatively large co­
administered doses.
Morley et al. (2004) attributed the underlying protective effects of cannabinoids to 
their antioxidant properties. This conclusion was based on the finding that the selective 
antagonist SR 141716, while reversing the cannabinoid agonist effects on MDMA- 
induced hyperthermia did not change the partial protection against serotonin depletion. 
This finding indicated a CB]-independent mechanism was responsible for the 
neuroprotection.
Morley and colleagues (2004) posited that the cannabinoids (THC and CP 55,940) 
acted as antioxidants and may have counteracted the oxidative stress produced by 
MDMA. Cannabinoids contain a phenolic structure typical of many antioxidants isolated 
from plants. In contrast, the synthetic cannabinoid WIN 552122 lacks the structural 
moieties that chemically define the antioxidative activity (Chen & Buck, 2000).
Summary
The neurocognitive changes that may be attributed to chronic marijuana use are subtle 
and may depend on prolonged and heavy levels of consumption. That is, marijuana does 
not produce severe impairment of cognitive function like that observed with heavy 
alcohol use. Daily marijuana use over many years may produce subtle impairments in 
learning and memory, attention and executive function. Impairment seems to be reversed 
by an extended period of abstinence.
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Moreover, well-controlled studies, using sophisticated methods of investigation (e.g., 
fMRI, PET) have failed to demonstrate gross structural change in the brains of heavy, 
long term marijuana users. These negative results are consistent with the evidence that 
cognitive effects o f chronic marijuana use are subtle, and hence unlikely to be manifest as 
gross structural changes in the brain.
101
CHAPTER 3 
METHOD
Aim o f  the Proposed Study
As concomitant marijuana and other polydrug use have been deemed a possible 
confound in previous ecstasy research, the primary aim of this study was to evaluate 
auditory verbal learning and memory performance, as measured by the Auditory Verbal 
Learning Test (ÀVLT) (Rey, 1964; Schmidt, 1996), in ecstasy users while controlling for 
the extent of marijuana and other illicit drug use. Marijuana use was controlled for by 
enrolling marijuana-only users and, subsequently, by specifying the extent of marijuana 
use, in both the ecstasy and marijuana-only user groups. Marijuana use was categorized 
as either heavy or light, with heavy use defined as using marijuana five or more times per 
week and light marijuana use defined as using marijuana less frequently than five times a 
week.
To minimize polydrug use among the user groups, the apriori exclusionary criteria 
established for other illicit drug use stated that the frequency of other illicit drug use 
(except alcohol and nicotine) was not to exceed more than ten occasions in a participant’s 
lifetime. This criterion was relaxed post-hoc to not more than 15 lifetime uses for each of 
the drugs inventoried in this study. This was done in order to include a few participants 
who reported greater than 10 lifetime uses of one or two of the multiple drugs surveyed.
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Moreover, this had the advantage of increasing the power of the statistical analyses by 
increasing the number of participants in the drug user groups.
Additionally, alcohol use was accounted for by not including participants who 
reported regular heavy alcohol use. Regular heavy alcohol use was defined as severe 
drunkenness occurring at a frequency of at least twice a month over six months or longer 
within the last two years.
Participants
One hundred and nine undergraduate university students ages 18 years and older with 
a history of ecstasy and/or marijuana use were recruited from introductory psychology 
courses via an announcement placed in the psychology department subject pool, 
Experimetrix. Students without a regular history of drug use were also recruited to 
participate. All groups were matched for age, education level, and verbal intellectual 
ability. While there were not an equal number of females and males in the groups, there 
was not a statistically significant difference in the gender ratio among the groups.
To optimize data collection and reduce participant attrition rates, experimental testing 
was conducted over one session, under laboratory conditions. Consequently, participants 
were notified via the Experimetrix recruitment announcement to abstain from all illicit 
drug use for at least 24-hours prior to reporting for experimental testing. This measure 
was necessary to ensure that participants were free of acute residual drug effects.
Written informed consent was obtained to ask participants about their drug use within 
the last 24-hours. Participants that provided verbal confirmation of adherence to the 24- 
hour abstinence period were permitted to begin experimental testing. Alternatively,
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participants that reported they had not adhered to the 24-hour abstinence criterion were 
given the option of either receiving half a research credit and no longer being eligible for 
future participation in the study, or reporting back for testing at a later date when they 
were able to meet the abstinence criterion and be eligible to receive full credit for 
completion of the entire experimental protocol.
Once it had been established that a participant was eligible for experimental testing, 
written informed consent was obtained for the experimental protocol. The experimental 
testing session was comprised of two parts: neuropsychological assessment and 
completion of the drug use history questionnaire.
Neuropsychological testing was conducted first and began with the evaluation of 
verbal learning and memory performance using the AVLT (Rey, 1964; Schmidt, 1996). 
The first portion of the BFLT-E was administered during the AVLT 20-minute delay 
(i.e., learning trials 1 through 5, interference List B, recall of List B designs, immediate 
recall of List A designs). The remaining trials on the BFLT-E (delayed recall after a 20- 
minute delay and recognition), were administered following completion of the 20-minute 
delay. Intellectual function (IQ) was assessed within the BFLT-E 20-minute delay and 
immediately after AVLT testing was complete. The verbal subtest of the Wechsler Adult 
Intelligence Scale, Third Edition (WAIS-III) was used to infer verbal intellectual 
functioning (Wechsler, 1997).
In the second part of the experimental testing session, participants were asked to 
complete a dmg use history questionnaire, in which prior levels of drug use for the 
previous week, month, year, and lifetime were recorded (see Appendix E). The drug use 
questionnaire data were used retrospectively to assign participants to one of five
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experimental groups. Data collected on participants who did not meet the inclusion 
criteria were not included in any of the statistical analyses.
Experimental Groups
Marijuana-Only Users. Marijuana-only users were separated into two groups. The 
only difference between the two marijuana-only user groups was the extent of marijuana 
use. The groups were labeled marijuana-only light users (M l) and marijuana-only heavy 
users (M h). Categorization of marijuana users as light or heavy was based on the self- 
report data collected from the drug use history questionnaire and resembled the criterion 
used by Fried, Watkinson, James, and Gray (2002). Specifically, heavy marijuana use 
was defined as using marijuana five or more times per week and light marijuana use was 
defined as using marijuana fewer than five times a week.
Additional inclusion criteria for the marijuana-only user groups included: (1) 
consistent use of marijuana over the past year, (2) no prior use of ecstasy, (3) no current 
or prior history of regular illicit drug use other than marijuana (the frequency of using 
other illicit drugs could not exceed more than 15 occasions in the participant’s lifetime), 
and (4) no regular heavy alcohol use (defined as severe drunkenness occurring at a 
frequency of at least twice a month over six months or longer within the last two years) 
(Daumann et al., 2003; Gouzoulis-Mayfrank et al., 2000; Gouzoulis-Mayfrank et al., 
2003; Yip & Lee, 2005).
Fifty participants met these criteria and were retrospectively assigned to either the Ml 
user group or Mh user group. The Ml user group was comprised of 28 participants, 12
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females and 16 males, while 22 participants, 8 females and 14 males, were assigned to 
the Mh user group.
Ecstasy-Marijuana Users. Like the marijuana-only users, there were two concomitant 
ecstasy-marij uana user groups. One group of ecstasy users was classified as ecstasy- 
marijuana light users (E +M l) if  they reported using marijuana fewer than five times per 
week, while the other ecstasy user group was defined as concurrent heavy marijuana 
users (E + M h) if they used marijuana five or more times per week. In accordance with 
other ecstasy investigations (e.g.. Von Geusau et al., 2004; Bedi & Redman, 2006;
Lamers et al., 2006; Parrott et al., 1998; Rizzo et al., 2005), participants were eligible for 
inclusion into the ecstasy user groups if they had used ecstasy on a minimum of at least 
10 occasions, with at least one occasion in the most recent year.
Based on these criteria, 34 participants were assigned to either the E + M l user group 
or the E + M h user group. Fifteen participants, 8 females and 7 males, were assigned to the 
E +M l user group and 19 participants, 6 females and 13 males, were assigned to the 
E+M h user group.
While the issue of impurity in illicit ecstasy tablets was a problem for researchers 
in the early 1990s (Spruit, 2001), impurity is far less of an issue now (Parrott, 2006). For 
instance, during the late 1990s, the proportion of ecstasy tablets containing MDMA 
increased to around 80 to 90 percent. The latest reports suggest that non-MDMA tablets 
are very infrequent, with purity levels between 90 and 100 percent being the norm 
(Parrott, 2004a). Moreover, many of the psychological effects reported by illicit ecstasy 
users is similar to those reported by participants in clinical MDMA studies (Cami et al. 
2000; Grob et al. 1996; Vollenweider et al., 1998a). Increases in positive mood, energy,
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difficulty concentrating, and alterations in perception have been documented in both 
retrospective and clinical studies. Taken together, these findings suggest that the 
recreational ecstasy user is probably consuming MDMA and so using data from 
recreational ecstasy users to estimate the human neuropsychological consequences of 
repeated MDMA exposure is considered herein to be reasonable.
Like the criterion for the marijuana-only user groups, participants were not included 
in the combined ecstasy and marijuana user groups if  their frequency of other illicit drug 
use exceeded more than 15 occasions in their lifetime and/or they reported regular, heavy 
alcohol use.
Non-Drug Using Controls. The fifth group of participants consisted of non-drug using 
controls. The inclusion criteria for assignment to this group included: (1) no prior use of 
ecstasy, (2 A) no previous use of marijuana, (2B) no previous or current history of other 
illicit dmg use, such as hallucinogens, cocaine, stimulants, or opiates (the frequency of 
using other illicit dmgs should not exceed more than 15 occasions in the participant’s 
lifetime), and (3) no regular heavy alcohol use (defined as severe drunkenness occurring 
at a frequency of at least twice a month over six months or longer within the last two 
years). The control group (C) consisted of 25 participants, 15 females and 10 males. The 
only dmg use reported by the C group was alcohol and nicotine.
Similar to many of the well-controlled ecstasy studies (e.g., Croft et al., 2001 ; Curran 
& Verheyden, 2003; Fox et al., 2001; Gouzoulis-Mayfrank et al., 2000; Gouzoulis- 
Mayfrank et al., 2003; Lamers et al., 2006; McCardle et al., 2004; Quednow et al., 2006; 
Reneman et al., 2001; Reay et al., 2006; Rizzo et al., 2005; Semple et al., 1999; Simon & 
Mattick, 2002; Thomasius et al., 2003), participants in each group were not included if
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they had: (1) a current or previous history of an Axis I psychiatric disorder (except for 
drug abuse in the user groups), (2) any organic brain disorder, (3) a history of head injury 
with loss of consciousness requiring hospitalization, (4) a medical or neurological 
condition that might affect cognitive function, or (5) regularly used legal or illegal 
psychotropic drugs such as opiates or benzodiazepines (the frequency o f using other 
psychotropic drugs should not exceed more than 15 occasions in the participant’s 
lifetime).
Dependent Measures
Verbal Learning and Memory. The AVLT (Rey, 1964; Schmidt, 1996) was used to 
evaluate auditory verbal learning and memory performance. The AVLT is a standard 
neuropsychological test o f explicit memory that measures delayed recall performance for 
lists of unrelated words. Explicit long-term memory tasks have been shown to rely 
critically on the hippocampus. This is supported by a review of 147 case studies of 
amnesia patients involving hippocampal damage, which found that all cases showed 
severe deficits in conscious retrieval (i.e., explicit memory), but intact non-conscious 
retrieval (i.e., implicit memory) (Spiers, Maguire, & Burgess, 2001). Also, in functional 
magnetic resonance imaging (fMRI) studies, explicit memory has been found to be 
associated with neural activation of the hippocampus, as well as activation of sensory 
areas o f the cortex (Thiel, 2003).
Explicit memory tests, such as the AVLT, are particularly sensitive to hippocampal 
functioning because the filled delay prohibits the retention of words in working memory 
between study and test. In addition, memory for unrelated words involves less elaborative
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and/or associative processing than other memory tasks, such as the verbal paired- 
associates task. The elaborative and/or associative processing of words has been shown in 
functional neuroimaging studies to activate specific parts of the prefrontal cortex in 
addition to the hippocampus (Posner, Peterson, Fox, & Raichle, 1988; Roskies, Fiez, 
Balota, Raichle, & Peterson, 2001; Schreckenberger et al., 1998). This distinction served 
as the basis for selection of the verbal learning memory task used in this investigation.
Additionally, the AVLT has been utilized in several ecstasy and marijuana 
investigations (e.g., Bolla et al., 1998; Curran et al., 2003; Fox, Toplis, et al., 2001; 
Gouzoulis-Mayfrank et al., 2000; Lamers et al., 2006; McCardle et al., 2004; Quednow et 
al., 2006; Reneman et al., 2000; Solowij et al., 2002; Thomasius et al., 2003; Yip & Lee, 
2005) and was selected so that direct comparisons could be made between the findings in 
these previous studies and those obtained in this study.
The QPSS computerized version of the AVLT-AB was used to enable real-time 
recording and scoring of the test (Poreh, 2004). The QPSS software utilizes the same set 
of standardized instructions and is administered in the same manner as the paper and 
pencil version of the AVLT.
The software was installed on two laptop computers. The experimenter was seated in 
front o f the computer and controlled the presentation of the instructions and the stimuli. 
Additionally, the experimenter was responsible for recording participants’ responses. All 
instructions and stimuli (i.e., words) were read by a pre-recorded voice on the computer.
On each trial, a configuration of buttons that correspond to the AVLT words was 
displayed on the computer screen. Once the participant started to verbalize a response 
(i.e., recall a word from the word list), the experimenter used the mouse to click on the
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corresponding word-picture button. If the participant responded with a word that did not 
appear in the list, the experimenter recorded the word as either a confabulation or as an 
association. Error confabulations were defined as words unrelated to those in the stimulus 
list, whereas error associations were defined as words that were semantically or 
phonemically related to those in the stimulus list.
For the recognition trial on the AVLT, a word appeared one at a time on the computer 
screen. The experimenter saw the word, while the participant heard it played by the 
computer. Participants’ were asked to verbally answer either “yes” if  the word they just 
heard was from List A or “no” if it was not. The experimenter clicked on the “yes” button 
if the participant answered yes or on the “no” button if  the participant responded no.
There was an undo function, in the event the experimenter clicked on the wrong word- 
picture, yes-no button, or incorrectly typed in a word that was not on the stimulus list.
The AVLT required participants to leam a list of 15 words (List A) across five 
successive trials (trials 1 through 5). All words from the list were concrete nouns and 
were presented at the rate of one word every two seconds (inter-trial interval = 20 
seconds). The order of word presentation was the same on each trial and the same for all 
participants. At the end of each trial, participants were required to recall as many words 
from the list as possible. Additionally, participants were instructed that the order in which 
they recalled the words did not matter.
Following the fifth learning trial, a second list of 15 unrelated words from List B was 
presented to participants across a single trial (trial B). After recall of the interference list, 
participants were asked to recall the List A words (trial 6). This trial represented 
participants’ short-delay or immediate recall performance. Following a 20-minute delay,
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participants were asked again to recall the List A words (trial 7). This trial represented 
participants’ long-delay or delayed recall performance.
A recognition test followed the 20-minute delayed recall trial. Participants were asked 
to identify as many words as possible from the first list (List A) when presented with a 
list of 50 words containing items from both Lists A and B, as well as words that were 
semantically related or phonemically similar to words on Lists A and/or B. Participants 
heard each word one at a time and were asked to verbalize a response of “yes” if the word 
was from List A or “no” if the word was not from List A.
Memory scores were calculated for each individual trial and reflected the number of 
words correctly recalled. The number of words recalled after the first presentation of List 
A was defined as immediate word span or supraspan. Supraspan reflects attentional 
processes related to the acquisition of information prior to storage (Fox, Toplis et al., 
2001; Lezak, 2004).
Like trial 1 of List A, the interference trial (List B) involved initial mnemonic 
processes on a new word list. However, unlike trial 1, the interference trial assessed 
participants’ supraspan ability immediately following learning.
A score for total acquisition was calculated by summing the number of words 
recalled on trials 1 through 5. Error confabulations (words unrelated to those in the 
stimulus list) and error associations (words semantically and phonemically linked to 
those in the stimulus list) were recorded along with intrusion errors fi'om List A to B and 
vice versa. A high number of intrusion errors is usually associated with confabulation, 
which is often interpreted as an inability to accurately evaluate any retrieved information 
(Burgess & Shallice, 1996). High levels of confabulation errors are predominantly
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reported in patients who have frontal cortical lesions (Mayers & Daum, 1997). In 
contrast, an increase of association errors is indicative of retrieval problems, such as the 
“tip-of-the-tongue” syndrome, where participants reveal that they know the correct word 
but are unable to actually recall it (Brown & McNeill, 1966).
Non-Verbal Distracter Task. The Biber Figure Learning Test-Extended (BFLT-E) is 
pattemed after the AVLT (Glosser, Cole, et al., 2002). The paper-pencil version of the 
BFLT-E was employed as a distracter task and was administered during the 20-minute 
delay of the AVLT. The basis for selection of this distracter task was that it takes 
sufficient concentration to effectively to prohibit the continuous rehearsal of words 
between the study- test phases of the AVLT. Also, the use of non-verbal stimuli was 
intended to minimize the opportunity for interference between the distracter task and the 
AVLT stimuli.
In the BFLT-E, participants completed five trials in which 15 designs from List A 
were presented at a rate of one every three seconds. After each trial, participants were 
asked to recall as many of the 15 designs as they could in any order by drawing the 
designs. Following figure recall on the fifth trial, a second set o f designs was presented 
from List B (interference trial). After the recall of List B designs and without additional 
exposure, participants were asked to draw the original 15 designs from List A (immediate 
recall).
Following a 20-minute delay, recall and recognition memory were tested. For the 
recall portion, participants were asked to reproduce the designs presented in List A. The 
recognition trial consisted of 45 designs, the original 15 designs seven designs from the 
distracter list (List B) and 23 foils (i.e., designs that had not been presented before). The
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45 designs were shown one at a time. Participants were asked to verbalize a response of 
“yes” if  the design was from List A or “no” if  the design was not from List A.
Memory scores were calculated for each individual trial and consisted o f the number 
of designs correctly recalled. The number o f designs recalled after the first presentation 
of List A will specifically be defined as immediate span or supraspan. Similar to trial 1 of 
List A, List B also involved initial mnemonic processes on a new word list. However, 
unlike trial 1, List B assessed participants supraspan ability immediately following 
learning. The number o f designs recalled on trial 6 (the trial immediately following recall 
of designs from interference List B) represented participants immediate recall scores, 
while the number of designs recalled on trial 7 (after a 20-minute delay) was referred to 
as participants’ delayed recall scores. Also, the number of designs correctly identified on 
the recognition trial was calculated and scores for total acquisition were calculated by 
summing the number of designs recalled on trials 1 through 5.
Verbal Intelligence (IQ). To control for pre-existing differences in general cognitive 
capacity among groups, IQ was assessed from performance on the vocabulary subtest of 
the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III) (Wechsler, 1997). In 
order to permit time for neuropsychological testing, an estimate o f Full Scale IQ (FSIQ) 
was derived from the vocabulary subtest.
Sattler (2001) maintains that the vocabulary short form has been substantiated 
statistically, as this subtest has a moderate correlation with FSIQ (r = .80) and high 
reliability (r = .93) (The Psychological Corporation, 1997). Ringe, Saine, and Cullum 
(1999) provide further evidence supporting the use of the vocabulary subtest as an 
estimate of FSIQ. These researchers observed an excellent correlation (r = .94) between
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estimated IQ from the vocabulary subtest and FSIQ in a population of mixed neurological 
and psychiatric patients (n = 63). Moreover, they conducted multiple regression analyses 
which demonstrated that the vocabulary subtest accounted for 90 percent of the variance 
in FSIQ scores among the sample. The internal consistency reliability for the vocabulary 
subtest was high (r = .93) (The Psychological Corporation, 1997).
The WAIS-III vocabulary subtest assesses word knowledge by requiring the subject 
to verbally provide a dictionary style definition for 33 words that increase in order of
difficulty. The examiner read the question, “What does mean?” The easiest word in
the test is “bed,” but administration began with the fourth word, “winter,” which is the 
normal procedure (Lezak, 2004). The test continued until the participant failed six words 
consecutively or until the list was exhausted. The most difficult word on the WAIS-III is 
“tirade.” A score of either zero, one, or two points was given depending on the accuracy, 
precision, and aptness of each definition. This measure is heavily influenced by formal 
education and literacy, as well as age and gender. The vocabulary test took approximately 
15- to 20-minutes to administer.
Vocabulary subtest raw scores were converted to age-corrected standard scaled scores 
based on normative data provided in the WAIS-III manual. The age-corrected scaled 
scores were then summed and converted into an estimated FSIQ based on the method and 
tables established by Sattler (2001).
Drug Use History Questionnaire. All participants completed the drug use history 
questionnaire (see Appendix II). The questionnaire consisted of two parts. The first part 
consisted of items pertaining to demographic and health information. Details of age,
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gender, level of education, past or present history of a medical illness, and prior diagnosis 
of a major psychiatric (Axis I) disorder were obtained.
The second part of the questionnaire was composed of items that probed for previous 
patterns of drug use. Specifically, the questionnaire was used to evaluate the age of onset, 
fi'cquency (consumption episodes in a given week, month, and year), and duration of use 
o f a number of often abused psychoactive drugs. For every substance a participant had 
actually consumed, the following information was requested: (1) the total lifetime 
consumption of each drug, (2) the frequency of consumption episodes per week and 
month, (3) the age of onset of use, and (4) the number of years that have elapsed since the 
onset o f use. In addition to these items, participants who reported ecstasy use were asked 
to provide information regarding (1) the average number of pills used in each episode and 
(2) the largest number of pills ingested in an episode of use.
Procedure
No biological screening for drug use was carried out. However, it was requested that 
participants abstain from using ecstasy and other drugs for at least 24-hours prior to 
testing. Notice to abstain from all drug use was specified in the study advertisement 
placed in Experimetrix. Individuals who reported for testing that had not met this 
requirement were not allowed to participate at that time.
It was emphasized in the informed consent form that neither the experimenter nor the 
University condoned illicit drug use. Additionally, it was emphasized that this 
investigation should not be seen as approval or encouragement for the use of ecstasy and 
marijuana or other illegal drugs, particularly since they could have serious side effects. It
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was also stated in the informed consent form that taking part in this study was voluntary 
and that a participant could withdraw from the study at anytime without giving a reason.
Participants were informed that the data would be treated as strictly confidential. A 
participant’s name never appeared on the drug history questionnaire nor was it used to 
code files associated with the experimental tests. Rather, a six digit numerical code 
created by the random number generator function in Microsoft Excel was assigned to 
each participant following completion of the informed consent form. The master list of 
participant names and the numerical code assigned to each of them was deleted promptly 
after credit was assigned to the participant, which occurred immediately following the 
completion of the protocol. This was done in order to ensure that there was no record 
which could link data to a particular participant. Furthermore, electronic data obtained 
from the computerized version of the AVLT and the drug use history questionnaire were 
promptly removed from the hard drive and stored on a master disk which was locked in a 
filing cabinet along with the other participant data.
All neuropsychological testing and completion of the drug history questionnaire were 
administered under laboratory conditions, in one experimental session. Experimental 
testing lasted approximately two hours. Data collected on participants who completed 
testing but did not meet the study’s inclusion criteria were not included in any of the 
statistical analyses. Participants received one research credit for each hour they 
participated in the experiment. All participants ran through the entire experimental 
protocol and, consequently, received two credits for participation.
Participants reported one at a time to the UNLV Psychopharmacology Laboratory and 
experimental testing was conducted in a quiet room, by either the primary investigator or
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an undergraduate research assistant. The research assistants received extensive training 
on administration of the experimental protocol by the principal investigator. Training 
included verbal explanations and hands-on familiarization with the administration of the 
neuropsychological tests (WAIS-III vocabulary subtest, AVLT, BFLT-E), drug use 
history questionnmre, informed consent forms and information or debriefing sheet. 
Moreover, a written set o f instructions regarding the protocol administration was 
provided. Each research assistant was evaluated by the principal investigator prior to 
conducting experimental testing and periodically throughout data collection to ensure 
reliability.
Predictions
Additive Effects. One possible outcome hypothesized in this study was that combined 
use of ecstasy and marijuana would have negative additive effects on AVLT word recall 
performance. Additive effects are the simplest case of combined drug action and indicate 
that each drug acts independently to produce its own effects. The effects of the drugs 
simply summate, that is, the combined effect of the two drugs equals the sum of their 
individual effects in isolation.
Figure 2 provides an example of possible negative additive effects of both ecstasy and 
marijuana use on AVLT recall performance. In the example, examination of the 
difference between marijuana-only users and the combined ecstasy-marijuana users, at 
each level of marijuana use should reveal that the addition of ecstasy decreased word 
recall by two units [(M l- E+Ml) = (10 - 8 )  = 2 = (Mh -  E+Mh) = (6 -  4) = 2].
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Figure 2. Predictions for additive effects of ecstasy and marijuana use on the number 
of words recalled on the AVLT. The effect of marijuana is independent of the effect of 
ecstasy. The differences between marijuana only light users and ecstasy-marijuana light 
users (10 -  8 = 2) and the marijuana-only heavy users with ecstasy-marij uana heavy users 
(6 - 4 = 2) is equal.
Positive Synergistic Effects (Neuroprotection). Another possible outcome observed in 
this study is that marijuana interacts with ecstasy in such a way that marijuana reduces 
the impact of ecstasy’s effects on verbal learning and memory performance. The extent to 
which marijuana minimizes the reduction of recall scores will depend upon the extent of 
marijuana use. This prediction is based on Morley and colleagues (2004) findings in rats, 
which suggest that cannabinoids attenuate the long-term neurotoxic effects caused by the 
addition of MDMA, especially at high doses of marijuana. If Morley et al.’s (2004) 
animal findings are applicable to human verbal learning and memory performance then 
marijuana use in the combined user groups should reduce the rate of decline in the 
number of words recalled on the AVLT, with the greatest minimization of deficits
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occurring in the heavier marijuana users. Moreover, heavy marijuana use will attenuate 
the effect of ecstasy, making it comparable to the performance of the marijuana-only 
users. Figure 3 provides an example of positive neuroprotective effects of marijuana on 
ecstasy. From this example, the difference between the marijuana light groups is greater 
than the marijuana heavy groups [(M l-  E +M l) = (1 0 -9 )  = 1 > (M h -  E +M h) = (6 -  6) = 
0].
Positive Synergistic Effects-Neuroprotection
I
I w.
I 6»
■No Ecstasy (marijuana-only) 
■ Ecstasy
Light Heavy
Marijuana Use
Figure 3. Predictions for positive synergistic effects between ecstasy and marijuana 
use on the number of words recalled on the AVLT. Ecstasy and marijuana use are not 
independent, rather marijuana acts synergistically with ecstasy to minimize recall deficits 
caused by the addition of ecstasy use. The reduced effect of ecstasy is even greater in the 
marijuana heavy condition.
Negative Interactive Effects (Negative Synergistic Effects). The other potential 
outcome that could occur is that marijuana interacts synergistically with ecstasy to
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produce memory impairment that is greater than that observed by the sum of the deficits 
produced by either ecstasy or marijuana alone (see Figure 4 for an example). This 
prediction is based on Young et al.’s (2005) findings in rats, which demonstrated 
synergistic disruption in working memory performance in rats that were co-administered 
MDMA and THC. The amount o f synergistic disruption produced was dependent upon 
the dose of marijuana, such that greater synergistic disruption was observed under high 
marijuana dose conditions compared to lower marijuana dose conditions.
Negative Synergistic Eflects
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Figure 4. Predictions for negative synergistic effects between ecstasy and marijuana 
use on the number of words recalled on the AVLT.
Marijuana and ecstasy use do not act independently to impair performance, rather
ecstasy interacts synergistically with marijuana to produce greater impairment than that
observed by the sum of the deficits produced by each drug alone. The magnitude of the
impairment depends on the extent of marijuana use. A greater synergistic disruption of
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recall performance is seen in ecstasy-marijuana heavy users versus ecstasy-marij uana 
light users.
If these data are applicable to human verbal memory performance, then among the 
drug users in this study, the combined ecstasy-marij uana users should exhibit more 
impaired word recall than the marijuana-only users. Moreover, the magnitude of 
impairment observed in the ecstasy-marijuana heavy users would be greater than that 
observed in the ecstasy-marijuana light users [(M l-  E+M l) = (1 0 -7 )  = 3 <  (M h -  
E +M h) = (6 -  2) = 4].
Statistical Analyses
Statistical analyses were performed using SPSS 15.0 software for Windows (SPSS 
Inc., Chicago, IL). An alpha level of 0.05 was used for all analyses. A Multivariate 
Analysis of Variance (MANOVA) was conducted on the descriptive statistics of the 
participants’ age, gender, education level, and verbal intelligence scores as measured by 
the WAIS-III vocabulary subtest, with group assignment as the single between-subject 
factor (i.e., C, M l, M h, E +M l, and E +M h). Similarly, a MANOVA was performed on the 
participants’ drug use characteristics and included age of onset of use, frequency of use 
episodes, per week and per month, total lifetime use, and the number of years that have 
elapsed since the onset of use. Two additional drug use characteristics were computed for 
ecstasy: a) the average number of pills taken in an episode, and b) the largest number of 
pills taken in an episode.
Two separate sets of Multivariate Analyses o f Covariance (MANCOVAs) were 
performed on the AVLT and the BFLT-E data, with group assignment as the single
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between-subject factor. The first set of MANCOVA analyses treated age, education, and 
verbal intelligence scores as covariates. It is well established that these factors affect 
verbal learning and memory performance (Lezak, 2004). Furthermore, since visual 
memory tests correlate with performance on tests of verbal learning and memory these 
same factors were also treated as covariates in the BFLT-E analyses (Lezak, 2004).
In addition to age, education, and verbal intelligence, the second set o f MANOCVA 
analyses of the word and figure data treated monthly use of alcohol and nicotine and 
cumulative lifetime use of drugs other than ecstasy and marijuana as covariates. Selection 
of these drugs specifically was based on MANOVA findings that indicated the use of 
these drugs was significantly different among the groups. In particular, cumulative 
lifetime uses of the following drugs were accounted for; cocaine, mushrooms, LSD, 
solvents, heroin, oxycontin (hyrdrocodone), muscle relaxers, xanax, percocet, valium, 
ritalin/adderall, ambien/lunesta, morphine, methadone, and demerol.
Separate Analyses of Covariances (ANCOVAs) were calculated for each of the 
dependent measures that reached significance in both the first and second sets of 
MANCOVA analyses. Scheffe post-hoc tests and simple effects analyses via ANCOVAs 
were performed on the AVLT and BFLT-E dependent measures that reached significance 
in each of the MANCOVA analyses.
The AVLT dependent measures examined were the total number o f words recalled on 
trial 1 (supraspan), trials 2-4, trial 5 (final acquisition level), interference (trial B), trial 6 
(immediate recall), and trial 7 (delayed recall). Additionally, total acquisition (sum of the 
number of words recalled on trial 1 through trial 5), the amount learned in five trials (trial 
5 - trial 1), proactive interference (trial 1 - trial B), retroactive interference (trial 5 - trial
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6), number of repetitions (words that were repeated), sum of error associations across 
trials 1 through 7 and trial B (words semantically or phonemically related to those in the 
stimulus list), and sum of error confabulations (words unrelated to those in the stimulus 
list) were measured.
Also, AVLT recognition hits and recognition errors were measured. Specifically, the 
types of recognition errors that were observed included: semantic association with either 
a List A (SA) or B (SB) word, phonemic association with either a List A (PA) or B (PB) 
word, and semantic-phonemic association with either a List A (SPA) or B (SPB) word.
The dependent measures examined on the BFLT-E included the number of figures 
recalled on trial 1 (supraspan), trials 2 - 4 ,  trial 5 (final acquisition level), interference 
distracter trial (List B figures), trial 6 (immediate recall), trial 7 (delayed recall). In 
addition, recognition performance, the sum of figures recalled on trials 1 through trial 5 
(total acquisition), the amount learned in five trials (trial 5 - trial 1), scores on the 
reproduction trials, and extraneous responses were included in the MANCOVA analyses.
Extraneous responses were summed for all of the BFLT-E trials, except the 
recognition trial. Both perseverations and extraneous responses constituted extra 
responses. Perseverations were defined as the repetition of a design, whereas, an extra 
response meant drawing a design that was unrelated to those in the stimulus list.
In the first MANCOVA analyses, where age, education, and WAIS-III vocabulary 
scores were covaried, the AVLT dependent measures that were significantly different 
among the groups were total acquisition, interference, immediate recall, delayed recall, 
and recognition. Also, gender X drug group interactions were observed for interference 
(trial B), proactive interference (trial 1 - trial B), and error associations. The BFLT-E
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dependent measures that reached statistical significance on the first MANCOVA analyses 
were immediate recall and extra responses. No interactions were observed on the BFLT- 
E data.
The second MANCOVA analyses, which additionally controlled for cumulative 
lifetime use of other illicit drugs (i.e., drugs other than ecstasy and marijuana), yielded 
the same set of significant outcomes on the AVLT measures as the first analyses, except 
for one the gender X drug group interaction for interference. Thus, significant findings 
were observed for total acquisition, interference, immediate recall, delayed recall, and 
recognition. Subsequently, gender X drug group interactions were observed for proactive 
interference and error associations on the AVLT. In contrast, none of the BFLT-E 
dependent measures that reached significance in the first MANCOVA analyses yielded 
significance in the second MANCOVA analyses.
Regression analyses were used to predict the contribution of drug use as reported by 
poly drug users in this study to memory performance on both the AVLT and BFLT-E. 
Total lifetime drug consumption as indicated by the total number o f times a drug was 
used was selected as the parameter of interest since lifetime consumption of cocaine and 
methamphetamine, for example, has previously been observed to correlate negatively 
with both immediate and delayed recall scores on the AVLT (Croft et al., 2001 ; Reneman 
et al., 2001 ; Thomasius et al., 2003).
In addition, regression analyses were used to examine the relationship of weekly and 
monthly marijuana use, and the average and largest dose of ecstasy consumed in an 
episode, to memory performance. The current frequency of regular use o f ecstasy and
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marijuana were thought to indicate most effectively the extent of pattern of use, with 
higher frequencies of use more likely to impart an influence on memory function.
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CHAPTER 4 
RESULTS
Descriptive Statistics
Descriptive statistics including means, standard deviations, range, and gender ratios 
for the groups are shown in Table 5. MANOVA analyses conducted on these data 
indicated that the groups did not differ with respect to age, education, or verbal IQ (p >
1). Additionally, the ratio of males to females was not statistically different among the 
groups. However, there were approximately half as many females to males in the Mh and 
E+Mh user groups compared to the M l and E+M l user groups who were more evenly 
matched (see Table 5).
Table 5 Demographic characteristics in the control group and the drug user groups.
Ç Ml Mh E+Mi E+My
N 25 28 22 15 19
Age in years (SD) 
r= range
20 (2.6) 
r=  18-27
20(1.8) 
r= 18-25
20(1.7)
1=18-23
21 (2.1) 
1=18-25
21 (2.9) 
1=18-29
Gender 15 F/IOM 12F/16M 8F/14M 8F/7M 6F/13M
Education in years (SD) 
r=range
14(1.3)
r=12-16
14(1.4)
r=12-18
14(1.5)
r=13-17
15 (2.0) 
1=12-20
15(2.1)
1=12-19
Estimated IQ (SD) 12 (2.4) 11 (2.6) 12(2.1) 13 (2.4) 12 (2.8)
Means and standard deviations were computed for age, education, and estimated IQ. The range (r) is also 
reported for age and education. The number of females (F) and males (M) in each group is reported in the 
row labeled gender.
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Information pertaining to drug use is reported in Table 6 (see Appendix I). The means 
and standard deviations represented in Table 6 are based on the total number of 
participants in each group who reported use of a particular drug. In some instances, only 
one participant in a group reported using the drug and so just that participant’s individual 
data are reported. For example, only one participant in the Mh group reported 
methamphetamine-amphetamine use, so the subsequent data for that group in Table 6 
represent the drug use by that one participant only.
Because of the exclusionary criteria used to establish group membership the only 
drug use reported by participants assigned to the control group (C) was alcohol and 
nicotine. MANOVA analyses of the drug use data across groups yielded a main effect of 
group for the following alcohol use characteristics; number of years used, F’(l,4) = 3.163, 
p  < 0.017, weekly use, F (\A ) -  4.671,/? < 0.002, and monthly use, F(\,A) = 5.016,/? < 
0.001. For nicotine, the drug use characteristics that were significantly different among 
the groups were age of onset, F(\,A) = 7.627,/? < 0.001, number of years used, F(\,A) = 
5.957,/? < 0.001, weekly use, F(\,A) = 5.711,/? < 0.001, and monthly use, F(l,4) = 3.831,
p  < 0.006.
Scheffe post-hoc tests conducted on the drug use characteristics related to alcohol 
showed the C group had used alcohol for a lesser number of years (p < 0.022) and 
consumed fewer alcoholic beverages on both a weekly (p < 0.003) and monthly (p < 
0.002) basis than the E+Mh group. None of the other group comparisons were significant.
For nicotine, Scheffe post-hoc tests indicated that the C group started using cigarettes 
at a significantly older age than the M l users (p < 0.010), E+M l users (p < 0.042), and 
the E+Mh users (p < 0.010). The E+Mh users had smoked for a longer period of time (p <
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0.010) and smoked more cigarettes a month (p < 0.007) than the C group. Weekly use of 
cigarettes was greatest among the combined user groups (i.e., E + M l and E+Mh) (p < 
0.010 for both).
With regard to ecstasy use, participants retrospectively assigned to either the E + M l or 
E+M h groups all exceeded the apriori criterion for assignment to the ecstasy use groups, 
which was consumption of at least ten ecstasy tablets within the past year. As expected, 
the MANOVA analyses yielded a significant main effect of group for all ecstasy drug use 
characteristics.
Scheffe post-hoc tests confirmed the ecstasy user groups (E +M l and E + M h) were 
similar on every aspect of ecstasy use, except the largest number of pills taken in an 
episode. The E +M h users reported taking a significantly larger number of pills in an 
episode (mean = 3.5 pills) compared to the E +M l users (mean = 2.2 pills) (p < 0.028).
Participants assigned to either the combined ecstasy-marijuana user groups or the 
marijuana-only user groups reported consistent marijuana use over the past year. Recall 
that participants were classified as light marijuana users if they reported use of marijuana 
fewer than five times per week, whereas participants who reported using marijuana five 
or more times per week were classified as heavy marijuana users. None of the 
participants assigned to the marijuana-only user groups reported ever using ecstasy.
For marijuana use, the MANOVA analyses indicated significant main effects o f 
group, as expected from the group assignments, for age of onset, F(\,A) = 289.506,/? < 
0.001, number of years used, F(\,A) = 19.093,/? < 0.001, time since last use, F(\,A) = 
10.631,/? < 0.001, cumulative lifetime use, F(\,A) = 6.780,/? < 0.001, weekly use, F(\,A) 
= 15.154,/? < 0.001, and monthly use, F(\,A) -  16.398,/? < 0.001. Scheffe post-hoc
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comparisons showed that both the M l and E +M l user groups smoked less marijuana a 
week and less a month compared to the M h and E+M h user groups {p < 0.001; p  <
0.001). Moreover, the comparisons of marijuana use between the M l and E + M l users and 
the M h and E +M h users were not significant (p > 1), which indicated that these groups 
frequency of marijuana use was similar to each other.
Marijuana abstinence periods (i.e., time since last use in weeks) were significantly 
longer in the M l users compared to both the M h and the E+M h user groups (p < 0.001 ; p  
< 0.001) indicating that the heavier marijuana user groups used marijuana more recently 
than the lighter user groups. There was not a significant difference in the time since last 
marijuana use in the M l and E +M l users (p > 1).
The M l and E+M h users also differed significantly with regard to the number o f years 
they had used marijuana (p < 0.001) and in the total number of times that they had used 
in their lifetime (p < 0.004). The E +M h group smoked marijuana for a longer period of 
time (p < 0.007) and smoked far more times in their lifetime than the M l users (p <
0.005). None of the marijuana user groups differed significantly from each other with 
respect to the age at which they began smoking marijuana.
With respect to other drug use (i.e., drugs other than marijuana and/or ecstasy), 
participants in the drug user groups reported use of the following drugs in the drug use 
questionnaire; cocaine, mushrooms, methamphetamine/amphetamine, LSD, solvents, 
heroin, oxycontin (hyrdrocodone), muscle relaxers, xanax, percocet, valium, 
ritalin/adderall, ambien/lunesta, morphine, methadone, and demerol. While data were 
collected for each of these drugs and drug use characteristics, cumulative lifetime use was 
used to assess the quantity of drug use among the groups because this measure reflected
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the total number of times a drug was used in a participant’s lifetime. Furthermore, 
cumulative drug use is one of the most widely used drug use characteristic evaluated in 
drug investigations. For example, there is evidence that shows cumulative use of cocaine 
for example is closely associated with deficits on AVLT trial 7 (Fox et al., 2001; 
Thomasius et al., 2004).
The MANOVA and subsequent ANOVA analyses conducted on cumulative lifetime 
uses o f other drugs showed that there were significant differences in the total number of 
times the drug user groups had taken cocaine (F(l,3) = 10.051,p  < 0.001), LSD (Ffl,3) = 
5.060,p < 0.003), oxycontin (hydrocodone) (F(l,3) = 2.962, p  < 0.037), percocet (Ffl,3) 
= 2.780,p  < 0.046), and xanax (F(l,3) = 2.886,p < 0.041). The Ml user group consumed 
the least amount of cocaine compared to the other drug user groups (M h,P < 0.039; 
E+ML, P < 0.007, E+Mh,P < 0.001). The Mh users and the E+M l users’ lifetime cocaine 
use did not differ but cocaine use was greater in the E+Mh users compared to the Mh 
users.
Participants in the E+Mh users also had taken a significantly greater amount of LSD 
across their lifetime than each of the other groups (M l,p  < 0.001; E + M l,p  < 0.003; 
E+M h,p < 0.004). Hyrdocodone use was greater in the Mh (p < 0.007) and E+ Mh user 
groups (p < 0.036) compared to the M l user group. No differences were observed in the 
E+M l user group. The cumulative use of percocet was significantly higher in the E+Mh 
user group relative to the M l users (p < 0.026) and E+M l users (p < 0.040). Furthermore, 
with respect to cumulative use of xanax, the Mh users reported a significantly greater 
lifetime use of xanax compared to the M l (p < 0.013) and E+M l (p < 0.049) user groups. 
There were no significant difference in cumulative use of xanax among the Mh users and
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E+Mh users (p > 1). When these findings are taken together, they indicate that the E+Mh 
user group consumed both a wider variety of other drugs, as well as a greater amount of 
those drugs, relative to the other drug user groups.
With the exception of hydrocodone and xanax use in the Mh users, the mean total 
number of times drugs other than marijuana and/or ecstasy were used did not exceed the 
apriori exclusionary criterion of not more than ten uses of any drug other than alcohol 
and nicotine in a lifetime. This criterion was relaxed post-hoc to not more than 15 
lifetime uses for each of the drugs inventoried in this study. This was done in order to 
include a few participants who reported greater than ten lifetime uses of one or two of the 
dmgs surveyed. Moreover, this had the advantage of increasing the power of the 
statistical analyses by increasing the number of participants in the drug user groups.
A VLT Task Data
Total Acquisition. Group means and standard deviations for total acquisition are 
reported in Table 7. The first column in Table 7 reflects the observed group means and 
standard deviations, that is, the means for each group prior to the treatment of factors as 
covariates in the MANCOVA and subsequent ANCOVA analyses. The second column 
represents the group means and standard deviations after age, education, and verbal IQ 
scores were treated as covariates. The third column reflects the group means and standard 
deviations after monthly use of alcohol and nicotine and cumulative lifetime use of other 
drugs were added as covariates (in addition to age, education, and verbal IQ).
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As mentioned earlier, the initial MANCOVA analyses conducted on the AVLT data 
treated age, education, and verbal IQ as covariates. The results indicated that there was a 
significant main effect of group for total acquisition scores, F(\,A) = 4.133,p  < 0.004.
Table 7 Mean total acquisition scores on the AVLT for each group (standard 
deviations are in parentheses)
Group
Observed
Means*
Adjusted
Means**
Adjusted
Means***
C 58.120(4.2) 57.558 (2.3) 58.073 (2.7)
Ml 56.071 (6.5) 56.965 (2.2) 57.081 (2.4)
Mh 53.773 (6.4) 53.660 (2.4) 52.629 (2.8)
E+Ml 52.773 (6.7) 52.135 (3.0) 51.236 (3.2)
E+Mh 52.316(5.7) 52.342 (2.6) 53.396 (3.5)
Notes; * = means before the covariate analyses; ♦* = means after age, education, and verbal IQ were 
treated as covariates; *♦♦ = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Figure 5 illustrates group mean total acquisition scores and standard errors before the 
adjustment for covariates. Subsequent Scheffe post-hoc tests showed that the sum of 
words recalled across trials 1 through 5 was significantly higher for group C and the M l 
users compared to the M h ip < 0.020;p  < 0.044), E +M l ip < 0.005; /? < 0.011), and 
E+M h users (p < 0.004; p  < 0.008). Total acquisition scores were similar among the M h, 
E +M l, and E +M h users (p > 1 ).
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Figure 5 Mean AVLT total acquisition scores and standard errors for each group.
When monthly use o f alcohol and nicotine and cumulative lifetime use of other drugs 
were added as covariates in the MANCOVA analyses, the pattern o f findings was 
identical to that given above. A main effect of group was observed, F(\,A), = 3.403, p  < 
0.013, where the sum of the words recalled on trials 1 through 5 was highest for group C 
(M h, P  < 0.008; E +M l,/?  < 0.003; E +M h, p  < 0.006) and M l users (M h, p  < 0.023; 
E +M l, p  < 0.006; E +M h, p  < 0.001). AVLT total acquisition scores were similar among 
the M h, E +M l, and E +M h users (p> 1).
Taken together, these findings showed a dose response effect o f marijuana use and a 
possible neuroprotective effect of ecstasy on marijuana. Heavier or more frequent use of 
marijuana affected word learning more profoundly than lighter marijuana use. This was 
evidenced by the difference in total acquisition scores between the Ml and Mh users.
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In contrast, when ecstasy use was present, the dose response effect for marijuana was 
attenuated. The lack of difference between total acquisition scores in the combined user 
groups (E + M l and E +M h) might reflect a “basement effect.” However, since the E + M l 
and E +M h user groups were matched on every aspect of ecstasy use and differed with 
respect to their marijuana use, it is possible that ecstasy use attenuated the degree to 
which heavy marijuana use produced the observed impairment in the acquisition of words 
across five learning trials. Finally, the lack of significant differences in total acquisition 
scores among group C and the M l users (p > 1) suggests that the M l users particular 
pattern of marijuana use was not sufficient to impact adversely the ability to learn a list of 
words.
Interference Trial. Scores on interference trial B represented the number of words 
recalled following a single presentation of a new word list (List B). List B assessed 
participants’ supraspan ability immediately following learning, that is, the attentional 
processes related to the acquisition of information prior to storage. Group means and 
standard deviations for the interference trial are presented in Table 8.
Table 8 Mean number of words recalled on the interference trial for the groups 
(standard deviations are included in parentheses)
Group
Observed
Mean*
Adjusted
Means**
Adjusted
Means***
C 6.800(1.9) 6.611 (0.7) 6.540 (0.8)
Ml 7.321 (2.1) 7.514(0.7) 7.545 (0.7)
M h 6.046(1.7) 6.042(1.3) 5.764 (0.9)
E+M l 6.667(1.5) 6.501 (0.9) 6.108(1.0)
E+M h 5.895 (1.6) 5.994 (0.8) 6.676(1.1)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
134
The initial MANCOVA and subsequent ANCOVA analyses showed that there were 
significant group differences in the number of words recalled on List B, F(\ ,4) = 3.034 , 
p  < 0.021. The number of words recalled from the interference list (List B) was similar 
for group C and each of the drug user groups. However, the M l users recalled 
significantly more words on the interference trial than the Mh users {p < 0.004) and the 
E+Mh users (p < 0.004). Figure 6 displays the observed mean number of words recalled 
on the interference trial for the groups.
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Figure 6 Mean number of words recalled on the interference trial (List B) of the 
AVLT for each group.
These findings along with a lack of significant differences between the Mh users and 
the E+M l and E+Mh users indicates that heavier marijuana use and not ecstasy use, is
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more closely associated with producing a decrease in the number of words recalled or 
disruptions in attentional processes needed to learn a new list of words.
The first analyses also indicated there were differences in the number of words 
recalled by males and females on the interference trial. This was supported by 
MANCOVA-ANCOVA findings of a significant gender X group interaction, F(l,4) = 
2.512,/? < 0.047. Interference trial means and standard deviations for males and females 
in the groups are reported in Table 9.
Table 9 Interference scores for males and females in each group (means and 
standard deviations)
Observed Adjusted Adjusted
Means* Means** Means***
Group Females Males Females Males Females Males
C
Ml
Mh
E+Ml
E+Mh
6.200(1.9)
7.846(1.9)
6.250(1.4)
7.250(1.8)
5.714(1.4)
7.700(1.6) 
6.867(2.1) 
5.928 (1.9) 
6.000 (0.8) 
6.000 (1.8)
6.009 (0.9) 
7.696(1.0) 
6.123(1.2) 
6.771 (0.9) 
5.369 (1.5)
7.987(1.1) 
6.997(1.0) 
6.001 (0.9) 
6.547 (0.9) 
6.201 (1.1)
6.034(1.0)
7.228(1.2)
6.168(2.1)
7.034(1.1)
6.175(0.8)
7.949(1.2) 
7.402(1.1) 
5.975(1.4) 
6.247 (1.2) 
5.733 (0.9)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Tests of simple effects conducted via ANCOVA analyses revealed that females in 
group C recalled significantly fewer words than males (/? < 0.010). Figure 7 illustrates the 
gender differences in interference performance. The finding of poorer recall performance 
in the females assigned to the C group was tmexpected, since females tend to perform 
better on tests of verbal learning and memory than males (Lezak, 2004).
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Gender x Drug Group Interaction Means-Interference (AVXT)
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Figure 7 Observed means and standard errors for females and males in each group on 
the interference trial of the AVLT.
When monthly and cumulative use of other drugs were added as covariates, in the 
second MANCOVA-ANCOVA analyses, the main effect of group remained significant 
for interference scores, F(l,4) = 2.577 ,p  < 0.043. Likewise, post-hoc tests confirmed the 
dose response effect of marijuana use. This was demonstrated by the finding that the M l 
users recalled more words from interference List B than the Mh users (p < 0.004).
Unlike the post-hoc findings in the first analyses, however, the E +M h user group’s 
word recall performance was no longer significantly worse than the M l users’ (p > 1). 
This result demonstrates that other drug use is associated with the word recall deficit 
observed for interference in the E +M h users and highlights the importance of accounting 
for polydrug use in ecstasy research.
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An effect of ecstasy use on AVLT interference performance was also observed in the 
second analyses. This was demonstrated by the fact the E +M l users recalled significantly 
fewer words from interference List B compared to the Ml users (p < 0.028). Given that 
these groups were matched for marijuana use and that other drug use was treated as a 
covariate, the increased impairment observed in the E+M l users is likely attributable to 
ecstasy use. It is possible that ecstasy use affected word recall in the E +M h users, too, but 
may have been masked by the effects generated from taking other drugs. Finally, the 
gender x drug group interaction for interference observed in the initial analyses was not 
observed in the second set of analyses.
Proactive Interference. Proactive interference scores were calculated for each 
participant by subtracting the sum of words recalled on interference trial B from the sum 
of words recalled on trial 1 (trial 1 -  trial B). This measure reflects the extent to which 
List A learning interfered with the ability to learn words from List B. Greater word recall 
scores in trial 1, compared to trial B (e.g., +1.1) indicate a more pronounced effect of 
proactive interference, while scores of zero or lower (e.g., -1.1) indicate that List A 
learning did not interfere with word learning in List B or that no proactive interference 
effect was obtained.
Table 10 contains the observed means and standard deviations calculated for AVLT 
proactive interference for each group. There were significant differences in the amount of 
proactive interference exhibited among males and females within a group. This was 
confirmed in the first set of MANCOVA-ANCOVA analyses by a significant gender X 
group interaction, F(l,4) = 2.512,/? < 0.047.
138
Table 10 Proactive interference scores for males and females in each group (means 
and standard deviations)
Observed Adjusted Adjusted
Means* Means** Means* **
Group Females Males Females Males Females Males
C 1.133 (2.0) 0.100 (1.4) 1.256 (0.9) -0.084(1.1) 1.617(1.1) 0.146(1.3)
Ml -0.692(2.1) 0.267 (2.2) -0.591 (1.1) 0.179 (1.0) -0.152(1.1) 0.113(1.0)
Mh 0.625 (2.2) 1.214(1.7) 0.750 (1.4) 1.143(1.0) 0.675(1.5) 0.785(1.2)
E+Ml -0.750 (2.4) 0.714(1.5) -0.424(1.4) 0.342(1.6) -0.218(1.5) 0.698(1.6)
E+Mh 1.714 (2.1) 0.417(2.3) 2.695 (1.8) -0.155(1.3) 2.733 (1.9) -1.091 (1.5)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; ♦♦• = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Figure 8 illustrates proactive interference scores on the AVLT for females and males 
in each group. Scheffé post-hoc comparisons after the first set of analyses showed that 
females in the E+M h user group had greater difficulty learning List B words because of 
interference created by List A learning than males (p < 0.004).
•1.50
Gender x Drug G roup Interaction-Proactive Interference (AVLT)
■ Females 
■Males
**0,50 -
ConuM
- 1.00 -
aligUt MiryuauaHcavy Ecni^^uai'ijuaua Ecstasy-Marijuaua
Heaiy
Drug Ch oup
Figure 8 Observed means and standard errors calculated for proactive interference 
for each group.
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The gender X group interaction for proactive interference scores remained significant 
after accounting for other drug use, F(\,A) = 3 .4 8 7 ,< 0 .0 1 1 . Likewise, post-hoc tests 
also showed that the female E+M h users experienced more proactive interference from 
List A learning than the males {p < 0.001) which indicates that females showed a 
decreased ability to suppress previous List A learning during the acquisition of List B 
words.
Trial 6 (Immediate Recall). Scores on trial 6 of the AVLT reflect the number of 
words recalled from List A, immediately following a single presentation and recall of 
interference List B. Group means and standard deviations for the number o f words 
recalled on AVLT trial 6 are displayed in Table 11. The initial MAN CO V A-AN COV A 
analyses showed there were significant group differences in the number of words recalled 
on trial 6, F("l ,4) = 3.112 ,/? <0.018.
Table 11 AVLT trial 6 (immediate recall) scores for each group (means and standard 
deviations are reported)
Observed Adjusted Adjusted
Group_________Means*_____ ________ Means**  Means***
c 13.040(1.6) 12.959 (2.3) 12.972(1.1)
Ml 12.214 (2.2) 12.436(1.0) 12.643(1.0)
Mh 11.000(3.4) 11.011 (1.0) 10.096(1.2)
E+Ml 11.333 (2.4) 11.071 (1.3) 11.148 (1.4)
E+Mh 11.000(2.7) 10.974(1.1) 11.650(1.5)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Figure 9 displays the group means and standard errors for the AVLT immediate recall 
trial. Post-hoc tests showed that immediate recall performance for groups C and Ml were
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similar (p > 1). However, group C recalled significantly more words after the 
presentation of the interference list than the Mh ip < 0.023), E+Ml ip < 0.044) and E+Mh 
user groups (p < 0.011).
Additionally, a dose response effect of marijuana use was demonstrated by the fact 
that the M l users recalled significantly more words after the presentation of the 
interference list than the Mh users (p < 0.047). Immediate recall performance in the M l 
users was also significantly higher than the E+Ml ip < 0.024) and E+Mh user groups (p < 
0.012). There were no observed differences in scores on trial 6 among the Mh users and 
either o f the combined user groups (E+Ml and E+Mh) (for both p  > 1).
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Figure 9 Mean number of words recalled on AVLT trial 6 for each group.
When cumulative use of other drugs were controlled for in the second MANCOVA-
ANCOVA analyses, group main effects remained significant for trial 6, F(\,A) = 3.448,p
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< 0.012. However, the post-hoc comparisons that reached significance were different in 
the second set of analyses. For instance, neither of the combined user groups (E +M l and 
E+M h) no longer recalled significantly fewer words than group C or M l users (for both p  
>1), which indicates that the word recall deficits observed in the E +M l and E +M h user 
groups in the first set of analyses are probably more appropriately attributed to the use of 
other drugs. The Mh users recalled fewer words from List A following the interference 
trial than M l users ip < 0.002) suggesting that there may be a dose response effect for 
marijuana use on immediate recall.
Trial 7 (Delayed Recall). Group means and standard deviations for trial 7 of the 
AVLT are displayed in Table 12. The groups differed with respect to the number of 
words recalled after a 20-minute delay. This was evidenced by a main effect for group in 
the first MAN CO VA-AN CO VA analyses, F (\,4) = 5.119 ,p  < 0.001.
Table 12 Trial 7 (delayed recall) scores for each group (means and standard 
deviations)
Group
Observed
Means*
Adjusted
Means**
Adjusted
Means***
C 13.440 (1.4) 13.361 (0.9) 13.200(1.0)
Ml 12.464 (2.0) 12.706(0.8) 12.818(0.9)
Mh 11.636(2.6) 11.639(0.9) 11.243 (1.0)
E+Ml 11.200(2.3) 10.936(1.1) 11.109(1.2)
E+Mh 11.000(2.8) 10.954(1.0) 11.322(1.3)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use o f other drugs were treated as covariates.
Figure 10 illustrates the differences between the groups performance on AVLT trial 
7. Group C recalled more words after the 20-minute delay than the Mh ip < 0.007), the 
E +M l (p  < 0.001), and E +M h user groups ip < 0.001). The M l users recalled significantly
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more words after the long delay than the E+Ml users (p < 0.013) and the E+Mh users (p < 
0.008).
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Figure 10 Mean number of words recalled on trial 7 of the AVLT for each group.
The main effect of group remained significant in the second MANCOVA-ANCOVA
analyses, F(\,4) = 2.925,p  < 0.026. Post-hoc tests indicated that group C recalled more
words after the 20-minute delay than the Mh (p < 0.008), the E+Ml (p < 0.011), and
E+Mh users (p < 0.037). Moreover, the Ml users recalled significantly more words than
the Mh users (p < 0.026) and the E+Ml users (p < 0.024) on trial 7. The comparison
between the E+Mh users and the M l users delayed recall performance was not far from
approaching significance (p < 0.067).
Taken together, these findings suggest that the fi-equency of marijuana use primarily
affects delayed recall performance. Heavier marijuana use was associated with greater
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reductions in the number of words recalled on trial 7 than lighter use. While ecstasy use 
also had a negative impact on delayed recall scores, its effects tended to be less robust.
Recognition. Group means and standard deviations for hits or the number of words 
accurately discriminated as List A words on the AVLT recognition trial are reported in 
Table 13. There were significant differences among the groups with respect to hits on the 
recognition trial. This was confirmed in the initial MANCOVA and subsequent 
ANCOVA analyses yielded a main effect of group, F(l,4) = 3.181 ,p  < 0.017 on 
recognition scores.
Table 13 Recognition scores for each group (means and standard deviations)
Group
Observed
Means*
Adjusted
Means**
Adjusted
Means***
C 14.880 (0.4) 14.809 (0.4) 14.805 (0.4)
Ml 14.429 (0.8) 14.539 (0.3) 14.544 (0.1)
Mh 14.318(0.7) 14.293 (0.4) 14.015 (0.4)
E+Ml 13.867(1.5) 13.821 (0.5) 13.858 (0.5)
E+Mh 14.368(1.0) 14.364 (0.4) 14.656 (0.5)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use o f other drugs were treated as covariates.
Figure 11 graphically displays group performance on the AVLT recognition trial. The 
C group accurately recognized more words from List A than the Mh users (p < 0.043) 
and E +M l users (p < 0.001). Recognition performance was also significantly better in the 
M l users than in the E +M l users (p < 0.013). There were no detectable differences among 
the M h users, E +M l users, and E +M h users (p>  1).
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Figure 11 Observed group means and standard errors for hits on the AVLT 
recognition trial.
Group differences remained significant when other drug use was controlled in the 
second MANCOVA-ANCOVA analyses, F (\,4) = 3.680 , p  < 0.008. Scheffé post-hoc 
tests showed that group C recognized more words than the Mh users (p < 0.006) and the 
E +M l users (p < 0.003) The M l users recognized more words than the E + M l users (p < 
0.019), which illustrates a negative impact o f ecstasy use given these groups were 
matched for marijuana use and other drug use was treated as a covariate. Interestingly, 
the E +M h users recognized more words than the E +M l users (p < 0.018) and did not 
differ statistically from the other groups (p >  1). No obvious reason for this result is 
apparent in the data.
Error Associations. An error association was defined as the recall o f a word that 
was either semantically or phonemically related to a word in the stimulus list. An
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increase in association errors is indicative of retrieval problems such as “tip-of-the- 
tongue” syndrome,_where participants’ reveal they know the correct word but are unable 
actually to recall it (Brown & McNeil, 1966). Error associations were summed for AVLT 
trials 1 through 7 and the interference trial.
In the initial set of MANCOVA-ANCOVA analyses, a significant gender X group 
interaction was observed for AVLT error associations, F(\,4) = 3.478,p  < 0.011, 
demonstrating that there were differences in the number of associations committed by 
males and females in a group. Error association means and standard deviations for males 
and females in each group are reported in Table 14.
Table 14 Error association scores for males and females in each group (means and 
standard deviations)
Observed
Means*
Adjusted
Means**
Adjusted
Means***
Group Females Males Females Males Females Males
C 0.1 (0.3) 0.9 (1.6) 0.0 (0.6) 0.9 (0.7) 0.1 (0.9) 0.8 (1.1)
Ml 0.5 (0.7) 0.4 (0.8) 0.5 (0.4) 0.3 (0.4) 0.6 (0.9) 0.4 (1.0)
Mh 0.1 (0.4) 1.0 (1.3) 0.2 (0.7) 1.0 (0.5) 0.1 (1.2) 0.7 (1.0)
E+Ml 0.8 (1.5) 2.0 (3.0) 0.7 (2.0) 2.0 (2.1) 0.6 (1.2) 2.3 (1.3)
E+Mh 2.1 (3.6) 0.3 (0.6) 2.8 (2.1) 0.2 (1.5) 2.7 (1.5) 0.2 (1.2)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; ♦•♦ = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Figure 12 illustrates the mean number of associations made by males and females in 
the groups. Tests of simple effects revealed that the females in the E+Mh user group 
made significantly more error associations on the AVLT than the male E+Mh users (p < 
0.050) suggesting that ecstasy use combined with heavier marijuana use produced greater 
difficulty with word retrieval in females.
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Figure 12 Mean number of error associations made by males and females in each 
group on the AVLT.
Similarly, the gender X group interaction for AVLT error associations was observed 
in the second analyses, Ffl,4) = 4.513, p  < 0.050. Tests of simple effects revealed the 
males in the E +M l user group made significantly more AVLT error associations than 
females in the E +M l group (p < 0.049). Alternatively, females in the E + M h user group 
made significantly more association errors than the male E +M h users (p < 0.048).
BFLT-E Tasks
Trial 6 (Immediate Recall). Like the AVLT, trial 6 of the BFLT-E represents 
immediate recall, that is, the number of figures recalled from List A following the 
presentation of a new list of figures (List B). The initial MANCOVA-ANCVOA analyses 
that treated age, education, and verbal IQ scores as covariates yielded a main effect of
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group for BFLT-E immediate recall scores, F(\,A) = 2.676,p  < 0.014. The observed and 
adjusted group means and standard deviations for the immediate recall trial on the BFLT- 
E are reported in Table 15.
Table 15 BFLT-E immediate recall scores for each group (means and standard 
deviations)
Group
Observed
Means*
Adjusted
Means**
Adjusted
Means***
C 39.320 (5.3) 39.571 (2.3) 39.905(1.3)
Ml 37.750 (5.9) 38.362 (2.2) 37.873 (1.2)
Mh 37.727 (4.5) 37.847 (2.4) 37.738(1.4)
E+Ml 36.933 (6.8) 35.871 (3.0) 37.571 (1.6)
E+Mh 35.105 (6.7) 34.573 (2.6) 33.638(1.7)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Figure 13 illustrates BFLT-E immediate recall performance for each of the groups. 
Scheffé post-hoc tests showed that the E+Mh user group recalled significantly fewer 
figures from List A following the presentation and recall of a new list o f figures 
compared to group C (p < 0.005) and the Ml user group (p < 0.028). None of the other 
comparisons were significant.
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Observed group means and standard errors for the BFLT-E immediate
When monthly use of alcohol and nicotine and the cumulative use of other drugs were 
added as covariates in the second set of MANCOVA-ANCOVA analyses, immediate 
recall scores were no longer significantly different between the groups (p > 1). This 
indicates that the use of other drugs accounted for a significant proportion of the 
immediate recall impairment observed in the E +M h drug user group in the first set of 
analyses.
Extra Responses. Extra responses were summed for all of the BFLT-E trials, except 
the recognition trial. Both perseverations and extraneous responses constituted extra 
responses. Perseverations were defined as the repetition of a design, whereas, an extra 
response meant drawing a design that was unrelated to those in the stimulus list. Means 
and standard deviations for BFLT-E extra response data for each group are presented in 
Table 16.
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Table 16 BFLT-E extra responses for each group (means and standard deviations)
Group
Observed
Means*
Adjusted
Means**
Adjusted
Means***
C 0.200 (0.4) 0.231 (1.6) 0.483 (0.9)
Ml 1.464(2.8) 1.144(1.5) 1.598 (0.8)
Mh 2.546 (5.2) 2.454(1.7) 2.321 (1.0)
E+Ml 2.667 (6.8) 3.256 (2.0) 2.968(1.1)
E+Mh 4.211 (6.7) 4.282(1.8) 3.663 (1.2)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were 
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and 
cumulative lifetime use of other drugs were treated as covariates.
Initial MANCOVA-ANCOVA analyses conducted on the BFLT-E extra response 
scores yielded a main effect of group, F(\,4) ~ 3.454, p  < 0.011, demonstrating that there 
were significant differences in the number o f extra responses made across the groups. 
Post-hoc tests confirmed that the ecstasy-marijuana user groups (E + M l and E +M h) made 
more extra responses than group C (p < 0.022; p  < 0.001). Also, the E + M h users 
committed more errors on this BFLT-E measure than the M l users (p < 0.009). Figure 14 
displays the differences in the number of BFLT-E extra response committed for each 
group.
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The observed mean total number of extra responses made on BFLT-E trials 
and on interference trial B for each group.
In contrast, the main effect of group for the BFLT-E extra response data did not reach 
significance in the second set of MANCOVA-ANCOVA analyses (p >1). This suggests 
that the group differences initially observed in the first set of analyses were closely 
associated with the consumption of drugs other than ecstasy and marijuana.
Taken together, the second set of analyses conducted on the immediate recall and 
extra response data emphasize the importance of accounting for polydrug use in 
recreational ecstasy users. Moreover, these findings call into question the conclusions 
drawn in previous studies that did not take into account the use of dmgs other than 
ecstasy.
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Regression Analyses
Two standard multiple regression analyses were conducted to examine the degree to 
which ecstasy, marijuana, and other drug use predicted performance on the AVLT 
dependent measures that were significant in the MANCOVA-ANCOVA analyses which 
treated age,_education, verbal IQ, and other drug use as covariates. In both regression 
analyses, the following AVLT dependent measures were treated as criterion variables: 
total acquisition, interference, immediate recall, delayed recall, and recognition.
In the first regression analysis, one drug use characteristic for ecstasy and six drug 
use characteristics for marijuana were used as predictor variables. The drug characteristic 
used as a predictor for ecstasy was cumulative lifetime use. This decision was based on 
regression analyses conducted earlier on all eight ecstasy use characteristics (refer to 
Table 6 for the drug use characteristics associated with ecstasy) which revealed 
cumulative lifetime ecstasy use was the only significant predictor, R  ̂= .030, F (l, 101) = 
2.10,p < .05. The following marijuana use characteristics were treated as predictors: age 
of onset, number of years used, time since last use, amount of weekly use, amount of 
monthly use, and cumulative lifetime use.
The seven predictors accounted for 16.3 percent of the variance in total acquisition 
scores on the AVLT, R̂  = .163, F (\, 101) = 2.80,p  < .05. The simultaneous solution 
suggested that the number of years marijuana had been used was the primary predictor 
that explained AVLT total acquisition scores, P = -.374, /(lOl) = -3.07,p  = .003. This 
indicates that more deficits were observed in word learning performance with longer use 
of marijuana. Furthermore, none of the other marijuana use or ecstasy use predictors were
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found significantly to explain the variance for the other AVLT dependent variables: 
interference, immediate recall, delayed recall, and recognition.
The second multiple regression analysis treated monthly use of alcohol and nicotine 
and cumulative use of cocaine, LSD, oxycontin (hydrocodone), xanax, and percocet as 
predictors to examine the contribution that these drugs had on verbal learning and 
memory performance on the same significant AVLT dependent measures evaluated in the 
first regression analysis. These drugs were selected as predictor variables because prior 
MANOVA analyses conducted on the drug use data revealed the groups differed 
significantly with respect to the total number of times these drugs had been used.
Collectively, the seven predictor variables accounted for 4.5 percent o f the variance 
of AVLT total acquisition scores, ^  = .045, F (\, 95) = 5.08, p  < .05. This indicates that 
more deficits were observed in word learning performance when total lifetime uses of 
cocaine, LSD, oxycontin (hydrocodone), xanax, and percocet were greater. No one 
predictor contributed significantly to the variance of the total number of words recalled 
on the first five AVLT learning trials, although, cumulative LSD use was found to 
approach significance, ̂  = -.170, t(95) = -1.81, p  = .072.
Likewise, the seven predictors together accounted for 11 percent of the variance in 
delayed recall scores on the AVLT, = .110, F( \ , 95) = 5.08,p  = .05. The most 
important predictor observed was cumulative LSD use, P = -.304, t(95) = -2.92, p  < .05, 
which is consistent with previous findings (Croft et al., 2001 ; Fox et al., 2001). These 
findings demonstrate that greater lifetime uses of cocaine, oxycontin (hydrocodone), 
xanax, percocet, and especially LSD are associated with reductions in the number of 
words recalled after a long delay. None of the other predictors were found to be
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significant for interference, immediate recall, or delayed recall performance on the 
AVLT.
In summary, the regression analyses corroborated findings obtained in the secondary 
AVLT MANCOVA-ANCOVA analyses, which showed effects o f ecstasy, marijuana, 
and other drug use on total acquisition and delayed recall performance. With respect to 
total acquisition, more deficits were observed in word learning performance with longer 
use of marijuana and to a lesser extent, with greater lifetime use o f ecstasy. Still further, 
larger deficits were observed for total acquisition when total lifetime uses of cocaine, 
LSD, oxycontin (hydrocodone), xanax, and percocet were greater. The fact that 
cumulative LSD use approached significance in the regression analyses suggests that 
total LSD use may affect word learning to a greater extent than the other drugs examined. 
Finally, greater reductions in word recall after a long delay were observed with greater 
lifetime use of other drugs, especially LSD use.
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CHAPTER 5 
DISCUSSION
The primary goal of the present study was to investigate the extent to which word 
learning and memory deficits, previously observed in studies of recreational ecstasy 
users, are associated with concomitant marijuana use and/or the use of other drugs rather 
than ecstasy per se. The results that emerged from this study both complement and 
contradict the findings of earlier studies that have investigated the effects of ecstasy use 
on verbal learning and memory performance.
The results in the present study demonstrate that verbal learning and memory 
deficits occurred on the AVLT in the combined ecstasy-marijuana users relative to non­
drug using controls, which is consistent with a number of previous memory studies of 
recreational ecstasy users (e.g., Croft et al., 2001; Dafters et al., 1999; Fox et al., 2001; 
Gouzoulis-Mayfrank et al., 2000; Klugman et al., 1999; Lamers et al., 2006; McCann et 
al., 1998; McCardle et al., 2004; Morgan, 1999; Parrott & Lasky, 1998;Parrott et al.,
1998; Quednow et al., 2006; Reneman et al., 2001; Thomasius et al., 2003; Verkes et al., 
2001; Wareing et al., 2000; Yip & Lee, 2005). Similarly, greater word recall deficits were 
observed in heavier marijuana users than in non-drug using controls (e.g.. Block & 
Ghoneim, 1993; Bolla et al., 1998; Bolla et al., 2002; Croft et al., 2001; Dafters et al., 
2004; Fletcher et al., 1996; Gouzoulis-Mayfrank et al., 2000; Kanayama et al., 2004;
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Lamers et al., 2006; Pope et al., 2001; Pope & Yurgelxm-Todd, 1996; Solowij et al.,
2002).
Of more direct relevance to the primary research question was the finding that, 
generally speaking, verbal learning and memory impairments in the concurrent ecstasy- 
marijuana user groups resembled those in the heavy marijuana-only user group, 
indicating that the deficits observed in the combined ecstasy-marijuana users may be 
more attributable to marijuana use than ecstasy use. Moreover, marijuana’s negative 
effects on word learning and memory were dose dependent, which is consistent with 
other published findings (e.g., Accordino et al., 2006; Bolla et al., 2002; Bolla et al.,
1998; Fletcher et al., 1996; Fried et al., 2002; Hall et al., 2004; Kouri et al., 1995; Solowij 
et al., 1998). In this context, it should also be noted that the illicit use of psychoactive 
substances other than ecstasy or marijuana also negatively impacted word recall in the 
drug user groups.
More specifically with regard to the use of marijuana, dose response effects were 
demonstrated for total acquisition, interference, immediate recall, and delayed recall trials 
on the AVLT. On each of these dependent measures, heavier marijuana-only users 
experienced greater difficulty learning two lists of words and subsequently retrieving 
words from those lists than lighter marijuana-only users. Subsequently, heavier marijuana 
use disrupted the ability to freely recall words from List A both immediately after list 
presentation (immediate recall) and 20-minutes following List A presentation (delayed 
recall). In contrast, to its effects on free recall, marijuana has no effect on recognition of 
previously presented words within a list of old and new words. As previously mentioned, 
these dose-response effects of marijuana are in agreement with other published findings.
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For example. Block and Ghoneim (1993) have reported that relative to a matched group 
of non-dmg using controls, heavy marijuana users had significant impairments in 
memory retrieval along with deficits in verbal expression and mathematical reasoning. 
Similarly, a large prospective study using younger and older populations o f Costa Rican 
marijuana users and matched controls found that prolonged use of marijuana is associated 
with deficits in free recall and list learning tasks (Fletcher et al., 1996).
The results also imply that lighter marijuana users are not impaired to an extent that 
would interfere with memory functioning in their daily lives. The Ml drug user group 
performed similarly to the non-drug control group on total acquisition, immediate recall, 
delayed recall, and recognition trials o f the AVLT. The Ml users reported smoking 
marijuana 243 times in their lifetime, an average of once a week over a period of three 
years, with two weeks elapsing since the time of their last use. In contrast, the Mh user 
group reported using marijuana a total of 2,241 times in a four year period, smoking an 
average of 12.5 times a week, with less than half a week elapsing since they had last used 
marijuana.
Two lines of evidence suggest that the deficits in the combined ecstasy-marijuana 
drug user groups were not related primarily to ecstasy consumption. The first is that if 
ecstasy or the combination of ecstasy and marijuana were responsible for the cognitive 
deficits seen on the AVLT, then it would be expected that the participants who used both 
ecstasy and marijuana would perform more poorly than those who had used only 
marijuana, whereas if marijuana were primarily responsible for the deficits then there 
should be no difference between the groups. Thus, the present finding that neither of the 
ecstasy-marijuana user groups performed worse than the heavier users of just marijuana
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on total acquisition, interference, immediate recall, and delayed recall trials suggests that 
the deficits obtained in the combined user groups were not primarily associated with 
ecstasy use. Second, that the number o f years of marijuana use was the best predictor of 
AVLT total acquisition performance in the regression analyses further substantiates 
marijuana’s contribution to the word learning and memory deficits observed in the 
current work.
Further support for the argument that ecstasy use is not predominantly responsible for 
poorer word recall performance can be derived from the second set of MANCOVA- 
ANCOVA analyses, which treated other drug use as a covariate (i.e., monthly use of 
alcohol and nicotine and the cumulative lifetime use of cocaine, amphetamine- 
methamphetamine mushrooms, LSD, solvents, heroin, oxycontin (hyrdrocodone), muscle 
relaxers, xanax, percocet, valium, ritalin/adderall, ambien/lunesta, morphine, methadone, 
and demerol). This other drug use was responsible for a significant proportion of the 
differences among the drug user groups on interference, immediate recall, and delayed 
recall scores on the AVLT. Moreover, the regression analyses showed that other drug use 
explained 4.5 percent of the differences in total acquisition scores on the AVLT, with 
LSD falling just short of approaching significance as the best predictor o f total 
acquisition performance. Indeed, LSD accounted for the largest proportion of the 
variance observed in delayed recall scores among the drug user groups. Similarly, other 
illicit drug use was strongly associated with figure recall deficits and errors committed on 
the BFLT-E dependent measures.
Although heavier marijuana and other illicit drug use were closely associated with the 
observed word learning and retrieval failures in the present study, subtle negative effects
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of ecstasy use were, in fact, found. For example, E+M l users exhibited greater difficulty 
learning new sets of words, as shown by lower total acquisition and interference scores, 
than the M l users. Moreover, female E + M h users experienced a greater inability to 
suppress previous List A learning while trying to acquire List B words than male E +M h 
users. Additionally, males in the E +M l user group and females in the E + M h user group 
made significantly more errors of association than the corresponding marijuana-only user 
groups. Finally, the E +M l users also had more difficulty with word retrieval after the 20- 
minute delay and with word recognition than the M l users.
Taken together, the above articulated subtle effects of ecstasy do not invalidate the 
robust verbal learning and memory deficits reported in other ecstasy research, they just 
were not observed in the present study. Differences in word recall performance were 
primarily associated with heavier marijuana use and the illicit use of other psychoactive 
substances. To some extent, ecstasy use negatively affected word learning rates, free 
recall abilities, and the number of errors committed on the AVLT. However, the extent of 
ecstasy’s contribution to verbal impairment seems far less reaching than that of marijuana 
and other drugs.
The disparity between the results observed in this study and other published research 
on ecstasy may be, in part, explained by differences in participants’ ecstasy use 
characteristics. The total number of ecstasy tablets taken among the ecstasy-marijuana 
user groups in this study was substantially less than in previous studies (see Table 3 in 
Appendix I). For example, in this study, the ecstasy-marijuana user groups reported a 
mean cumulative lifetime use of 30.3 (E + M l) and 33.4 (E +M h) ecstasy tablets compared 
to ecstasy users in the Thomasius et al. (2003) study, who reported a mean cumulative
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use of 1,033 ecstasy tablets and relative to the ecstasy users in the Quednow et al. (2006) 
study who had used 457 ecstasy pills in their lifetime.
It should be noted that heavy marijuana smokers (M h and E +M h)  reported a higher 
rate of use of other drugs, which is consistent with findings from other investigations 
(Bolla et al., 1998; Hall et al., 1995; Kouri et al., 1995; Pope et al., 2001; Solowij et al., 
2002). Both of the heavier marijuana groups used a wider variety of drugs and more of 
them. Other studies show that as polydrug use widens, it also intensifies, with polydrug 
users being also the heaviest users of alcohol, tobacco, and other stimulants (e.g., Kouri 
et al., 1995; Milani et al., 2000; Parrott et al., 2001).
The present study extends the existing ecstasy literature related to cognitive and 
memory function. This study dealt with the methodological shortcomings and 
confounding variables that have plagued a number of earlier ecstasy-related 
investigations by adequately matching participants with regard to intellectual function, 
education level, gender and age. Moreover, specific consideration for the concomitant use 
of other illicit drugs by ecstasy users, specifically marijuana, was controlled.
Given that the cause of the learning and memory deficits obtained in this research 
seems to lie primarily at the feet of marijuana, it seems appropriate to devote the balance 
of this discussion to a number of potential neurochemical explanations for the observed 
verbal learning and memory impairments in heavy marijuana users, whether or not they 
are concurrently using ecstasy. In so doing, this researcher does not intend to imply that 
ecstasy and other psychoactive drugs do not have adverse effects on learning and 
memory but instead that the effects of marijuana in this context seem to be pervasive and 
deserving of further consideration.
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The serotonin (5-HT) system is a diverse and intricate system composed of at least 14 
identified receptor subtypes (Barnes & Sharp, 1999). Serotonergic nerve fibers originate 
in the raphe nuclei of the hindbrain and project widely throughout the brain innervating 
almost every major brain structure (Abrams et al., 2004). One interesting aspect of the 
serotonin system is the reciprocal interactions many of its receptors have with one 
another. For example, 5-HTia and 5-HTiA receptors appear to exhibit opposing roles 
(Araneda & Andrade, 1991; Darmani et al., 1990). Specifically, activation of 5-HT,A 
receptors typically results in cellular hyperpolarization and inhibition of cell firing, 
whereas activation of 5-HT2a receptors induces cellular depolarization and increased cell 
firing (Araneda & Andrade, 1991). Additionally, these two receptors appear to elicit 
opposing behavioral responses, with 5-HT ia receptor activation inducing hyperphagia, 
increased male sexual behavior, anxiolysis, and hypothermia, whereas activation of the 5- 
HT2A receptor induces hyperthermia, reduced male sexual behavior, anxiogenesis, and 
hypophagia (Abdel-Fattah et al., 1995). Concomitant activation o f one serotonin receptor 
results in functional inhibition of another. This suggests that the net effect of serotonergic 
activity is delicately regulated by the balance of serotonin receptors (Hill et al., 2003).
The endocannabinoid system is a neuromodulatory system in the brain that shares a 
high level of overlap with the serotonergic system in terms of the physiological processes 
it regulates. For example, both the serotonergic and endocannabinoid systems regulate 
body temperature, feeding behavior, sleep and arousal, and emotional processes 
(Chaperon & Thiebot, 1999; Hill et al., 2005).
In vitro and in vivo work has suggested that cannabinoids might influence 5-HT 
release. Cannabinoid receptor (CB|) agonists suppress electrically- and calcium -
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stimulated 5-HT release from cortical slices (Nakazi et al., 2000) and THC inhibits the 
release o f 5-HT in the hippocampus (Egashira et al., 2002). This suppression of 
serotonergic neurotransmission by cannabinoids is believed to be involved in the memory 
deficits produced by THC. Pretreatment with a 5-HT precursor, 5-hydroxytryptophan (5- 
HTP), or a 5-HT reuptake inhibitor, clomipramine, reverses these THC-induced deficits 
(Egashira et al., 2002).
Biochemical work has further suggested that endocannabinoids may enhance 5-HTia 
receptor-mediated responses but attenuate 5-HT2a receptor-mediated responses (Boger et 
al., 1998). This finding is supported by behavioral studies that have found that both short 
and prolonged administration of potent CBi receptor agonists potentiated 5-HT2a 
behaviors while reducing 5-HT%A receptor behaviors (e.g.. Cheer et al., 1999; Darmani, 
2001; Gorzalka et al., 2005; Hill et al., 2003).
Shifting our consideration to another neurotransmitter, cannabinoids increase 
dopamine neurotransmission in the nucleus accumbens (Di Chiara & Imperato, 1988; 
Nestler, 2002; Wise, 2002). Cannabinoids participate in the regulation of dopamine 
synthesis, release and turnover (Gardner & Vorel, 1998). It is possible that the negative 
memory effects observed in the present study were associated with the sustained use of 
marijuana which is known to produce decreased dopamine neural transmission via 
systemic down regulation of dopamine receptors in the hippocampus, especially D2 
receptors (Fujishiro et al., 2005).
Hippocampal dopamine neurons project fi’om the ventral tegmental area, with some 
of dopamine fibers in the posterior hippocampus originating from the substania nigra
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(Vemey et al., 1985). In fact several studies have shown that disturbances in 
dopaminergic systems induce learning and memory in rats (Fujishiro et al., 2005).
Herkenham and colleagues (1990) demonstrated that cannabinoid receptors (CB,) are 
located throughout the brain by using a synthesized ligand (CP 55940) that is structurally 
similar to THC. They found that this ligand exhibited high density binding to CB| 
receptors in the cerebellum, basal ganglia, cerebral cortex and hippocampus. The finding 
that CBi receptors are located in the hippocampus and that the THC-like ligand readily 
binds to these receptors correlates with marijuana's negative effects on learning and 
memory fimction.
The hippocampus is located in the inferior medial temporal lobe. It has been shown to 
be involved in memory functioning through studies with brain-damaged patients who, in 
extreme cases, suffer anterograde amnesia, which is the inability to form new long-term 
memories due to damage to the bilateral hippocampus (Gazzaniga et al. 1998). Rather 
than the hippocampus actually storing or retrieving memories, it is critical in the transfer 
of short-term memories into long-term memories by encoding and consolidating new 
information.
Chan and colleagues (1998) have investigated the neurotoxicity o f THC on cultured 
rat hippocampal neurons and slices. THC not only caused the shrinkage of cell bodies 
and nuclei of neurons, but also caused genomic DNA strands to break. Neuronal toxicity 
was found even with low doses, which were comparable to normal human consumption, 
by Chiang & Barnett (1984). As expected, the rate of cell death increased with THC 
concentration. There is speculation, which is consistent with findings of Herkenham et al. 
(1990), that THC targets hippocampal neurons because there is an abundance of CB,
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receptors in the hippocampus. When THC binds to these CBj receptors, it sets off 
transcriptional-dependent cell death. It would seem to follow that there would also be 
neurotoxicity of cells in the basal ganglia, cerebellum, and the cerebral cortex, since CBi 
receptors have also been found in abundance there. However, Chan et al. (1998) found 
that hippocampal neurons are more sensitive to THC than other cultured cortical neurons.
Chan et al. (1998) proposed that because THC is hydrophobic, neuronal death may be 
due to interactions with membrane lipids rather than with the CBj receptors. However, 
they found that the CBi receptor antagonist SR141716A completely inhibited neuronal 
death, which led Chan and colleagues to conclude that the actual binding of THC to 
cannabinoid CBi receptors in hippocampal neurons was responsible for the observed 
neuronal death.
Although Chan et al.’s (1998) research was well-controlled and informative; this 
experiment was done on rat hippocampal neurons in vitro, which begs the question of 
whether it can be extrapolated to human hippocampal neurons in vivo. Even if this 
extrapolation were accepted, it needs still to be determined in humans whether permanent 
memory loss would occur due to the neuronal death of these cells by THC because 
previous human data suggests that the effects of marijuana use on learning and memory 
are reversible (e.g.. Pope et al., 2001; Solowij et al., 2002; Sullivan, 2006).
Brain imaging studies have also tried to pinpoint the neural physiological alterations 
induced by marijuana use. For example. Amen and Waugh (1998) attempted to find a 
correlation between chronic marijuana usage and changes in localized brain activity using 
single photon emission computer tomography (SPECT). SPECT measures changes in 
cerebral blood flow by radioactive decay, which can then be visualized and interpreted as
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metabolically active regions in the brain. In Amen and Waugh's (1998) study, patients 
diagnosed with attention deficit/hyperactivity disorder (ADHD) were compared with 
other ADHD patients who used marijuana. The ADHD controls showed only a decreased 
perfiision in the prefrontal cortex but no abnormalities in the temporal lobes. In contrast, 
the ADHD-marijuana smokers exhibited a greater, dose related, decrease in activity of 
the prefrontal cortex and decreased perfusion in the temporal lobes. Based on these 
results. Amen and Waugh concluded that chronic marijuana usage changed the cerebral 
perfusion pattern of the brain, specifically in the temporal lobe region. In this context, it 
should be noted that Kandel and Schwartz (1985) had previously demonstrated that 
memory deficits were associated with abnormal activity in the temporal lobes.
While Amen and Waugh's study was thorough, their reasoning behind using only 
ADHD subjects can be questioned. Their justification for not studying a normal group of 
marijuana users with a normal control group was that even a normal group adds an 
element of uncertainty because so many marijuana users have additional diagnoses. This 
is a weak argument since it seems ADHD patients who smoke marijuana will have the 
complication of not only having ADHD, but additional diagnoses, since they too are 
marijuana users. Nonetheless, their work sets the stage for future imaging studies to 
examine the degree to which heavy marijuana use changes the brain physiologically with 
respect to memory.
In a study of hippocampal lesioned patients. Drew et al. (1980) used a test battery 
consisting of a series of psychometric tests including Babock Story Recall, Digit Span, 
Paired-Associate Learning, and Murdock Retention Test. These tests were used to assess 
recent memory function where the standard procedure was to provide a list o f items that
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marijuana intoxicated subjects first memorized and then were asked to recall immediately 
and after a delay. During the delay, the subject was engaged in another mental activity 
(i.e., counting backwards in three's) to prevent rehearsal.
Drew and colleagues (1980) results showed that acute marijuana intoxication did not 
affect memory retrieval from short term/working memory when the list was recalled 
immediately after learning. However, after the delay period the number of items recalled 
by the intoxicated subjects significantly decreased compared to the control group. The 
interesting portion of this study here is that the performance of marijuana- intoxicated 
subjects was also compared with hippocampal brain damaged patients. The results 
indicated that these two groups performed similarly on the test battery. These findings 
suggest that being under the influence of marijuana may be similar to creating a 
temporary lesion in the hippocampus with respect to impaired memory function.
Given the range of possible reductive mechanisms that might underlie the behavioral 
data obtained in the present study, more research is clearly needed to evaluate the long­
term, and possibly permanent, effects of marijuana use on memory. Future experiments 
should examine acute users, chronic users, and ex-users of marijuana, and the effect of 
the length and frequency of marijuana use on memory functions. Furthermore, behavioral 
studies and brain imaging investigations should prove beneficial in more adequately 
pinpointing the physiological aspects that lead to functional memory impairments in 
marijuana users. A direct benefit of understanding fully the memorial effects of 
marijuana is that it would permit a better understanding of the combined effects of 
marijuana and other psychotropic dmgs, starting with the combined effects of marijuana 
and ecstasy.
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APPENDIX I
TABLES
Table 1 Studies investigating explicit long-term verbal learning and memory in 
ecstasy users with relatively strong control over the influence of drugs apart fi'om ecstasy
Investigation Immediate
Recall
Delayed
Recall
Memory Test Variables Controlled
Croft et al. 
(2001)
.ns# ns Coughlan List and 
Design Learning 
Test
compared MDMA-cannabis users, 
cannabis-only controls and non­
drug users; matched on cannabis 
and IQ; performed covariate 
analyses for total cannabis, total 
MDMA, frequency of cannabis and 
MDMA use
Curran &
Verheyden
(2003)
.ns sig.+DD RBMT Prose 
Recall &
Buschke Selective 
Reminding Task
compared male ex- and current- 
MDMA; users with male polydrug 
controls matched for cannabis use 
and IQ and non-drug users; 
manipulated MDMA
Dafters, Hoshi, 
& Talbot 
(2004)
.ns# .ns# RBMT 
Immediate & 
Delayed Passage 
Recall
use in MDMA-cannabis group- 
heavy/light; matched on cannabis 
and IQ; performed; covariate 
analyses for other drug use
Fox, Toplis et 
al. (2001)
slg.+DD sig.+DD AVLT compared short-term and long-term 
MDMA; users and polydrug 
controls; statistically; controlled for 
other drug use; matched for IQ
Gouzoulis- 
Mayfrank et al. 
(2000)
sig.+DD sig. VLMT-German 
version AVLT
compared MDMA-cannabis, 
cannabis-only and non-drug users; 
matched for cannabis use; cannabis 
use was associated with some 
VLMT measures
Halpem et al. 
(2004)
.ns .ns WMS-Verbal
Paired
Associates/CVLT
compared MDMA and polydrug 
users
Lamers et al. 
(2006)
.ns# .ns AVLT compared MDMA-cannabis and 
cannabis only users with non-drug 
users
McCardle et al. 
(2004)
sig. sig. AVLT compared MDMA and polydrug 
users; statistically controlled for 
cannabis use; matched for IQ
Montgomery,
Fisk,&
Newcombe
(2005)
sig. .ns Verbal Paired 
Associates
compared MDMA and polydrug 
users matched on other drug use 
and IQ; covariate analyses revealed 
cannabis use affected performance
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Table 1 continued
Investigation Immediate Recall Delayed Recall Memory Test Variables
Controlled
Quednow et al. 
(2006)
.ns sig.+DD; recall
consistency;
recognition,
retroactive
interference
German version- 
AVLT
compared 
abstinent MDMA 
users cannabis- 
only users, and 
non-drug users; 
statistically 
controlled for 
cannabis use
Reneman, Majoie 
et al. (2001)
sig.+DD .ns AVLT SERT densities 
were lower in 
recent ecstasy 
users but not in 
abstinent ecstasy 
users
Semple et al. 
(1999)
.ns ns+DD CVLT compared 
MDMA users and 
non-users; after 
controlling for IQ 
results were .ns; 
lifetime doses of 
MDMA was 
associated; with 
memory 
impairment
Simon & Mattick 
(2002)
.ns .ns WMS-111
Auditory
Memory
regression 
analyses 
approached sig. 
for the effect of 
current frequency 
of cannabis use
Thomasius et al. 
(2003)
sig.+DD sig.+DD AVLT compared ex- and 
current-MDMA 
users; ex-users 
memory was 
worse than 
current users; 
SERT availability 
was reduced only 
in current users
Yip & Lee (2005) sig. sig.+DD Chinese version-
AVLT;
recognition
compared “pure” 
MDMA users and 
non- drug users; 
matched IQ
Note, sig, = significant deficit in ecstasy uses compared to controls. Unless otherwise stated, the findings shown are in 
comparison to a control group of drug users who don’t use ecstasy, .ns = no significant difference between ecstasy 
users and controls, p > .05. .ns# = no difference between ecstasy users and other drug users, but significantly different 
from non-drug using controls. DD = Dose Dependence to some measure of ecstasy use.
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Table 2 Verbal learning and memory studies that exercised less control over the 
influence of drugs apart from ecstasy and other possible covariates
Investigation Immediate
Recall
Delayed
Recall
Memory Test Notes
Back-Mad ruga 
et al. (2003)
.ns .ns AVLT no drug use exclusion criteria 
were applied to controls
Bhattachery & 
Powell (2001)
sig.+DD sig. +DD RBMT-Prose
recall
compared novice-, regular-, 
abstaining MDMA users and non­
drug users; matched on IQ; 
differed on frequency of cannabis 
use over past month
Bolla et al. 
(1998)
sig.+DD .ns AVLT no statistical control over the 
influence of cannabis or other 
drugs; controlled for IQ
Curran & 
Travill (1997)
sig. sig. Prose recall compared MDMA users and 
alcohol drinkers; no statistical 
control over the influence of 
cannabis use or other potential 
covariates
Fox, Parrott et 
al. (2001)
.ns ns 24 single words 
drawn from 6 
semantic 
categories
no statistical control of cannabis 
or other drugs
Krystal et al. 
(1992)
sig. sig. WMS Initial &
delayed
paragraph
compared MDMA users to age- 
matched normative data
Morgan (1999) sig. sig. RBMT-Story
recall
statistical differences between 
groups on IQ and other drug use
Parrott & Lasky 
(1998)
sig. sig. Auditory word 
recall
compared novice- and regular - 
MDMA users with non-drug 
users; no statistical control over 
cannabis use or IQ
Reneman, 
Lavalaye et al., 
(2001)
.ns sig. AVLT no statistical control over the 
influence of cannabis use or other 
possible covariates
Rodgers (2000) sig. sig. WMS-Verbal compared MDMA-cannabis and 
cannabis only and non-drug users
ns ns Paired
Associative/
Logical
Memory
groups; considerable cannabis use 
among both user grps; MDMA use 
was light (20 tabs)
Verkes et al. 
(2001)
.ns sig. Word recognition compared moderate- and heavy- 
MDMA users with non-drug 
users; no statistical control over 
the influence of cannabis use or 
other potential covariates
Zakzanis& 
Young (2001)
sig. sig. RBMT-Story
recall
longitudinal study (over 1 yr) of 
15 MDMA users; memory 
declined from baseline to follow- 
up; MDMA use increased as did 
other drug use
Note. sig. = significant deficit in ecstasy uses compared to controls. Unless otherwise stated, the findings shown are in 
comparison to a control group of drug users who don’t use ecstasy, .ns = no significant difference between ecstasy 
users and controls, p > .05. .ns# = no difference between ecstasy users and other drug users, but significantly different 
from non-drug using controls. DD = Dose Dependence to some measure of ecstasy use.
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Table 3 Cumulative lifetime dose (unless otherwise specified) o f MDMA and 
cannabis use in studies investigating explicit long-term verbal memory performance in 
ecstasy users
Investigation Ecstasy/MDMA Use Marijuana/Cannabis Use
Back-Madruga et al. (2003) M = 74.6 (SD = 100.6) MDMA 
users
M = not reported for non-drug 
users
M = not reported MDMA users 
M = not reported for non-drug 
users
Bollaetal. (1998) M = 60 MDMA users 
M = 0 non-drug users
M = not reported MDMA users 
M = not reported non-drug users
Croft et al. (2001) M = 41.9 (SD = 49.3) MDMA 
users
M = 0.6 (SD = 1.3) Cannabis- 
only users
M = 0 non-drug users
M = 10,964.9 (SD= 13,235.5) 
MDMA users
M = 7762.4 (SD = 14,480.9) 
Cannabis-only users 
M = 0.5 (SD = 0.8) non-drug 
users
Curran & Travill (1997) M = not reported MDMA users 
M = not reported non-drug 
users
M = not reported MDMA users 
M = not reported non-drug users
Curran & Verheyden (2003) M = 4.33 (2.89) yrs of use 
current MDMA users 
M = 3.49 (2.63) yrs of use ex- 
MDMA users 
M = 0 non-drug users
M = 6.7 (4.2) yrs of use current 
MDMA users
M = 7.2 (5.1) yrs of use ex- 
MDMA users
M = 7.4 (6.7) yrs of use non­
drug users
Dafters et al. (2004) less than 50 tabs MDMA light- 
cannabis users
50 or more tabs MDMA heavy- 
cannabis users 
M= 0 Cannabis-only users 
M = 0 non-drug users
M = 1252.9 (SD= 1078.1) 
MDMA light-cannabis users 
M = 1680.7 (SD = 838.2) 
MDMA heavy-cannabis users 
M = 1023.1 (SD = 670.7) 
Cannabis-only users 
M = 0 non-drug users
Fox, Parrot et al. (2001) M = 364.6 MDMA users 
M = 0 Polydrug users
M = not reported MDMA users 
M = not reported Polydrug users
Fox, Toplis et al. (2001) M = 8II.5 (SD = 981.8) Long­
term MDMA users 
M = 223.9 (SD = 387.3) Short­
term MDMA users 
M = 0.6 ± 0.9 Polydrug users
M = 10,306.8 (SD = 22,119.5) 
Long-term MDMA users 
M = 1617.3 (SD = 2898.4) 
Short-term MDMA users 
M = 447.3 (SD= 629.2) Polydrug 
users
Gouzoulis-Mayfrank et al. 
(2000)
M = 93.4 (SD = 119.9) MDMA 
users
M = 0 Cannabis-only users 
M = 0 non-drug users
M = 650 (SD = 635) avg daily 
dose mg MDMA users 
M = 724 (SD = 608) avg daily 
dose mg Cannabis-only users 
M = 0 non-drug users
Halpem et al. (2004) M = not reported MDMA users 
M = not reported non-drug 
users
M = not reported MDMA users 
M = not reported non-drug users
Krystal et al. (1992) M = 133.8 (SD= 101.3) 
MDMA users
M = not reported MDMA users
Lamers et al. (2006) M = not reported MDMA 
users
M = 0 Caimabis-only users 
M = 0 non-drug users
M = 932.4 (SD = 873) 
MDMA users 
M = 1581.6 (SD = 1432.5) 
Cannabis-only users 
M = 1.2 (SD = 2.1) non-drug
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Table 3 continued
Investigation MDMA Use Cannabis Use
McCann et al. (1999) M = 215(SD = 33) MDMA 
users
M = 0 non-drug users
M = not reported MDMA users 
M = not reported non-drug 
users
McCardle et al. (2004) M = 30 MDMA users 
M = 0 non-drug users
M = smoke occasionally; not 
specifically reported MDMA 
users
M = 0 non-drug users
Morgan (1999) M = not reported MDMA users 
M = 0 Polydrug users 
M = 0 non-drug users
M = 13.74 (SD = 11.6) joints 
consumed per week MDMA 
users
M = 9.28 (SD= 11.5) joints 
consumed per week Polydrug 
users
M = 0 non-drug users
Montgomery, Fisk, & 
Newcombe (2005)
M = 315.30 (SD = 330.10) 
MDMA users 
M = 0 non-drug users
M = 2,128.71 (SD = 2,401.96) 
MDMA users
M = 1,082.54 (SD= 1,439.33) 
non-drug users
Parrott & Lasky (1998) M = not reported MDMA users 
M = not reported Non-drug 
users
M = not reported MDMA users 
M = not reported Non-drug 
users
Quednow et al. (2006) M = 457.9 (SD = 433.9) 
MDMA users
M = 6.7 (SD = 24) Cannabis- 
only users
M = 547.1 (SD = 502.7) 
MDMA users 
M = 1033.4 (SD= 1348.6) 
Cannabis-only users
Reneman et al. (2001) M = 485 (SD = 598) Current 
MDMA users 
M = 268 (SD = 614) Ex- 
MDMA users 
M = 0 non-drug users
M = 326.9 (SD = 514.9) joints 
in past year Current MDMA 
users
M =456.7 (SD = 881.9) joints 
in past year Ex-MDMA users 
M = 15.3 (SD = 16) joints in 
past year non-drug users
Rodgers (2000) M = 20 times (over a 5-yr 
period) MDMA users 
M = 0 Cannabis-only users 
M = 0 non-drug users
M = 4  days per week (over a
10-yr period) MDMA users 
M = 4 days per week (over a
11-yr period) Cannabis-only 
users
M = 0 non-drug users
Semple et al. (1999) M = 672 (SD = 647) 
M = 0 Polydrug users
M = not reported MDMA users 
M = not reported Polydrug 
users
Simon & Mattick (2002) M = 258 (SD = 574) MDMA 
users
M = 5 Cannabis-only users
M = 67.9 joints per month 
MDMA users 
M = 62.6 joints per month 
Cannabis-only users
Thomasius et al. (2003) M = 1,033.77 (SD= 1702.44) 
Current Male users 
M = 600.42 (SD = 565.28) 
Current Female users 
M= 987.31 (SD = 824.50) Ex- 
Male users
M = 533.80 (SD = 317.22) Ex- 
Female users
M = 566.78 (SD= 1187.98) 
Current MDMA users 
M = 2132.91 (SD = 2199.77) 
Ex-MDMA Users 
M = 1247.66 (SD= 1290.57) 
Polydrug Users
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Table 3 continued
Investigation MDMA Use Cannabis Use
Verkes et al. (2000) M = 741 Heavy MDMA users 
M = 169 Moderate MDMA 
users
M = 0 non-drug users
M = 1,850 Heavy MDMA 
users
M = 1,890 Moderate MDMA 
users
M = 0 non-drug users
Yip & Lee (2005) M = 35.84 (SD =13.21) Ex- 
MDMA users 
M = 0 non-drug users
M = 0 Ex-MDMA users 
M = 0 non-drug users
Zakzanis & Young (2001) M = 19 MDMA users (at 
baseline)
M = 55 MDMA users (at 
follow-up)
M = 14% of MDMA users 
reported cannabis use (at 
baseline)
M = 15% of MDMA users 
reported cannabis use (at 
follow-up)
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Table 6 Patterns of drug use by drug in the drug user groups and the control group 
(means and standard deviations)
Ecstasy
Group
Age of 
Onset
# of Yrs 
Used
Time 
Since 
Last Use
Total # 
of 
Times 
Used
# of 
Times 
Used a 
Week
# o f 
Times 
Used a 
Month
Avg 
# of 
Pills 
Taken 
in an 
Episode
Lrgest 
# o f  
Pills 
Taken 
in an 
Episode
C 0 0 0 0 0 0 0 0
Mi. 0 0 0 0 0 0 0 0
M„ 0 0 0 0 0 0 0 0
E+ Ml 18.1 2.6 34.5 30.3 0.1 0.7 1.6 2.2
(1.4) (2.1) (61.8) (71.4) (0.5) (2.1) (0.7) (1.5)
E+ Mh 18.8 2.1 14.3 33.4 0.3 1.6 1.9 3.5
....(1:7) (2.0) (11.0) (43.2) (1.2) (4.6) (1.0) (2.4)
Marijuana
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time
Since
Last
Use
Total # of 
Times 
Used
# ofTimes 
Used a 
Week
# o f  
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 100% 16.1 3.3 1.9 242.9 1.3 5.2
(2.6) (2.5) (1.8) (564.6) (0.9) (3.6)
Mh 100% 15.6 4.3 0.3 2241.2 12.5 49.9
(2.1) (2.9) (0.5) (4261.6) (13.6) (54.3)
E+ Ml 100% 16.0 4.4 1.4 509.5 2.0 8.3
(2.0) (2.8) (2.3) (437.3) (1.3) (5.0)
E+ Mh 100% 15.3 6.1 0.3 3178.9 16.8 65.2
(2.4) (3.0) (0.4) (3700.1) (15.9) (55.9)
Cocaine
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time
Since
Last
Use
Total # of 
Times 
Used
# ofTimes 
Used a 
Week
# ofTimes 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 14% 18.3 1.5 96.3 1.0 0.0 0.0
(2.1) (1.3) (44.4) (0.0) (0.0) (0.0)
Mh 50% 17.8 0.8 43.6 3.8 0.0 0.5
(1.3) (0.9) (43.9) (2.9) (0.0) (1.2)
E+ Ml 40% 18.3 2.0 15.8 6.8 0.0 0.0
(2.5) (1.6) (27.7) (3.1) (0.1) (0.0)
E+ Mh 68% 19.0 1.7 43.4 7.2 0.0 0.2
(2.0) (1.6) (72.9) (2.9) (0.0) (0.4)
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Table 6 continued
Methamphetamine/Amphetamine
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 11% 17.3
(2.5)
1.3
(1.5)
93.7 (54.0) 1.0 (0.0) 0.0 (0.0) 0.0 (0.0)
Mh 5% 15 3 108 10 0 0
E+ Ml 20% 19.0 
. (3.0)
2.0
(1.0)
89.3 (57.9) 1.3 (0.6) 0.0 (0.0) 0.0 (0.0)
E+ Mh 21% 19.5
(4.0)
1.2
(0.9)
139.0(83.4) 6.8 (2.2) 0.0 (0.0) 0.0 (0.0)
Mushrooms
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 25% 17.1
(2.3)
2.5
(2.0)
81.9(135.7) 6.9 (5.5) 0.0 (0.1) 0.1 (0.4)
Mh 41% 18.6
(1.9)
1.1
(1.2)
33.8 (42.5) 3.3 (3.5) 0.0 (0.0) 0.0 (0.0)
E+ Ml 53% 18.0
(0.9)
2.6
(1.8)
70.0 (60.9) 5.1 (3.0) 0.0 (0.0) 0.0 (0.0)
E+ Mh 79% 18.5
(2.9)
1.9
(2.0)
87.5 (105.6) 4.7(3.1) 0.0 (0.0) 0.0 (0.0)
LSD
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
#o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
Mh 5% 17 1 16 4 0 0
E+ Ml 7% 18 4 208 1 0 0
E+ Mh 37% 19.9
(4.1)
0.7
(0.4)
133.9
(153.3)
4.6 (4.0) 0.0 (0.0) 0.3 (0.5)
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Table 6 continued
Solvents
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 • 0 0 0 0 0
Ml 14% 17.8 1.6 98.5 1.5 0.0 0.0
(3.3) (2.9) (69.5) (1.0) (0.0) (0.0)
Mh 18% 17.0 2.3 72.5 5.5 0.0 0.0
(2.6) (2.1) (40.1) (4.2) (0.0) (0.0)
E+Ml 13% 18.0 2.0 55.0 2.0 0.0 0.0
(0.0) (2.8) (69.3) (1.4) (0.0) (0.0)
E+ Mh 32% 18.0 1.5 104.8 3.0 0.0 0.0
(2.1) (1.6) (156.1) (1.5) (0.0) (0.0)
Heroin
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
M„ 0 0 0 0 0 0 0
E+Ml 7% 19 3 104 10 0 0
E+Mh 5% 19 0 1 1 0 0
Hydrocodone
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
#of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 25% 17.0 2.3 91.9 5.4 0.0 0.1
(2.1) (2.0) (74.2) (5.2) (0.0) (0.4)
Mh 50% 17.8 2.0 33.2 12.8 0.0 0.3
(1.1) (1.7) (50.7) (8.0) (0.0) (0.5)
E+ Ml 60% 17.2 3.2 94.3 7.8 0.0 0.3
(1.9) (1.4) (101.4) (8.4) (0.0) (0.5)
E+ Mh 68% 18.0 4.2 69.4 7.9 0.0 0.2
(1.6) (6.1) (99.3) (5.7) (0.0) (0.6)
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Muscle Relaxers
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f  
Times 
Used a 
Month
C 0 0 0 0 0 0 0
M l 7% 16.5 3.5 130.0 6.5 0.0 0.0
(0.7) (0.7) (36.8) (4.9) (0.0) (0.0)
M h 5% 18 1 4 10 0 1
E+ Ml 13% 18.0 1.0 10.5 3.0 0.0 0.0
(0.0) (0.0) (13.4) (1.4) (0.0) (0.0)
E+ Mh 21% 18.0 1.8 51.0 8.3 0.0 0.0
(1.4) ...(1:8) (37.7) (3.5) (0.0) (0.0)
Xanax
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 11% 16.7 2.7 95.3 2.7 0.0 0.0
(0.6) (1.5) (65.4) (2.1) (0.0) (0.0)
Mh 27% 17.7 1.5 39.0 13.7 0.0 0.2
(1.6) (0.8) (50.6) (8.9) (0.0) (0.4)
E+ Ml 20% 17.7 1.7 156.0 2.7 0.0 0.0
(2.1) (2.1) (52.0) (2.1) (0.0) (0.0)
E+ Mh 32% 18.8 2.0 92.8 9.5 0.0 0.2
(1.0) (1.3) (121.4) (6.2) (0.0) (0.4)
Percocet
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 11% 17.0 3.3 69.7 1.3 0.0 0.0
(1.0) (0.6) (59.5) (0.6) (0.0) (0.0)
Mh 23% 18.0 1.8 30.2 8.2 0.0 0.0
(1.9) (2.5) (32.9) (8.7) (0.0) (0.0)
E+ Ml 0 0 0 0 0 0 0
E+ Mh 37% 17.9 5.2 93.0 6.1 0.0 0.0
(1.8) (8.3) (141.1) (3.0) ...... i0:0) .... (0.0)
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Valium
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 4% 16 4 104 5 0 0
Mh 9% 16.0 1.0 79.5 6.0 0.0 0.0
(0.0) (1.4) (108.2) (5.7) (0.0) (0.0)
E+ Ml. 7% 17 4 208 5 0 0
E+ Mh 11% 18.0 2.5 87.0 7.5 0.0 0.0
(1.4) (0.7) (89.1) (3.5) (0.0) (0.0)
Ritalin/Adderall
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
Mh 5% 16 2 108 4 0 0
E+ Ml 13% 19.0 0.5 114.0 1.0 0.0 0.0
(1.4) (0.7) (132.9) (0.0) (0.0) (0.0)
E+ Mh 26% 19.0 0.2 78.2 5.0 0.0 0.4
(1.7) (0.4) (97.0) (8.5) (0.0) (0.9)
Ambien/Lunesta
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
Mh 5% 18 0 52 2 0 0
E+Ml 0 0 0 0 0 0 0
E+ Mh 0 0 0 0 0 0 0
Morphine
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
#of 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
M l 0 0 0 0 0 0 0
M h 0 0 0 0 0 0 0
E+ M l 0 0 0 0 0 0 0
E+ M h 11% 20.0 0.5 14.0 4.5 0.0 0.0
(1.4) (0.7) (15.6) (4.9) (0.0) (0.0)
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Methadone
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total#
ofTimes
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
Mh 0 0 0 0 0 0 0
E+ Ml 0 0 0 0 0 0 0
E+Mh 5% 21 1 52 6 0 0
Demero
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
Total # 
ofTimes 
Used
# ofTimes 
Used a 
Week
# o f 
Times 
Used a 
Month
C 0 0 0 0 0 0 0
Ml 0 0 0 0 0 0 0
Mh 0 0 0 0 0 0 0
E+ Ml 0 0 0 0 0 0 0
E+ Mh 5% 22 1 3 5 0 1
Alcohol
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
# ofTimes 
Used a 
Week
# ofTimes 
Used a 
Month
C 84% 16.9 3.2 21.9 1.2 4.7
(2.3) (3.7) (39.9) (2.3) (8.9)
Ml 84% 15.3 4.5 1.8 4.3 18.0
(2.1) (2.9) (2.7) (4.3) (19.5)
Mh 91% 15.7 4.5 2.8 4.3 17.3
(2.2) (2.5) (6.9) (3.7) (14.4)
E+ Ml 100% 15.9 4.6 29.8 4.3 17.6
(1.3) (2.7) (107.0) (3.3) (13.0)
E+ Mh 100% 15.1 6.1 1.6 6.2 24.6
(2.2) (3.4) (2.4) (6.2) (21.0)
Nicotine
Group
% of 
Users in 
Each 
Group
Age of 
Onset
# of Yrs 
Used
Time Since 
Last Use
# ofTimes 
Used a 
Week
# ofTimes 
Used a 
Month
C 12% 15.7 3.7 89.3 0.7 3.3
(1.5) (4.0) (105.1) (1.2) (5.8)
Ml 61% 15.4 3.6 45.4 22.9 94.8
(2.8) (3.2) (120.0) (44.8) (185.9)
Mh 50% 16.0 3.4 9.6 15.7 132.5
(1.9) (1.7) (20.9) (20.7) (252.0)
E+ Ml 60% 15.8 5.2 0.4 26.2 104.7
(1.9) (3.2) (1.3) (22.2) (89.0)
E+ Mh 84% 16.1 5.3 34.4 52.5 212.5
(2.1) (3.6) (129.6) (57.6) (234.6)
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APPENDIX II 
DRUG USE HISTORY QUESTIONNAIRE
Instructions
Part I: Demographic and Health Information
Now we will complete the drug use history questionnaire. The questionnaire is 
divided into two parts. For the first part, I will ask you to provide me with basic 
demographic and health information. There are 11 questions for this portion. For some of 
the questions, if you answer yes, you will be asked to provide additional information. For 
the last item on this portion of the questionnaire, I will ask you if you’re currently taking 
any prescribed medications. Please report only those medications that a doctor has 
specifically prescribed to you and you are taking in the recommended manner. 1 will ask 
you to report illicit prescription drug use in the second portion of the drug use 
questionnaire.
Part II: Drug Use Inventory
In the second portion of the questionnaire, 1 will ask you to report your drug use 
history for a variety of drugs. For each drug that you have taken, 1 will ask you: at what 
age did you begin using the drug, how many times have you used in your lifetime, 
weekly and monthly usage, and time since last use. Specific to ecstasy, 1 will also ask you 
how many pills you take on average per drug episode and what was the largest number of
179
pills you ever used in an episode. On the last item on this portion of the questionnaire, I 
will ask you if you have ever illicitly used prescription drugs. Illicit prescription drug use 
refers to taking a medication that was not specifically prescribed to you and/or taking a 
medication that was prescribed to you, but not in the manner it was prescribed (e.g., 
taking more than was prescribed).
Demographic and Health Information
1. Age
2. Gender
3. Years o f Education
4. Do you have a history of head 
injury with loss of consciousness 
requiring hospitalization?
5. Do you have a past or present 
history of medical illness?
If yes, please explain.
6. Have you ever been diagnosed 
with a major psychiatric disorder? 
If yes, please explain.
7. Have you ever been diagnosed 
with a learning disorder? If yes, 
please explain.
8. Is your health good?
P. Are you currently taking any prescribed medications?
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Drug Use Inventory
Drug
Age
of
Onset
# o f
Yrs
Used
Time
Since
Last
Use
Total
# o f
Times
Used
# o f
Times
Used
a
Week
# of 
Times 
Used 
a
Month
Average 
# o f  
Pills 
Taken 
in an 
Episode
Largest 
# o f  
Pills 
Taken 
in an 
Episode
Ecstasy
Marijuana
Cocaine
Methamphetamine/
Amphetamine
LSD
Mushrooms
Heroin
Solvents
Alcohol
Nicotine
Prescription Drugs
Prescription Drugs
Prescription Drugs
Prescription Drugs
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